Identification of haemorrhagic and ischaemic stroke by neuroimaging : present practice and future needs by Keir, Sarah Louise.
THE IDENTIFICATION OF HAEMORRHAGIC AND ISCHAEMIC








Neuroimaging with computed tomography (CT) and magnetic resonance imaging (MRI)
has markedly improved the accuracy of diagnosis of stroke and its underlying causes. As
more treatment options and advanced imaging modalities, such as diffusion-weighted MRI
(DWI) and magnetic resonance perfusion imaging (PI) become available, it becomes
increasingly important to have an accurate idea of the capability of each modality in order
that the best use is made of a limited resource. Using a combination of systematic review
and new data, this thesis clarifies the strengths and limitations of CT, conventionalMRI and
DWI in the diagnosis of intracerebral haemorrhage (ICH) and ischaemic stroke.
The thesis is divided into three sections. The first section explores the consequences of not
using conventional neuroimaging (CT orMRI) in stroke, both for research and patient care.
Chapter 2 investigates the potential effect of different scanning policies on stroke incidence
studies and finds that because of too little neuroimaging, or the use of CT at a later time
than when it could reliably detect haemorrhage, epidemiological studies could be flawed in
the estimation of the frequency of ICH. Chapter 3 explores the effect on patient outcome
of not identifying haemorrhage and commencing antithrombotic therapy for secondary
prevention as for ischaemic stroke, and finds that although aspirin may be beneficial and
heparin is likely not to be, the data are lacking to be certain.
The second section explores the sensitivity of CT and conventional MRI in the
identification of haemorrhage. Systematic reviews of CT and conventional MRI reveal the
lack of robust data and weak study methods in imaging studies, making it impossible to
make a quantitative judgement of sensitivity. Two new studies, including the largest study
to date to directly compare CT and conventional MRI, demonstrate that signs of
haemorrhage that disappear from CT remain visible on certainMR sequences, most notably
gradient-echo imaging, for years if not indefinitely. Also, in patients with minor stroke
scanned an average of three weeks after symptoms, CT missed ICH in 75% of cases
identified on MRI, and this had consequences for clinical decision-making.
The third section explores the capabilities of CT, conventional MRI and DWI to positively
identify ischaemic stroke. A systematic review of published studies of sensitivity of CT and
conventional MRI in the positive identification of ischaemic stroke reveal widely varying
values for sensitivity for both CT and MRI with little direct comparisons. Data from our
own study comparing CT and MRI in minor strokes demonstrates a similar efficacy for
each modality. A systematic review of the literature on DWI and PI in the positive
identification of ischaemic stroke reveal that though highly promising, the data are not
available to determine their clinical advantage over conventional imaging. A new study of
patients undergoing DWI following stroke demonstrates the clinical utility of DWI over
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Preface
Over the last decade, there has been a major shift in the approach to stroke care, as
services have become more organised and guidelines established on best practice1'2.
However, there is still considerable variation in certain aspects of stroke management,
particularly in the use of neuroimaging. At the moment, brain scanning with either
computed tomography (CT) or magnetic resonance imaging (MRI) is used in patients
with stroke chiefly to exclude important non-stroke pathology that may mimic stroke
symptoms (e.g. cerebral tumour), and to identify intracranial haemorrhage, thereby
avoiding inappropriate treatment. With the advent of thrombolysis for the treatment of
acute ischaemic stroke, there is an increasing need for better methods to make a positive
diagnosis of ischaemic stroke quickly and reliably2. This may mean that in the near
future, a 'negative' scan combined with the clinical signs of a stroke may not be enough
to plan further patient management appropriately. Advanced imaging modalities such
as magnetic resonance diffusion-weighted imaging (DWI) and perfusion imaging (PI)
are thought4 to be superior to conventional imaging in the positive identification of
ischaemic stroke and may thus represent the next stage in the evolution of neuroimaging
in stroke.
At present, the majority of patients with stroke in the United Kingdom who undergo
diagnostic imaging will have a CT scan. Only occasionally will conventional MRI be
used. More advanced imaging modalities are currently limited to only a few major
teaching hospitals. However, the use of CT in stroke has dramatically increased over
the last ten years, and the use of MRI is also increasing5'6. Precisely how we should be
scanning in stroke (e.g. timing and type of scan) is still under debate. Imaging is a
relatively expensive and limited resource that has to attempt to meet numerous
competing demands from different specialities. Stroke is a common medical problem.
To make best use of limited resources it is essential to understand the capabilities of the
different imaging modalities in stroke.
The aim of this thesis is to evaluate the strengths and limitations of CT, conventional
MRI, and DWI in the diagnosis and management of stroke, thereby enabling the Stroke
Physician to make a more informed judgement about choice of imaging, or to have a
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better idea of what information an available imaging modality can deliver. It does not
aim to explore the cost or organisational implications of differing scanning policies.
Study methods will focus on addressing three key questions:
1. Whatwould be the effects ofnot using scanning?
Without neuroimaging, the diagnosis of stroke and its underlying cause will be
inaccurate in a proportion of cases. Several studies demonstrating the improved
distinction of stroke from non-stroke (stroke 'mimics'), and intracerebral haemorrhage
(ICH) from ischaemic stroke, by clinicians when scanning is available are reviewed in
chapter 2. Further information on the proportion of stroke mimics in stroke
populations, and the relative importance of stroke expertise in the diagnosis of stroke
gained from systematic reviews of the literature will be presented.
A number of systematic reviews were performed during the course of this research.
This method, pioneered in the investigation of randomised controlled trials7, aims to
determine as comprehensively as possible the data available on a given subject and
thereby minimise the potential bias of a more selective review. The principles of
performing a systematic review are: to define the question to be addressed; to use a
defined search strategy to identify relevant studies; to select studies and extract data
using explicit criteria, and if possible, to synthesise evidence in a quantitative manner8.
Systematic review is less often used in the analysis of imaging literature. However,
although radiological studies are by their nature mainly observational, robust
methodology can still be applied, and by doing so, will produce better quality data. For
example, during imaging patients may move (decreasing the quality of the image), or be
unable to tolerate the scanner, and certainly there will be patients in whom MRI is
contraindicated. A retrospective collection of high quality scans does not give a realistic
impression of the sensitivity or practicality of a mode of scanning in a non-selected
stroke population. Also, although having knowledge of clinical history when
interpreting an image is clinically realistic, using other imaging against which to compare
scans would falsely increase the accuracy of results. Systematic review can be used to
assess the quality of available evidence and identify where more research or better
methodology is needed. A good stroke imaging study should give clear details of: its
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aim; the definition and characterisation of its study population (e.g. severity and type of
ischaemic stroke); the technical details of the imaging tests; whether the analysis was
prospective or retrospective; the timing of scanning in relation to onset of stroke
symptoms; how the images were analysed and read, and by whom; whether the reading
was blinded to clinical details and other imaging, and if comparisons within the study
population are made, an objective statistical analysis should be used to compare the
populations with a null hypothesis being clearly stated. Throughout this thesis, imaging
studies will be examined for their attention to objective study methods.
The inadequacy of clinical judgement alone in distinguishing ICH from ischaemic stroke
has important consequences both for research and patient care. In the remainder of
chapter 2, the potential effect of different scanning policies on stroke incidence studies
is explored; the hypothesis being that because of an inadequate approach to the use of
neuroimaging, studies of the frequency of stroke may have underestimated the incidence
of ICH. This will be tested by performing a systematic review of the scanning policies
in prospective community-based stroke incidence studies and will incorporate revised
estimates of the incidence of ICH.
Chapter 3 explores the effect on patient outcome of not identifying haemorrhage and
commencing antithrombotic therapy for secondary prevention as for ischaemic stroke.
The hypothesis is that the effect of antithrombotic agents (antiplatelet drugs or
anticoagulants) is qualitatively different in patients with ICH compared to that of
patients with ischaemic stroke. A systematic review of all randomised controlled trials
of antithrombotic agents in patients with intracranial haemorrhage, combined with
unpublished data from the International Stroke Trial9 and Chinese Acute Stroke Trial10
will collate all available evidence of the effects of antithrombotic drugs on intracranial
haemorrhage.
2. What are the relative sensitivities ofCTandMRI in the detection ofICH'?
The hypothesis is that the optimum imaging modality for the diagnosis of ICH will vary
between CT and MRI depending upon the timing of scanning after onset of stroke
symptoms and the clinical status of the patient. This will be tested using three different
strategies:
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• A systematic review of the existing literature of the sensitivity of CT andMRI in the
identification of ICH will be performed (chapter 4). All data on feasibility and
tolerability of scanningwill also be extracted.
• A prospective observational study of the sensitivity of MRI to detect evidence of
haemorrhage in patients with known ICH months after their index event (chapter
5).
• A prospective observational study comparing the capability of CT andMRI to make
a positive diagnosis of ICH in 228 patients presenting with minor stroke (chapter 5).
3. What are the relative sensitivities ofCTandMRI in thepositive identification ofischaemic stroke?
The hypothesis is that MRI, whether it be conventional imaging or DWI, is more
sensitive than CT in the positive identification of ischaemic stroke. This will be tested
using four strategies:
• A systematic review of published studies of sensitivity of CT and conventional MRI
in the positive identification of ischaemic stroke. This will also incorporate
information on the inter-observer reliability of scan interpretation (chapter 6).
• Data from our own study of CT versus MRI in minor strokes, on the relative
capabilities of each to make a positive diagnosis of ischaemic stroke (chapter 6).
• A systematic review of the literature on DWI and PI in the positive identification of
ischaemic stroke (chapter 7).
• A prospective observational case series of patients undergoing DWI following
stroke that will focus on two issues: the clinical utility of DWI over and above
standard scanning techniques, and the effect of clinical severity of stroke on the
sensitivity of DWI (chapter 8).
In summary, neuroimaging has markedly improved the accuracy of diagnosis of stroke
and its underlying causes. As more treatment options and imaging modalities become
available, it becomes increasingly important to have an accurate idea of the capability of
each modality in order that the best use is made of a limited resource. Using a
combination of systematic review and new data, my thesis aims to clarify the strengths
and limitations of CT, conventionalMRI and DWI in order to do so.
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The World Health Organization definition of stroke is 'rapidly developing clinical signs
of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or
longer or leading to death, with no apparent cause other than vascular origin1. It is not a
new disease; Hippocrates used the term 'apoplexy' to describe the sudden cataclysmic
event and subsequent paralysis that we would recognise as a stroke today2. The annual
incidence of stroke varies worldwide between approximately 300/100 000 to 500/100
000 for subjects aged between 45 and 84, the rate increasing with age3. It is the third
commonest cause of death (after coronary heart disease and cancer)4, and the leading
cause of severe disability in the community5. Based on epidemiological studies, between
73 and 86% of strokes are due to ischaemic stroke, between 8 to 15% to primary
intracerebral haemorrhage (PICH), and one to five percent to subarachnoid
haemorrhage3. This chapter will explore the pathophysiological processes that
culminate in stroke symptoms, the capabilities and limitations of clinical judgement
alone in the distinction of stroke from other conditions that can present with similar
symptoms as well as stroke subtype, and the reasons why neuroimaging can be of value
in achieving the correct diagnosis.
1.2 The AnatomyAnd Pathology Of Stroke
1.2.1 Cerebral vascular anatomy
The brain receives its blood supply from two pairs of vessels: the internal carotid
arteries, and the vertebral arteries. The internal carotid arteries arise from the common
carotid arteries, which on the right arises from the brachiocephalic trunk, and on the left
directly from the aortic arch. The vertebral arteries arise from the subclavian arteries
(figure 1) and, after passing through the foramen magnum of the skull, fuse into a single
midline vessel, the basilar artery. From the vertebrobasilar system, arises the anterior
spinal artery, the paired anterior and posterior inferior cerebellar arteries, superior
cerebellar arteries, and arteries to the brainstem. The basilar artery finally divides into
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the two posterior cerebral arteries. The internal carotid and vertebral arteries, are linked
at the skull base by an interconnecting set of vessels to form the circle ofWillis (figure




































Figure 1. Major cerebral arteries . Figure 2: circle of Willis (reproduced from Waxman,
S. G.: Correlative neuroanatomy, Lange6)
The internal carotid artery enters the skull via the carotid canal, curving forward through
the cavernous sinus, then up through the dura into the brain. The first vessel given off
is the ophthalmic artery, followed by the posterior communicating artery and the
anterior choroidal artery, both also arising directly from the internal carotid. It then
divides into its two terminal branches, the anterior and middle cerebral arteries.
The anterior cerebral arteries course around the genu of the corpus callosum, supplying the
anterior frontal lobes and medial aspect of the cerebral hemispheres. They are
connected by the anterior communicating artery, which becomes an important route of
collateral supply in the event of occlusion of an internal carotid. The middle cerebral artery
supplies around 70% of the hemisphere cortex, and is divided neuroradiologically into
several regions: the first part (the Ml segment) runs horizontally following the Sylvian
fissure and gives off multiple small terminal penetrating arteries with virtually no
collateral circulation (lenticulo-striate arteries), the second segment (M2) runs through
the insular cortex, and then as it branches further, segments are termed M3 to M57. The
posterior cerebral artery curves around the brainstem, supplying the occipital lobe and the
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choroid plexus of the third and fourth ventricles, the lower surface of the temporal lobe
and the midbrain (figure 3).
The descriptions above are simplified descriptions of the anatomy of the cerebral
vasculature. Autopsy studies have demonstrated that in reality, there is great variability
in the size and supply zone of various arteries. Anomalies of the circle of Willis are
frequent; the most common anomaly of the posterior communicating artery for
instance, is its direct origin from the internal carotid artery occurring in around 20
percent of people9. The territories supplied by each vessel also vary10, therefore when a
lesion is found on neuroimaging, it may not always be possible to infer which vessel is




Ischaemic stroke (or cerebral infarction) is the result of acutely reduced cerebral
perfusion, which can be provoked either by occlusion of a cerebral artery (ischaemic
stroke) or a fall in cerebral blood flow by other means. The most common causes of
occlusion of a cerebral artery are local thrombus formation or thromboembolus from a
distant site. Thrombus formation is thought to be triggered by vascular endothelial
damage, either due to erosion of endothelium or rupture of an atherosclerotic plaque.
The exposure of subendothelial structures then activates platelet adhesion and blood
Figure 3. Left: Diagram of vascular
territories as depicted in four axial sections.
ACA: anterior cerebral artery, MCA:
middle cerebral artery, PCA: posterior
cerebral artery, LSA: lenticulostriate
arteries, PP: posterior perforators, SCA:
superior cerebellar artery, PICA: posterior
inferior cerebellar artery, BP: basilar
perforators (adapted from Cinnamon
199?)
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coagulation factors leading to acute thrombus11. Areas prone to the build-up of clot or
atheroma are important sources of thromboembolus as friable tissue can break free,
enter the cerebral circulation and block cerebral arteries. Common sites for
atherosclerotic or clot build-up include the origin of the internal carotid arteries, the
arch of the aorta, and the heart.
The other common type of stroke, intracerebral haemorrhage (ICH) is caused by the
extravasation of blood through a critically weakened area of an intracerebral blood
vessel. There are many factors that may contribute to a reduction in the integrity of the
vessel wall such as the degenerative vascular changes seen in hypertension12 and amyloid
angiopathy13. Other factors may then predispose the vessel to rupture (for example
acute hypertension or sympathomimetic drugs), or exacerbate haemorrhage once it has
occurred (anticoagulation)14.
1.3 The Pathophysiology Of Stroke
1.3.1 Normal cerebral metabolism
Energy production
To function, biological systems need energy in the form of adenosine triphosphate
(ATP) and the richest source of it is the aerobic metabolism of glucose. The brain,
unlike other organs, uses only glucose as a substrate for energy production. In the
presence of oxygen, glucose is metabolised by a series of reactions to pyruvate. During
this process, the oxidised form of nicotinamide-adenine dinucleotide (NAD+) is reduced
(NADH). Pyruvate is then oxidised in the mitochondria to carbon dioxide (CO^ and
water (H20) with the resulting formation of 36 moles of adenosine triphosphate (ATP)
for every mole of glucose metabolised. If there are inadequate levels of oxygen
(hypoxia), this does not occur and instead, pyruvate is converted to lactate with the
production of far less ATP (two moles for each mole of glucose)15.
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Cerebral energy demand
The brain has a high metabolic rate, using about 125g of glucose per day and not
surprisingly has an extremely rich blood supply, utilising 15-20% of the total cardiac
output16. This is an entirely disproportionate amount in relation to the relative weight of
the brain in comparison to the total body weight (about 2%). Global cerebral blood
flow (CBF) is about 50ml/100mg/minute, with relatively higher values in the young
(less than 20 years) and lower values in the older (greater than 60 years). Grey matter
has a higher CBF compared to white matter due to its higher metabolic rate17. The
amount of oxygen extracted from the blood (oxygen extraction fraction, OEF) can vary
in times of increased metabolic demand, but under normal circumstances remains
roughly constant at around one third18.
Cerebral autoregulation
In the normal brain, CBF is maintained at a constant level, regardless of variations in
systemic arterial pressure in order to ensure a constant energy and oxygen supply. In
the normal brain, CBF is kept constant by the dynamic relationship between cerebral




The CPP is the difference between arterial pressure, forcing blood into the cerebral
circulation, and venous backpressure. CPP can be reduced by dropping arterial
pressure, or increasing intracranial pressure (ICP). Normally venous backpressure is
negligible and CPP equals arterial blood pressure. Usually changes in CPP over a wide
range have little effect on CBF due to alteration of CVR, a system termed
'autoregulation'. As cerebral vessels dilate, CBF (and cerebral blood volume, CBV)
increase, and decrease when vessels constrict. The normal range of mean arterial blood
pressure over which this system works is around 60 to 150 mmHg. If the capacity for
cerebral vessels to autoregulate is lost, the CBF through these vessels becomes directly
dependent upon systemic arterial pressure. In this situation, a small reduction in
systemic arterial pressure can lead to a marked reduction in cerebral perfusion19.
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1.3.2 Cerebral metabolism in the ischaemic brain
Ischaemia at a molecular level
In the hypoxic brain, anaerobic production of ATP leads to the accumulation of lactate
and unbuffered hydrogen ions, altering the acid-base status of the tissue. As energy
demands outstrip the capacity to make ATP, energy-dependent mechanisms including
ion pumps fail, leading to the deterioration of membrane ion gradients and equilibration
of intracellular and extracellular ions (anoxic depolarisation). As a consequence,
potassium ions move out of the cell, sodium and calcium move into the cell, and
excitatory neurotransmitters such as glutamate and aspartate are released in potentially
neurotoxic concentrations20. These metabolic disturbances lead to a rise in cell
osmolality, causing shifts ofwater into the intracellular compartment21.
Changes in cerebral blood flow in ischaemia - luxury versus misery perfusion
In ischaemic stroke, when cerebral blood flow is suddenly reduced, changes occur in
cerebral perfusion (CBF), and tissue oxygen consumption (CMROj). Animal studies
have identified four patterns of compensation22:
1. Cerebral blood volume is increased to maintain CBF (autoregulation). The brain's
dense network of collateral vessels may contribute to this, even producing areas of
relatively or absolutely increased CBF, termed 'luxury perfusion'.
2. Reduced CBF with a relatively preserved CMR02, achieved by increasing the oxygen
extraction fraction (OEF), a situation known as 'misery perfusion'.
3. Reduced CBF and CMR02 in spite of increased OEF, which results in the
development of ischaemia.
4. Very low levels of CBF and CMR02 leading to cell death22.
Degree of ischaemia is important; introducing the ischaemic penumbra
The degree of ischaemia that the brain could tolerate began to be explored on a
scientific basis in the 1970s, when it was noted that in patients undergoing carotid
endarterectomy, the EEG of the patient flattened when CBF was reduced to around a
third of normal23. Animal models showed that although the brain demonstrated loss of
electrical function at a CBF of around 20ml/min/100g, it was not until lower rates of
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CBF of around lOml/min/lOOg that there was failure of sodium/potassium ion pumps
with potassium release indicating membrane failure and cell death24. The functionally
silent but still viable tissue in between these two limits was named the 'ischaemic
penumbra' and raised hopes that therapeutic interventions could be developed to
salvage it before cell death occurred. As this situation was studied further, it became
clear that cell metabolism is affected before it becomes clinically evident, with different
brain and cellular functions breaking down at varying CBF levels23.
Duration of ischaemia is important; the ischaemic penumbra is a dynamic
concept
Following on from the discovery that the degree of reduction in CBF was important in
determining the extent of tissue damage, studies in monkeys demonstrated that these
CBF thresholds were not rigidly fixed, and that they also depended upon the length of
time for which the CBF remained at a certain level26. In one study for instance, tissue
with a CBF of 15ml/100mg/min could withstand about three hours of reduced blood
flow before infarcting, whereas in tissue with a CBF of 5ml/100g/min infarction
occurred after only two hours27. This introduced the concept of a region of ischaemia
as an ongoing dynamic process, far more complex than originally thought.
The size and shape of the ischaemic penumbra are controversial; various studies have
come to differing conclusions. One group noted volumes representing up to 65% of
the affected tissue to be within the 'penumbral range' (as determined by reduced CBF
and increased OEF) and to be demonstrable for up to 16 hours following the initial
insult28. Others (defining penumbra as tissue with an OEF of 50 to 70%) found much
smaller volumes that could be considered penumbra and raised doubts as to its
importance29. It is also not clear whether all salvageable tissue is situated in a 'rim'
around an infarcted core, or whether the zone at risk is comprised of islands of
ischaemic and infarcted tissue. The differing criteria used to define the penumbra will
almost certainly contribute to the variance in these results. This remains a source of
intense debate, with considerable doubt being expressed as to the merit of using the
OEF in the definition of the penumbra30. This issue must be resolved; if different
criteria are used to define the penumbra, it follows that different environments will be
studied, which will make interpretation of findings on neuroimaging impossible. Once
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an accurate definition of the penumbra has been established, it will then be necessary to
perform intervention studies to establish whether this tissue is salvageable or merely a
scientific curiosity.
Factors contributing to the amount of damage in ischaemic tissue
Although the extent, and duration of reduction in CBF are probably the most important
factors determining the area of ischaemic tissue, a number of other processes, occurring
around the time of the initial insult or for days afterwards may be important but are not
fully understood. Other examples of potential mediators of an ongoing ischaemic
process are described below.
Animal studies have demonstrated that temperature changes of as little as two degrees
can have a profound effect on the level of ischaemic damage; a rise in temperature
having similar effects to an increased duration of ischaemia, and reducing temperature
significantly reducing neuronal damage31. Ffyperglycaemia post-stroke, after correcting
for age, stroke severity and stroke sub-type, is associated with increased mortality and a
poorer outcome32. One mechanism that is suggested for its negative effect is the
exacerbation of ischaemia by the provoking of a 'spreading depression'-like increased
oxygen demand in ischaemic tissue.
'Spreading depression' is the term used to describe the phenomenon seen in brain tissue
of waves of depolarisation associated with an increased metabolic rate in the depolarised
tissue, responding to the activation of energy-dependent ion pumps25. In the normal
brain, the associated increase in demands for oxygen and glucose are coupled to an
increase in CBF33. In ischaemia, glutamate-propagated intermittent waves of
depolarisation, similar to spreading depression are seen. However, the consequent
energy demands are not linked to an appropriate increase in CBF34, and increases the
burden on already compromised tissue.
It may be that neurones are less salvageable than initially suspected if an ischaemic insult
triggers apoptosis, the term used to describe programmed cell death. It is distinct from
cell necrosis, whereby cell membranes and mitochondria break down, with the
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provocation of a potentially detrimental inflammatory response35. Features
characteristic of apoptosis have been identified in ischaemic brain tissue, although it
may just be that neuronal cell death demonstrates similar changes36. If apoptosis does
occur however, the implication is that an ischaemic insult may continue to cause damage
for a much longer time after the event than one would expect. Figure 4 gives a pictorial
representation of the ongoing insults triggered by ischaemia that could continue to cause

















Figure 4. Hypothetical representation of extent and temporal course of development of ischaemic
damage. (Reproducedfrom Weiss, 19992)
1.3.3 Intracerebral haemorrhage
When blood is extravasated through a critically weakened area of blood vessel it forms
rounded haematoma. As the haematoma expands, further haemorrhage may be
provoked as vessels surrounding it are compromised and rupture, producing a cascade
of secondary haemorrhage and consequently ischaemia37. The haematoma either by
virtue of its size, or combined with associated surrounding oedema may exert a
significant mass effect on adjacent cerebral structures; kinking vessels, impeding
cerebrospinal fluid flow and threatening vital functions.
At a cellular level, within minutes of the onset of bleeding, platelet aggregation occurs,
clotting pathways are activated and clot is formed. The stabilisation of the clot by the
cross-linkage of adjacent fibrin molecules causes it to retract, producing a heterogenous













disturbance of ion homeostasis
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after a few days, red cell lysis occurs, initially at the centre of the haematoma. As
oxygen levels drop within a haematoma, haemoglobin becomes deoxygenated to
deoxyhaemaglobin, and breakdown products such as methaemoglobin appear.
Serial CT scanning of intracerebral haemorrhages demonstrate that a significant number
of haematomas continue to expand for hours and sometimes days after onset of
stroke39;40. Intracerebral haematomas are not static, uniform collections of blood, rather
they are a heterogenous, dynamic entity. This heterogenous consistency, along with the
changing concentrations of breakdown products of haemoglobin can make acute
haemorrhage MRI difficult to interpret41 (further details follow in this chapter and
chapter 4).
1.4 The Clinical Examination And Its Limitations
Making a correct diagnosis of stroke is important
The diagnosis of stroke is made in patients who develop a clinical picture of rapid onset
focal or global cerebral disturbance42. However, this is not always straightforward.
There is no definition of the duration of time for 'rapid', symptoms vary widely and are
not always focal (such as confusion or memory loss). Also, a wide range of conditions
other than ischaemic stroke and ICH can cause identical stroke-like symptoms. 'Stroke
mimics' such as brain tumours or cerebral infection have markedly different prognoses
and their management is not the same as for stroke. Also, stroke due to vessel
occlusion or ICH may present with identical symptoms making the two impossible to
distinguish clinically. These issues will be discussed further in Chapter 2.
As our ability to treat conditions such as brain tumour improve, so it becomes
important to distinguish such conditions from stroke. When no treatments of any
proven benefit were available for stroke, identifying whether it was due to an ischaemic
event or an ICH was relatively unimportant. However, when aspirin was demonstrated
to be beneficial in ischaemic stroke for the prevention of death and stroke recurrence 43,
with the recognition that anticoagulation prevents recurrent stroke in patients with atrial
fibrillation, and with the advent of thrombolysis, which may be beneficial in ischaemic
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stroke, the management of ischaemic stroke and ICH has diverged. In the near future,
the management of patients with different levels of ischaemic damage may also vary.
However, to instigate appropriate treatment, the clinician has to be able to identify the
correct pathology.
The classification of stroke
Attempts have been made to define clinically important subgroups of ischaemic stroke.
Two of the most commonly used examples are the Bamford12 and the TOAST44
classification (appendix I). The Bamford classification is based primarily on clinical
findings and groups patients according to combinations of symptoms and signs;
ischaemic strokes may be large or small, involve cerebral cortex (cortical) or small areas
of deep structures (lacunar). Bamford classifications correspond with the site and size
of their lesion in the brain, from which underlying aetiology can be inferred and
outcome predicted. The TOAST classification44 combines the results of neuroimaging,
echocardiography and carotid Doppler ultrasound with clinical symptoms in an attempt
to determine the precise aetiology of the stroke. Which classification is used depends
on clinician preference and the context in which its use is being considered. For
example, the TOAST classification would not be useful if access to diagnostic facilities
are limited, or in the hyperacute situation when rapid diagnosis is the aim.
The need for neuroimaging
Currently, the diagnosis of stroke is still based on the judgment of a clinician confronted
with a patient with certain combinations of symptoms and signs. There are a number of
diagnostic aids that may be available to help the clinician feel more confident in their
diagnosis. Autopsy may be a 'gold standard' of diagnosis but would only confirm
diagnosis in those with the most severe strokes who die, not the more mild strokes who
do not die until years later. One of the best diagnostic methods is monitoring clinical
progress with time, as the clinical features of other conditions (such as tumours) become
manifest, or other investigations confirm or exclude differential diagnoses.
Neuroimaging with CT or MRI can improve and speed up the diagnostic process,
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sometimes excluding important differentials immediately, or actually confirming stroke
diagnosis.
Currently, most stroke physicians are constrained in their choice of imaging modality for
patients with stroke to CT, although access to MRI is increasing45. As the number of
neuroimaging techniques available to the stroke physician increases, so it becomes
increasingly important to know the sensitivity (the proportion of patients who truly have
the condition that is identified on imaging) and specificity (the proportion of patients
who truly do not have the condition that is not identified on imaging) of each. This
allows the clinician then to select the most appropriate technique for a given situation.
This will be dealt with further in later chapters. Also, to derive the maximum
information available from an image, it is helpful to understand how it was derived. The
following section describes the principles of CT and MRI.
1.5 Principles Of Computerized Tomography And Magnetic
Resonance Imaging
1.5.1 Computerised tomography (CT)
Development ofCT
Computerized tomography was first described by Hounsfield in 197346, for which he
was awarded the Nobel Prize. Its value in the differentiation of causes of stroke was
rapidly realised47; one exploratory case series found positive findings in all 66 patients
with intracerebral haemorrhage, and in 50% of those with ischaemic stroke48. Another
series of patients clinically diagnosed as having cerebrovascular disease found that in
those with a permanent neurological deficit, there was a corresponding lesion on CT in
57/58 (98%). In patients with transient neurological symptoms only 2/32 (6%) had an
abnormality on CT, and that 43% of patients with haemorrhage on CT had had a
clinical diagnosis of ischaemic stroke49.
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Principles of CT
To create an image using CT, a narrow beam of X-rays is passed through slices of the
body part under investigation from multiple angles, and is attenuated to varying degrees
depending upon the density (atomic number) of tissue it passes through. The beam is
detected by sensing devices always pointed at the X-ray source. Information from
multiple overlapping sources is then digitised and a two-dimensional image is
constructed from thousands of data bits (pixels), the brightness of each bit being
proportional to the degree of X-ray absorption46. Tissue contrast (a result of varying X-
ray attenuation) is measured in Hounsfield Units (HU), and is proportional to the
electron density, specific gravity or tissue water content of the tissue. For example, a
1% increase in tissue water content causes a decrease in attenuation of 2.5 HU, which
will be manifest as an area that is hypodense compared to tissue with lower water
content on imaging50. As scanners have evolved, the quality of image has improved as
pixel size has decreased, and scan time has diminished to the point where a current
spiral scanner can produce a set of images of the whole brain in as little as 20 seconds.
1.5.2 Magnetic resonance imaging (MRI)
Development ofMRI
MRI is a spectroscopic technique based on the principles of nuclear magnetic
resonance. This phenomenon was first described by Bloch and Purcell in 1946, both of
whom received the Nobel Prize in 1952. MRI was initially developed for chemical and
physical molecular analysis, but the idea of using it to detect disease within the human
body began to gain ground in 1971, when it was demonstrated that tumour and normal
tissue had different MRI properties ('relaxation times')51. In 1975 Richard Ernst
proposed a new method of performing and analysing MRI which formed the basis of
currentMRI techniques52, and in 1977 whole bodyMRI was first demonstrated53.
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The principles ofMRI
Magnetic resonance imaging (MRI) makes use of the phenomenon of nuclear magnetic
resonance; certain atomic nuclei, when placed in a magnetic field and stimulated by
radio waves of a particular frequency, absorb energy that they re-emit as radio signals
when the stimulation is switched off. Nuclear magnetic resonance occurs in atoms with
nuclei that contain an odd number of neutrons or protons (known collectively as
nucleons). Each nucleon has an intrinsic angular momentum, or 'spin', that generates a
magnetic field; paired protons and neutrons align in such a way that their spins cancel
out. Each nucleus thus behaves like a tiny bar magnet and normally they are orientated
at random. If the nuclei are placed within a magnetic field however, they will be
reorientated to become aligned with the applied field. Then, when a short
radiofrequency (RF) pulse is applied via a coil surrounding the sample, it produces a
second smaller magnetic field which will cause some of the aligned nuclei to experience
a torque which will displace the axis of the net nuclear magnetization vector from its
position parallel to the static field (figure 5). How much the axis is displaced depends
upon the strength and duration of the RF pulse.
Figure 5. When a radiofrequency (RF)
pulse is applied across a static magnetic
field (Bj, the net magnetic moment is
perturbed from its equilibrium position,
the angle (6) increasing as long as the
pulse remains on. When the pulse is
turned off, the vector gradually returns to
its originalposition, its rotation describing
the wall ofa cone as it does so (adapted
frcmPykett 1982™).
When the RF pulse is turned off, the magnetization vector returns to its position parallel
to the applied magnetic field, emitting a RF frequency signal that gradually diminishes.
This phenomenon is characterised by two sample-related time constants, known as
'relaxation times' (termed Tl and T2). The image derived from the decaying signal may
be a function of Tl, T2 or both relaxation times, as well as the proton density of the
sample. The extent to which each parameter contributes to image contrast depends







The most biologically important nucleus in terms of imaging the human body is 'H, as
the body is made up primarily of water and fat, both rich in hydrogen. Other NMR-
sensitive nuclei include 23Na, 13C and 31P, although their lower biological concentrations
make them less useful. As experience with MRI has progressed, the imaging
characteristics of normal and diseased tissue using different pulse sequences have been
identified. Certain sequences have proved more useful in the identification of certain
tissues or disease states and these will be discussed further.
1.6 Pathological Changes Seen On Neuroimaging
1.6.1 Ischaemic stroke
Ischaemia on CT
The quality of image produced by early CT scanners made positive identification of
ischaemia difficult55, but with increasing sophistication, scanners can demonstrate signs
of ischaemia within a few hours of stroke, although the signs may be subtle. Normal
grey and white matter differ in their water and fat content; grey matter is relatively
hyperdense with respect to white matter. In acute ischaemia, water moves into cells,
and the subtle differentiation between grey and white matter can be lost. If the lesion is
in the basal ganglia, there may be loss of outline of the lentiform nucleus and insular
ribbon'6"39, if cortex is affected, there may be loss of grey/white cortex differentiation
and swelling resulting in effacement of cortical sulci60 (figure 6).
Figure 6. CTshowing infarction (area ofhypodensity) in the leftparietal cortex (arrow)
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As the infarct becomes more established, both grey and white matter become
increasingly hypodense and lesions can become more obvious, although if small (e.g.
lacunar strokes) can still remain difficult to identify61*2. Infarcts of the middle cerebral
artery territoiy may be associated with a 'hyperdense middle cerebral artery sign'
(HMCAS) as distal occlusion causes reduced blood flow or stasis within the vessel
provoking clot formation. It has been noted in between 2763 and 50%64 of patients
scanned within four to 12 hours respectively ofMCA territoiy stroke (figure 7).
Figure 7. Hyperdensemiddle cerebral artery sign (HCMAS) (arrow)
As the infarct matures, by two to three weeks post ictus the previously hypodense lesion
can become far less conspicuous i.e. more isodense with normal brain and less swollen,
so-called 'fogging"'3, due to the infiltration of the infarcted tissue with macrophages, and
the seepage of proteins and erythrocytes into the area. As the infarct matures, it may
leave a sharply demarcated, shrunken area of roughly equivalent density to cerebrospinal
fluid (CSF) that will be hypodense on CT. Adjacent structures such as cerebral
ventricles may dilate as the area of infarction shrinks.
Ischaemia onMRI
On MRI, the tissue oedema produced by acute stroke results in hypointensity on Tl-
weighted images, and hyperintensity on T2-weighted and proton density images (figure
8). Changes may be demonstrated on Tl and T2 sequences within six hours of stroke66,
but this may not always be the case67. A more specialised FLAIR (fluid attenuated
inversion recovery) sequence may demonstrate changes at an earlier time-point68, as can
diffusion-weighted imaging (see chapters 7 and 8). The normal signal flow void in the
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supply artery may be lost if there is sluggish or stationary blood flow in a visible artery69,
which is the equivalent of the HMCAS on CT. As infarcts mature after several weeks,
leaving an area of reduced brain mass, the lesion is bright on T2 and dark on Tl like
CSF.
Figure 8. Ischaemia on MRI - Proton density sequence, hyperintensity in left occipital region (arrow)
associatedwith swelling causing the occipitalpole ofthe left lateral ventricle to bepishedforward
1.6.2 Intracerebral haemorrhage
Haemorrhage on CT
Haematoma has a specific gravity greater than that of water and consequently appears
on CT as an area of high density or whiteness (about 80 HU compared with 35 HU for
normal brain, figure 9). It appears rapidly after onset of symptoms70 i.e. virtually
instantaneously, is usually homogenous in intensity and surrounded by a varying area of
lower attenuation (due to tissue oedema or necrosis)60. Extensive haematomas may be
associated with intraventricular blood and behave as space-occupying lesions, provoking
shifts in brain. As the haematoma resolves over days to weeks depending upon its size,
the corresponding area of high density reduces until it becomes isodense with the
surrounding brain tissue making recognition of previous haemorrhage unreliable at this
time71. The time it takes for a haematoma to become isodense varies, with small
haemorrhages disappearing in a matter of days72. As the affected area organises over
weeks and months, there may be no residual signs, or only an area of non-specific focal
atrophy with the low density of a CSF-containing cavity indistinguishable from old
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ischaemic stroke, small patches of focal calcification, or a slit-like lesion usually only
found following deep haemorrhages73.
Figure 9. Haemorrhage on CT, haematoma demonstrated as area ofbyperdensity (arrow) producing
mass effect
Haemorrhage on MRI
The changes seen following brain haemorrhage on MRI are determined by the relative
concentrations of haemoglobin, oxyhaemoglobin, deoxyhaemoglobin, methaemoglobin
and haemosiderin. Deoxyhaemoglobin and methaemoglobin are paramagnetic, which
makes them capable of exerting a magnetic susceptibility effect that alters Tl and T2
relaxation times. Acute haemorrhage contains high quantities of oxyhaemoglobin,
which is not paramagnetic, consequently there may be little change in signal, or any
changes may be indistinguishable from an ischaemic lesion6". As the breakdown
product methaemoglobin is formed, the Tl image becomes hyperintense and the T2
image hypointense (figure 10)74. As the haematoma liquifies, the T2 image also becomes
bright, and after a few weeks images will be bright in the centre surrounded by a dark
rim seen more strikingly on T2 than Tl due to the persistence in brain tissue of
haemosiderin, a breakdown product of haemoglobin73.
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Figure 10. The evolution ofhaematoma seen on Tl and T2 imaging (adapted from Warlaw et al
200Cf°)
T2-weighted techniques introduced within the last few years that speed up image
acquisition whilst maintaining image contrast and resolution (Fast Spin-Echo, FSE),
have become the technique of choice in many institutions. However, there has been
debate as to its sensitivity in the detection of haemorrhage76. Another specialised
sequence (Gradient-Echo, GRE) has been shown to be particularly sensitive in the
detection of haemorrhage77 (figure 11). The relative merits of these sequences will be
explored further in chapter 5.
Figure 11. Haemorrhage on MRI. Left picture: T2 sequence - area of relative hypointensity right




A certain proportion of ischaemic strokes will undergo haemorrhagic transformation
(HTI). The exact frequency with which this occurs is unclear, as how often it is found
depends upon the timing and frequency of scanning. In one study in which patients
underwent repeated scanning, it was found that a proportion of ischaemic strokes had
developed haematomas radiologically indistinguishable from PICH78. This raises the
concerns that if patients are not scanned immediately upon presentation, a proportion
may be incorrectly labelled as having PICH, and HTI may be missed if patients are not
scanned repeatedly. The mechanism ofHTI is also unclear; post-mortem studies in the
1950s suggested that the primary cause was reperfusion of damaged vessels following
the break-up of an occluding embolus79. However, animal studies from around the
same time observed that HTI was more severe if occluded vessels did not re-open, due
to the leaking of vessels around the periphery of the infarct80.
HTI is usually distinguished from a PICH by the lack of homogeneity of the
haemorrhagic area, which appears within or on the edge of a presumed infarct. On CT,
these patchy areas of increased density throughout an infarct (figure 12) can be confused
with islands of surviving brain tissue can give a similar picture to the naked eye. The
two can be distinguished by measuring the density in Hounsfield Units of the relevant
areas on the CT console60. Very earlyHTI can be difficult to distinguish on MRI, but it
becomes more apparent as more obvious paramagnetic breakdown products appear
(figure 12).
Figure 12. Haemorrhage transformation. Left: CT showing a heterogenous area of kyperdensity
surrounded by hypodense oedema (arrow). Right:MRIgradient echo sequence, showing irregular area of
hypointensity surrounded by relative hyperintensity (arrow)
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1.7 Summary
The brain is a demanding organ; its high metabolic rate means that it commands a
disproportionate amount of cardiac output in relation to its size and its reliance on
glucose metabolism renders it uniquely vulnerable to fluctuations in energy supply.
These fluctuations however, can be compensated for, with some degree of success by
cerebral autoregulation (altering CBF and CBV) and varying the OEF. Tissue ischaemia
occurs when these compensatory processes are overwhelmed, setting in motion a vast
array of molecular responses that continue for days after the initial event. Brain
ischaemia is a dynamic process; the final degree of tissue damage being determined not
only by the extent of reduction in CBF, but also the length of time over which it occurs
and the ongoing molecular environment. Similarly, intracerebral haemorrhage is not a
static event, but a dynamic process that evolves and regresses over days and weeks.
The clinical signs and symptoms produced by a stroke can be readily identified by
clinicians, but are not specific enough to allow a very accurate diagnosis, either of stroke
versus non-stroke, or ischaemic stroke as opposed to intracerebral haemorrhage.
Neuroimaging with either CT or MRI improves the accuracy of diagnosis. Ischaemic
stroke and intracerebral haemorrhage produce changes on imaging that evolve with
time, and which become more or less easy to distinguish from normal brain tissue and
each other depending upon the method and timing of scanning.
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2 The Importance Of Neuroimaging In Making An Accurate
Diagnosis In Patients With Stroke Symptoms
2.1 Introduction
Conditions other than stroke can present with stroke-like symptoms
There are a number of intracerebral conditions that can present with symptoms similar
or identical to those seen in stroke. Tumour, encephalitis, abscess, demyelination or
degeneration can all provoke focal signs that can be difficult to distinguish from
ischaemia. Certain symptoms or signs, such as memory loss may imply a focal cerebral
impairment but can be caused by diffuse cerebral dysfunction. Even lesions outside the
brain such as vestibulitis or extra-ocular muscle dysfunction can confuse.
Differentiating such conditions from a stroke on clinical examination can be difficult.
Accurate determination of the pathological cause of stroke requires
neuroimaging
Distinguishing the pathological cause of stroke (i.e. ischaemic stroke or intracerebral
haemorrhage, ICH) on clinical judgement alone is also difficult. Typical but not specific
features of ICH such as headache, vomiting, early sedation and reduced consciousness
tend to reflect a rapid rise in intracranial pressure and are associated with large
haemorrhages. Cerebral infarction may cause similar symptoms and signs, and smaller
haemorrhages may have none of these symptoms. One study of a hospital population
found the initial bedside diagnosis of physicians to be accurate in only 69% of cases
examined1. To aid the clinician in the distinction of ICH, scoring systems were
developed. These made use of the presence or absence of factors found to be
associated with patients with known ICH. Two of the most well known examples are
the Allen probability guide (also known as Guy's Hospital Score)2 and Siriraj3 score
(appendix II), and are an improvement on clinical judgement alone. Using the Allen
guide improved clinician's accuracy in correctly distinguishing ischaemic stroke from
ICH from 84% to 90%2. The sensitivity of a Siriraj score of greater than one (for
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diagnosis of ICH) was 89.3%3. However, these scores are much less accurate when
used in a stroke population other than the one from which they were derived4. In one
study, the sensitivity of the Allen Score (using a cut-off of greater than 24 to indicate a
high likelihood of haemorrhage) dropped to 31% and the sensitivity of a Siriraj score of
greater than one, to 48%5. The gold standard against which these scoring systems were
compared when externally validated, was CT scanning.
The accuracy of these scores will have been compromised by the bias towards more
severe stroke seen in the populations from which they were derived. Hospitalised
patients were used, some of whom had their diagnosis confirmed at post mortem. As
CT scanning has become more available, the frequency of minor ICH has increased6,
and with it the realisation that patients with ICH won't necessarily present with severe
symptoms4. Therefore, for accurate determination of the cause of stroke, neuroimaging
is required. However, because of the limited amount of time that haemorrhage is visible
on CT (see chapter 1), it is vital to scan patients early after the stroke onset particularly
to avoid overlooking small haemorrhages.
How accurate are epidemiological estimates for the incidence of ICH and
ischaemic stroke?
Epidemiological studies of stroke incidence commonly attempt to determine the relative
proportions of ischaemic stroke and ICH. The data accrued from such studies are then
used in a wide range of Health Economics and research settings. There have been
numerous studies of stroke incidence, both hospital and community-based. Hospital-
based studies will provide an underestimate of incidence unless all patients with stroke
are admitted, and it is not possible to be sure that all cases are admitted without looking
in the community. Therefore, hospital-based studies cannot accurately measure
incidence in a population. The International Stroke Incidence Collaboration identified
comparable community incidence studies, mostly from the 1980's and early 1990's, and
found that between 73 and 86% of strokes were due to ischaemic stroke, between 8 to
15% to ICH, and one to five percent to subarachnoid haemorrhage7. No attempt was
made in these studies, to distinguish primary intracerebral haemorrhage from
haemorrhagic transformation (HTI). It can be difficult to distinguish the two and their
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relative frequency may vary depending upon timing of scanning8. Hospital admission
rates varied considerably between included studies; in the Oxfordshire Community
Stroke Project9 (OCSP), the admission rate was 55%, whereas in SEPIVAC10, in Italy
the admission rate was 85%.
Some studies included an 'unknown' category for cases where the cause was uncertain,
usually because the patient had not had a CT scan, or post mortem if they had died.
The methods used in these studies to diagnose the cause of the stroke varied though all
used brain CT scanning to some degree. However, the precise use of CT scanning (the
proportion scanned, within what time interval), and the influence this might have had
on the proportion of strokes diagnosed as ischaemic stroke or ICH has not been
reviewed.
Systematic reviews of studies of the proportions of stroke mimics found in
populations presenting with stroke symptoms, and the effect that scanning
methods may have on the results of community-based stroke incidence studies
To investigate these issues further, I performed two systematic reviews:
• To determine the potential proportion ofnon-strokes in a population presenting with stroke-like
symptoms. There are studies (with varying primary aims) that have documented the
proportions of stroke mimics in populations of patients presenting with stroke
symptoms. In general the gold standard by which the final diagnosis was made was
neuroimaging. Some assessed the ability of different populations of clinicians,
ranging from paramedics to neurologists, to be able to diagnose stroke accurately.
These studies were analysed for the range of conditions that can mimic stroke, the
proportions of a stroke population that they represent, and the relative importance
of neurological training in making a stroke diagnosis.
• To determine the effect of scanning methods on the results of corrmunity-based stroke incidence
studies. In order to determine the influence that neuroimaging may have had on the
documented incidence of ICH and ischaemic stroke, I performed a systematic
review of community-based studies that aimed to determine the incidence of stroke
and its pathological subtype. The scanning methods in these studies were examined,
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in order to analyse their impact upon the estimate of the proportion of all strokes
due to ICH.
2.2 Methods
2.2.1 The proportion of stroke mimics in populations of patients
presenting with stroke
Search strategy
In order to identify studies for both systematic reviews, electronic searches of the
medical databases, MEDLINE and EMBASE were performed. To make the searches as
inclusive as possible, an extended search strategy was used to identify articles relevant to
stroke (appendix III). This strategy, pioneered by the Cochrane Collaboration Stroke
Research Group11 for the identification of randomised controlled trials, identifies more
relevant references than a standard search that uses subject headings and specific text
words. Although this strategy has not been used to identify observational studies, I used
it as a starting point to maximise the number of references captured.
Data pertaining to the proportion of stroke mimics in a population were present in
studies with differing primary purposes, so a number of searches were undertaken. In
the electronic searches, title and text words for 'diagnosis' were added to the Cochrane
Library extended stroke strategy. A separate search using title and text words for
'timing' and 'delay' was also performed, as studies pertaining to the timing of admission
of patients with stroke symptoms to hospital, with reference to the potential delivery of
hyperacute stroke treatment occasionally contained relevant data. Abstracts of
conference proceedings concerned with time of arrival of patients with stroke
symptoms to hospital were identified and followed-up. Stroke incidence studies
identified for the review on scanning policies were also studied.
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Inclusions
Studies of specific populations of patients presenting with stroke symptoms, that
documented both the initial and final proportions of patients with the diagnosis of
stroke (compared with non-stroke) and details of the nature of stroke mimics were
included. Also included were studies that documented values for the final proportion of
true strokes in a population presenting with stroke symptoms, and where it could be
determined which health professional made the first clinical diagnosis were included.
Data extraction
Data were extracted on: the purpose and size of study, the profession of the person
making the initial clinical diagnosis, the gold standard by which final diagnosis was
made, the proportions of the study population with final diagnosis of non-stroke,
ischaemic stroke or ICH, values for sensitivity and specificity of diagnosis of stroke
compared to non-stroke, and ischaemic stroke compared to ICH. Data were analysed
with simple descriptive statistics. The mean value for sensitivity of diagnosis for
different health professionals was determined with 95% confidence intervals. The
studies in which Emergency Physicians had access to CT results were not included in
these calculations.
2.2.2 Scanning policies in stroke incidence studies
Search strategy
MEDLINE and EMBASE were searched from January 1980 to April 1999. To the
Cochrane Library extended search strategy the following text words were added: 'stroke
register, stroke registry, incidence, community' and subject heading 'incidence'. The
electronic search went no further back than 1980 because, although CT was clinically
available before this time, its use in community incidence studies was very limited. I
also examined reference lists and had discussions with other interested investigators,
including the International Stroke Incidence Collaboration.
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Inclusions and exclusions
All community-based stroke incidence studies in which the actual proportion of
ischaemic stroke and haemorrhage were reported were included. Hospital-based studies
were excluded, as were studies that did not report the frequency of ICH separately from
ischaemic stroke (i.e. just reported all 'stroke'), studies that documented either ICH or
ischaemic stroke only, or case fatality data only.
Data extraction
Data were extracted on year of publication and sample size of each study, the method of
diagnosing the pathological cause of stroke, use of scanning, the proportion with
ischaemic stroke or ICH, and any information on patients not scanned. Data were
entered into an Access database and analysed with descriptive statistics. Patients with
subarachnoid haemorrhage were excluded from both the denominator and numerator,
because although there may be patients with overlapping symptoms, this condition is
generally distinct from stroke due to infarction or intracerebral haemorrhage.
2.3 Results
2.3.1 The proportion of stroke mimics in populations of patients
presenting with stroke
Electronic searches captured 3794 references, and their abstracts were scanned for
relevant studies. Seventeen studies were identified that included data on the proportion
of stroke mimics in a population presenting with stroke (table 1). The total number of
patients presenting with stroke symptoms was 9316, and the median study size was 411.
The studies varied widely in their premise; seven (6228 patients) were stroke incidence
studies, in which the primaiy aim was not to determine the accuracy of the referring
clinician, rather to identify all strokes in a defined population 9;10;1246; seven (1982
patients) examined the accuracy of diagnosis of various professionals concerned in the
management of patients with acute stroke20;21l46 5°; three (1046 patients) were primarily
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concerned with the process of acute stroke care delivery17"19. Only in studies concerning
the accuracy of Emergency Physicians were CT results available at first point of
contact20121. Final diagnosis was made by a Neurologist or Physician with an interest in
stroke in fourteen studies, and unspecified in the remaining three. The proportion of the
study population that was eventually diagnosed as having a condition other than stroke
varied from one to 49%. The conditions identified that could mimic stroke were
numerous, the commonest conditions included intracerebral neoplasm (primary and
secondary), infections and subdural haematoma (table 2).
Excluding stroke incidence studies, the mean sensitivities of stroke diagnosis for
different groups of health professionals at first point of contact with the patient with
stroke symptoms were as follows: paramedics 74.9% (95% CI 68.8-81.0%); General
Practitioners 87.7% (95% CI 84.7-90.8); and Emergency Room personnel 71.1% (95%
CI 68.6-73.6%).
2.3.2 Scanning policies in stroke incidence studies
Included studies
Electronic searching captured 1903 references, and their abstracts scanned for relevant
studies. 49 studies were examined, 25 studies of which met the inclusion criteria (table
3). One included study specifically excluded subarachnoid haemorrhage22. 23 studies
(92%) included a category where the cause of stroke was 'undetermined'. In 12/23
studies (48%), 'undetermined' referred only to patients who did not undergo
postmortem or scanning at any time. In the remaining 11 studies, patients could be
categorized as ischaemic stroke, ICH or 'undetermined' even if no scan or postmortem
had been performed, i.e. they were classified on clinical judgement alone. This was also
the case for the two studies23;24 that classified all patients as either ischaemic stroke or
ICH. Two studies used the Allen score as a diagnostic aid10;25.
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Documented details of scanning policies
In the included studies, the details of scanning rates, times of scanning and exclusions
varied immensely; 5/25 (20%) studies gave no scanning details at all26"30. Of the 20 that
did give details, the proportion of patients scanned (or who had a postmortem) varied
from less than 30% to approaching 96% (figure 1). Although these 20 studies indicated
the proportion of patients scanned, only 13/25 (52%) mentioned the time interval from
onset of symptoms to CT scanning (figure 2). Information on timing of scanning was
documented in a number of different ways; one study gave a value for the mean time
interval from onset of symptoms to scanning for those patients who underwent
neuroimaging31, and two studies gave the median time interval from symptoms to
scanning14;32. The majority of studies, documented the proportion of patients scanned
within a certain time interval, ranging from seven days24;33;34, to 21 days35 and 30
days10;12;15'16'25,36. In no study was it explicit exactly what proportion of patients were
scanned when (i.e. within one week, two weeks, three weeks after stroke) making it
impossible to get a complete picture of the overall accuracy of the diagnosis of
ischaemic or haemorrhagic stroke.
In the nine studies that provided the information, patients treated at home, those who
died very early after their stroke, and the elderly were the groups most likely not to be
scanned at all (table 4). In the few studies which specifically mentioned an age barrier,
'elderly' was greater than 75 years.
42
Figure 1. Stroke incidence studies ranked according to proportions ofstrokes scanned overall (point
estimates ofPICHwith 95% confidence intervals). Note: scans may have been greater than two




























Figure 2. Stroke incidence studies ranked according to speed of scanning following onset of stroke
symptoms (point estimates ofPICHwith 95% confidence intervals). Note: not all patients scanned































Estimation of the 'true' incidence of PICH
The proportions of subjects defined as having PICH varied widely. Also, it is very likely
that some of the patients not scanned, or scanned late after stroke and were diagnosed
as ischaemic stroke, actually had PICH. However, it was impossible to determine from
the majority of studies how many patients this bias might have affected. Therefore, to
attempt to estimate what effect any underdiagnosis of PICH might have had on the
observed ratio of PICH/infarct, a 'best' and 'worst' case scenario was estimated. To do
this, only studies that scanned more than 30% of patients were used. In the 'best' case
scenario, it was assumed that no patients in the uncertain (i.e. unscanned) category had
PICH and in the 'worst' case scenario that all patients in the uncertain category had
PICH, as well as those actually classified as PICH. We calculated the mean proportions
per study (best and worst) and 95% confidence intervals. The mean study sample size
was 529 and the proportion of PICH ranged from an estimated 13 to 25% (95% CI, 10
-29%).
2.4 Discussion
Not everybody presenting with stroke symptoms is having a stroke
The primary purposes of studies including data on the proportion of stroke mimics
found in a population of people presenting with stroke symptoms varied from
documenting stroke incidence, to analysis of health professional accuracy, to examining
stroke process. This variation may contribute to the wide range of values for
proportion of stroke mimics reported. General physicians seemed to be better at
making a correct diagnosis than paramedics and emergency room personnel, although
confidence intervals were relatively wide. What these studies do highlight is that
diagnosis by clinician alone, without a corroborative scan, will be incorrect a significant
proportion of the time, and this proportion is less when scan results are available20. If
(as with thrombolysis) time to presentation to the acute stroke team is important, who
makes the first referral is relatively immaterial.
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Scanning policies in stroke incidence studies are not comprehensive
No community-based study of stroke incidence achieved a 100% CT scan rate within a
time-frame which would definitely allow distinction of PICH from ischaemic stroke (i.e.
within one week, see chapter 5.3). In general, studies either scanned quickly enough but
scanned relatively few patients, or scanned more patients but too late to identify ICH
reliably. It is therefore very likely that the incidence of ICH has been underestimated,
particularly the incidence of small haemorrhages, but there is no information to
determine by what degree. Our 'best and worst' estimate gives some indication of the
potential scale of the problem.
Why do scanning policies vary so widely?
These are community-based studies, some of which made exhaustive attempts to
capture all people in the region under scrutiny who experienced stroke-like symptoms.
Some studies were performed as far back as 1980, when being able to distinguish
whether a stroke was caused by ischaemia or haemorrhage made no difference to the
management of the patient. Access to CT for the investigation of stroke has improved
with time, but not uniformly throughout the world and this paper includes studies
where access is still difficult (although Western European studies have little excuse).
Early, comprehensive scanning may be impractical or unaffordable, and post-mortem
might be socially unacceptable. However, the fact remains that in those patients who
did not undergo CT scanning within an appropriate time frame, or post-mortem, it is
not possible to be unequivocally sure as to the pathological type of stroke.
Could it be that PICH is being overdiagnosed?
Very early haemorrhagic transformation (HTI) of a cerebral infarct can mimic ICH8 but
from the studies we reviewed there is no way of knowing how often this might have
been the case. The cause of HTI is unclear, as is the prognosis of patients with HTI.
Patients with HTI may respond differently to acute treatment and secondary prevention
(with antithrombotic drugs or anticoagulants) than those with either ischaemic stroke or
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ICH. Without more accurate categorisation of the condition by early scanning, it will be
impossible to address these issues.
Bias in scanning policies
It is more likely that the proportion of stroke due to PICH is being underestimated
rather than overestimated, due to late scanning, and the bias introduced by the
conspicuous lack of scanning in those patients managed at home, dying early or the
'elderly'.
Patients with milder strokes may not be seen at hospital at all or not until many days or
even weeks have passed, well beyond the time when CT can reliably differentiate
haemorrhage from infarct. On the basis of existing evidence, these patients are
generally considered less likely to have had a ICH than the more severe strokes that are
admitted to hospital earlier43, and are therefore managed as ischaemic strokes. This
assumption may not be correct, as ICH can be detected in patients with very mild
strokes, and even in patients with transient ischaemic attacks if scanned soon after
symptom onset37'6 (and chapter 5). Also, as the use ofCT in stroke has increased, so has
the incidence of smaller, more benign ICH6.
From what we do know about the outcome of patients with ICH, albeit from studies
that may have missed milder strokes, it seems that the more severe the stroke, the more
likely it is to be haemorrhage38. Therefore, in patients with severe symptoms (too sick
to scan), there may be an over-representation of ICH.
The median age for stroke to occur is 72 years, thus roughly half of all the strokes in a
population may not have been scanned in incidence studies that failed to scan the
elderly. The incidence of amyloid angiopathy, a risk factor for ICH, increases with age39,
and increasing use of magnetic resonance imaging has revealed that it is not uncommon
to find evidence of old, apparently asymptomatic haemorrhages in the brains of elderly
patients4441. It may be that older people are particularly at risk of ICH, and thus there
may be an over-representation of ICH in this group not being scanned in incidence
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studies. One cannot assume that the proportion of ICH to ischaemic stroke remains
constant across all ages.
Is scanning really necessary for population studies?
It is important to collect information on all strokes, especially in the developing world as
there is so little information available. Therefore, in this context, you could argue not to
bother with neuroimaging and just collect data on 'all strokes'. Accuracy could be
augmented by the use of clinical scoring systems, which are at least better than clinical
judgement alone in the diagnosis of severe strokes due to haemorrhage. However, in
the developed world, where it is increasingly essential to distinguish infarct from
haemorrhage, it seems inappropriate at the present time for any future incidence studies
not to ensure that they use CT or MRI to determine the actual cause of stroke as
precisely as possible across all age groups and severities of stroke.
Conclusion
Conditions that mimic stroke may have very different management strategies from true
stroke. They are not uncommon, and clinicians will not identify them accurately all of
the time. The advent of thrombolysis highlights the problem of increasingly
sophisticated (and potentially dangerous) management strategies that demand levels of
diagnostic accuracy that clinicians are not capable of achieving without neuroimaging.
On the evidence of community-based stroke incidence studies, ICH has probably been
underdiagnosed especially in mild strokes, the elderly and those who died soon after the
event. Comprehensive scanning in community-based studies is extremely difficult to
achieve. There are real and practical hindrances to widespread early scanning and these
issues continue to result in less than ideal scanning strategies42"45. However, because of
the weakness of scanning policies, we cannot really be sure precisely what proportion of
stroke in various countries is due to ICH rather than ischaemic stroke, and as a
consequence, any research relying on data from them, such as that into the genetics of
stroke, could be inherently flawed.
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Table 1. Studies documenting data on the proportion of patients with a final diagnosis of non-stroke in
populations presentingwith stroke symptoms
Study Date of
publication






OCSP't 88 1818 Community General practitioners 47.8 (first ever
stroke)
64.1 (TIA)
SEPIVAC10t 91 379 Community General practitioners
Hospital physicians
1.1
Perth12 93 883 Community Physicians & nursing
home supervisors
24.9
Belluno15 95 858 Community Physicians & some
neurologists
2
Inherred13 97 1169 Community Multiple sources 10.5
Erlangen 16 98 574 Community General Practitioners 1.7
Arcadia14 99 607 Community General practitioners 6
Zweifler46 98 71 Community Paramedics 6
Kothari47 95 86 Community Paramedics 28
Wester17 99 834 Community Emergency room nurse 36.9
























Horn49 97 229 Community General practitioners 3
Martin50 97 565 Neurovascular
clinic
General practitioners 27 (stroke)
40 (TLA)







tPatients in both studies were seen as soon as possible, often prior to scanning by a stroke physician or
neurologist, and excluded if thought not to have had a stroke.
"'Results of CT available
"'"'Results of CT available in 87%
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Table 2. Conditions presenting with stroke like symptoms and the ranges of their relative frequency in
the stroke populations identified
Final diagnosis Proportion of total stroke
population (%)
Study reference
Primary brain tumour 0.3-2.9 9; 10; 12; 14; 16; 17;21;35;46;48;51
Seizure 0.3-8.5 12;17;18;20;21;35;46-48;50;51
Toxic-metabolic state 0.2-3.9 12;17;18;20;21;46-48;51
Subdural haemorrhage 0.3-1.9 9; 10; 12; 14; 16; 17;21 ;48
Systemic infection 0.5-9.3 21;35;47;48;52
Cerebral infection 0.2-1.7 12; 14; 16;20;48;51
Migraine 0.4-3.0 12; 14;20;35;46;50;51
Vertigo/vestibular 0.2-4.0 12;20;21 ;35;48;50;51
Syncope 0.2-8.5 12;17;18;20;21;47
Psychogenic 0.2-2.7 12; 18;20;21;48;50;53
Peripheral neuropathy 0.5-9.3 14;18;20;21;47;51
Cerebral metastases 0.3-1.2 9;10;21;47
Transient global amnesia 0.1-1.2 12;47;48
Cardiac 0.6-2.3 35;47;48
Old stroke, nil new 1.0-1.5 17;18
Hypertensive encephalopathy 0.2-1.0 18;48
Dementia 0.5-0.8 14;48
Multiple sclerosis 0.2-1.7 14; 16;20;48;50
Total non-stroke 1-37
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Table 3. Included stroke incidence studies




Tilberg, Holland54 1980 152 52
Hisayama, Japan28 1981 203 0
Shibata, Japan26 1981 415 0
Beijing, China29 1983 130 0
Benghazi, Libya24 1986 329 80
Moscow, Russia27 1988 1538 0
Oxford, UK25 1990 675 89
Akita, Japan30 1990 109 60
Umbria, Italy10 1991 375 69
Dijon, France34 1991 984 89
Valle D'Aosta, Italy31 1992 254 82
Fredricksberg, Denmark55 1992 262 74
FINMONICA56 1992 3574 30
Malmo, Sweden33 1992 524 51
Perth, Australia12 1993 492 86
Warsaw, Poland22 1994 462 68
Brisbane, Australia57 1995 2056 31
Belluno, Italy15 1995 474 90
Rochester, USA23 1996 496 90
L'Aquila, Italy32 1997 819 89
Tartu, Estonia58 1997 829 32
Innherred, Norway35 1997 432 88
Erlangen, Germany16 1998 354 96
London, UK36 1999 612 88
Arcadia, Greece14 1999 555 82
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Oxford 89 1988 Rapidity of death, too ill to transfer, refusal,
65% of those not scanned > 75 years
Malmo 52 1992 'Mean age of those examined byCT less
than those not'
Perth 86 1993 Rapidity of death, too ill, too frail, refusal,
81% of those not scanned > 75 years
Brisbane 31 1995 'coma, lack of facility, too sick, age of the
patient, attitude of the physicians'
L'Aquila 89 1997 Very early death, refusal, exclusive home
care of very old patients, equipment
breakdown
Tartu 32 1997 'Of the 24% with no subtype (i.e. no scan),
76% treated at home'
Erlangen 96 1998 Of those treated at home, only 37.5%
scanned
London 88 1999 Community patients, died within 2 days
Arcadia 82 1999 Died early, very old, only home care, refusal,
equipment breakdown
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3 The Importance Of Diagnosis Of Intracranial Haemorrhage In
Patients Being Considered For Antithrombotic Treatment
3.1 Introduction
The dilemma of commencing antithrombotic treatment following intracranial
haemorrhage
Intracranial haemorrhage, either intracerebral or subarachnoid, is usually considered an
absolute contraindication to the use of antihaemostatic agents such as antiplatelet drugs
or anticoagulants. However, in clinical practice, there are many occasions when it is
appropriate to consider using these agents in patients with definite (or possible)
intracranial haemorrhage.
In patients with definite recent primary intracerebral haemorrhage (PICH), or previous
haemorrhage demonstrated with MRI, there may be an existing indication for
continuing antiplatelet or anticoagulant treatment such as ischaemic heart disease or
peripheral vascular disease, or a prosthetic heart valve. Or, a new indication for
anticoagulation may arise such as the development of a deep vein thrombosis,
pulmonary or peripheral embolus.
In patients with haemorrhagic transformation, there may be similar indications as above,
as well as the need to consider secondary prevention of stroke with antithrombotic
drugs if the patient is in sinus rhythm, or anticoagulants if in atrial fibrillation.
In patients with a recent stroke of unknown pathology, due to scanning not yet being
available1'2, there may be pressure to commence aspirin treatment as soon as possible if
the clinical features suggest that the stroke was unlikely to be haemorrhagic, even if
intracerebral haemorrhage has not been ruled out. This follows the results of the
International Stroke Trial and the Chinese Acute Stroke Trial which demonstrated the
benefit of aspirin if given within 48 hours of stroke onset3.
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A systematic review of the risks and benefits of antithrombotic drugs following
intracranial haemorrhage.
Meta-analyses of primary and secondary prevention studies of ischaemic stroke have
demonstrated a small but real risk of intracerebral haemorrhage following aspirin use4'5.
It would therefore, be helpful to know the effect of antithrombotic drugs or
anticoagulants on intracerebral haemorrhage in view of the need to consider their use.
To make an estimate how much harm (if any) might be caused by the administration of
antithrombotic drugs or anticoagulants to patients with recent intracerebral
haemorrhage, I undertook a systematic review of the available studies of this subject. In




I sought to identify all reports of randomised trials (or observational studies with a
concurrent comparison group), both published and unpublished, comparing antiplatelet
or anticoagulant therapy with control following recent (CT or MRI confirmed)
intracranial haemorrhage. The electronic databases MEDLINE and EMBASE were
screened from January 1980 to April 2001. I also searched the Cochrane Controlled
Trials Register, consulted reference lists in all articles found and cross-checked for
further references. I used the extended electronic search strategy for stroke (appendix
III) combined with medical subject headings: 'anticoagulant', 'anticoagulant agent',
'aspirin', 'acetyl salicylic acid', and text words 'aspirin' and acetyl salicylic acid. I
deliberately kept the search broad so as to avoid missing any relevant studies in this
obscure area. I searched no further back than 1980 because of the lack of readily
available CT scanning before this time.
Inclusion criteria
From the papers identified by the search, I included any randomised, quasi randomised,
or controlled clinical studies that described the use of antiplatelet drugs or
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anticoagulants following intracranial haemorrhage, due to subarachnoid or acute
intraparenchymal cerebral haemorrhage (which could be either primary intracerebral
haemorrhage (PICH) or haemorrhagic transformation of an infarct, i.e. any form of
bleeding inside the cranial cavity). Single case reports and studies with no concurrent
comparison group were excluded.
Data extraction
From included studies, myself and another reviewer independently and blind to each
other, sought and extracted data on the number and type of patients in the study, the
method of treatment allocation (e.g. randomisation), the number allocated to active or
control treatment, the type and dose of drug used, the duration of treatment (scheduled
treatment period), the timing of latest follow up, early (during the schedule treatment
period) and late (at the end of follow up) mortality, recurrent intracranial haemorrhage
and recurrent ischaemic stroke, and functional outcome at the end of follow up. For
recurrent intracranial haemorrhage, we sought the method by which the haemorrhage
was identified, whether it was symptomatic (i.e. temporally associated with a worsening
of neurological status) or not and the time when it occurred (i.e. within the scheduled
treatment period or by the end of follow-up). Any disagreements regarding data
extraction were resolved by discussion.
Additional individual patient data
Having identified that there were very few relevant studies in the literature, it was
apparent that the majority of data would therefore come from the two largest acute
stroke trials; the International Stroke Trial (1ST, n = 19435)6 and Chinese Acute Stroke
Trial (CAST, n = 21106)7, both of which investigated the use of antithrombotic therapy
in acute stroke. I had access to the data from these trials, both of which investigated the
use of antithrombotic therapy within 48 hours of acute stroke. About 17% were
randomised within six hours, and 33% within 12 hours. In these trials, patients could be
randomised before CT scanning if the clinical suspicion of acute intracerebral
haemorrhage was low and the CT scan was likely to be delayed. As a result, a small
proportion of patients who were randomised without a CT scan and started the trial
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treatment, were found to have had an acute intracerebral haemorrhage when scanned
subsequently (n = 773). These patients were described as having 'haemorrhagic stroke'
on the study's data forms. Prior to analysing the individual patient data, I also reviewed
the individual original 1ST record forms to extract any additional information on the
nature or timing of the intracranial haemorrhage and duration of trial treatment (i.e.
whether it was discontinued early or not).
Analyses
All trials were analysed together first of all (i.e. in patients with any intracranial
haemorrhage), and then I looked specifically at just intraparenchymal cerebral
haemorrhage and examined the effect of aspirin, heparin and other antiplatelet agents at
various early and late outcomes. Individual patient data were used when available.
RevMan software (as used in the Cochrane Database of Systematic Reviews) was used
to provide an estimate of treatment effect, using the Peto odds ratio (OR), fixed effects
method and 95% confidence limits. In view of the paucity of data, it did not seem
appropriate to undertake sensitivity analyses or attempt to give the studies a quality
score. Rather I focussed on ensuring that randomised studies genuinely used random




The search strategy identified 2779 papers on antithrombotic or anticoagulant treatment
or intracranial haemorrhage, but of these, only nine described a trial of antithrombotic
or anticoagulant treatment in patients with intracranial haemorrhage, and two described
retrospective observational studies. Of the nine trials (2043 patients) of antiplatelet
drugs (1997 patients) or anticoagulants (645 patients) given after acute intracranial
haemorrhage that were identified, including the 1ST and CAST6"14 (tables 1 and 2), eight
were randomised trials6"11'13'14, and one was a double-blind comparative study that gave
no information on whether treatment allocation was randomised or not12. However, on
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balance, it was decided to include it. An additional publication that added an extra
group of patients to a trial already included in the review11 was excluded13.
Characteristics of the included trials
The intracranial haemorrhage was due to subarachnoid haemorrhage in six trials (1224
patients)8"10'12"14, a mixture of acute intraparenchymal cerebral haemorrhage and
haemorrhagic transformation of cerebral infarction in two trials (773 patients)6'7, and
proven primary intracerebral haemorrhage in one (46 patients)12. In two of the
subarachnoid haemorrhage trials, the antiplatelet trial drugs were given after the
aneurysms had been surgically clipped to prevent rebleeding13'14; in one the antiplatelet
trial drugs were definitely started beftwe any clipping of the aneurysm10; and in three trials
there was no indication of whether the aneurysm had been securely treated or not prior
to starting the antiplatelet trial drugs8'9'12.
The duration of the scheduled treatment period ranged from eight days13 to three
months10, and three studies did not clearly specify the duration of treatment8'9'11 The
length of follow-up ranged from one7'13 to six6'9 months, and one study did not specify
length of follow-up11.
The primary outcome was (Table 1,2):
death in four studies: within the scheduled treatment period in two studies6'7, within the
follow-up period of six months in one study9; and the time period was not specified in
one study11; "neurological disability" measured by Glasgow Outcome Score in two
studies10'13; the Japanese Coma Scale in one study12 and was unspecified in two studies8,9,
functional outcome (i.e. Rankin or simplified equivalent) in three studies6'7'14; and
pulmonary embolus and deep vein thrombosis in one study11.
Three studies (466 patients - two in SAH and one in intraparenchymal cerebral
haemorrhage) systematically scanned patients at repeated time intervals8'11'12, but did not
define whether any recurrent intracranial haemorrhage that occurred had been identified
by routine scanning or because of clinical deterioration. Only two studies (773 patients)
documented that recurrent intracranial haemorrhage occurred during the scheduled
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treatment period6'7. The remaining studies did not specify whether recurrent intracranial
haemorrhage occurred within the scheduled treatment period or by the end of follow-
up. It was therefore assumed that any recurrent intracranial haemorrhages reported had
simply occurred at some point within the period of follow-up.
Additional individual patient data
The 1ST and CAST randomised 40541 patients, of which 7758 (19%) were first CT
scanned after randomisation. Of these patients, 773 (10%) were found to have an acute
intracerebral haemorrhage when scanned, of whom 398 patients had been allocated to
aspirin (375 to control), and 310 to heparin (289 to control). On review of the
individual 1ST forms, 58% of the intracerebral haemorrhages were said to be primary
intracerebral haemorrhage and 42% were said to be haemorrhage transformation of an
infarct. The trial treatment was stopped after the post-randomisation CT scan in 65%
of these patients who therefore only received a few doses of the trial treatment.
However, all 773 patients were included in the present analysis. We were not able to
compare outcomes in the patients who received only a few doses of antithrombotic
treatment with those who received more antithrombotic treatment because the sample
size was too small and confidence intervals already too wide to provide reliable
conclusions (see below). Nor unfortunately were we able to examine the effect of time
to randomisation on treatment for the same reasons.
Effect of antiplatelet treatment on outcome after acute intracranial haemorrhage
(i.e. subarachnoid or intraparenchymal cerebral haemorrhage) and after
intraparenchymal cerebral haemorrhage alone.
All recorded deaths
In patients with any acute intracranial haemorrhage (1997 patients), the odds ratio for
death among patients allocated to antiplatelet treatment compared with control was 0.85
(95% CI 0.63 to 1.15) (figure 1).
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In patients with just intraparenchymal cerebral haemorrhage (773 patients), the OR for
death among patients allocated to antiplatelet treatment compared with control was 0.96
(95% CI 0.62 to 1.50) (Figure 1).
Recurrent intracranial haemorrhage
In patients with any acute intracranial haemorrhage, the odds ratio for recurrent
intracranial haemorrhage among patients allocated antiplatelet treatment compared with
control was 1.00 (95% CI 0.73 to 1.37) (figure 2).
In patients with just intraparenchymal cerebral haemorrhage (773 patients) the odds
ratio for recurrent intracranial haemorrhage among patients allocated to antiplatelet
treatment compared with control was 1.02 (95% CI, 0.58, 1.8).
Functional outcome
Data on functional outcome at six months were only available from the 1ST5 (599
patients). Although data on functional outcome were collected in CAST7 this was only
at one month and therefore was regarded as too short term. The odds ratio for being
dead or dependent among patients with intracranial parenchymal haemorrhage allocated
to antiplatelet treatment compared with control was 0.68 (95% CI 0.46 to 1.02).
However, 65% of patients allocated to aspirin treatment received no more than a few
doses of aspirin, so this does not reflect the effect of full dose aspirin. In any case, 42%
were considered to be haemorrhagic transformation of an infarct in which case aspirin
may have had some beneficial effect.
Effect of anticoagulant treatment on outcome after acute intraparenchymal
cerebral haemorrhage
There were no data on the use of anticoagulants after SAH.
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All recorded deaths
Among patients with any acute intraparenchymal cerebral haemorrhage (645 patients)
comparing these allocated to heparin with control, the odds ratio for death in the
scheduled treatment period was 0.96 (95% CI 0.38 to 2.40) (figure 3). For the 599/645
patients from the 1ST included in this analysis, the heparin was stopped after a few
doses in 65% on discovering the intracranial haemorrhage.
Recurrent intracranial haemorrhage
Among patients with acute intraparenchymal cerebral haemorrhage, the odds ratio for
recurrent intracranial haemorrhage among patients allocated heparin compared with
control was 2.0 (95% CI 0.86 to 4.70) (figure 4).
Functional outcome
Among patients with acute intraparenchymal cerebral haemorrhage, data were available
only from the 1ST for functional outcome at six months (n = 599)6. The odds ratio for
being dead or dependent among patients allocated heparin compared with control was
0.97 (0.66 to 1.43).
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Data from observational studies
Two observational studies were also identified (table 3), both concerning patients with
subarachnoid haemorrhage. One retrospectively examined the effect of heparin given
during surgery if a neurological deficit occurred, or after surgery as prophylaxis,
compared with patients with subarachnoid haemorrhage who were not given heparin16.
In this study, there were less patients with recurrent haemorrhage in the group treated
with heparin (9.6% versus 26.1% for controls). The study by Juvela retrospectively
assessed the use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
prior to and after subarachnoid haemorrhage17. Since NSAID's primary mode of action
is not antiplatelet, we restricted our analyses to the aspirin and no aspirin groups. There
were fewer deaths and fewer recurrent haemorrhages among patients receiving aspinn
than among controls (Table 3).
3.4 Discussion
What are the limitations of these data?
To the best of my knowledge, this review summarises the totality of the evidence from
randomised trials or studies with a comparative control group on antithrombotic or
anticoagulant drugs after acute intracranial haemorrhage.
There are many limitations to these scant data. Sixty percent of the data on antiplatelet
agents came from patients with subarachnoid haemorrhage rather than intracerebral (i.e.
brain parenchymal) haemorrhage, and at least some (it is not clear from the papers how
many) of those patients had received definitive treatment of their aneurysm to prevent
rebleeding before starting the antiplatelet trial treatment. The subarachnoid
haemorrhage data may be of limited relevance to patients with primary
intraparenchymal cerebral haemorrhage. For the data on patients with intraparenchymal
cerebral haemorrhage, the extent to which conclusions may be drawn on the safety of
antithrombotic treatment are limited by the fact that in the majority (65%), the aspirin
or heparin was discontinued after only a few doses upon discovery that the stroke was
haemorrhagic. Therefore the data do not describe a situation where full dose aspirin (or
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heparin) was given to patients with intraparenchymal cerebral haemorrhage either for
two weeks in the acute stage, or indefinitely as might happen in error if a stroke was
assumed to be ischaemic on clinical grounds without exclusion of haemorrhage by
scanning. Almost all (94%) of the data on the effects of heparin in acute
intraparenchymal cerebral haemorrhage come from the 1ST - these were a highly
selected group of patients in the sense that it was only possible to randomise patients
into the 1ST prior to CT scanning if the local investigator felt that intraparenchymal
cerebral haemorrhage was unlikely to be the cause of stroke on clinical grounds. Out of
7758 patients randomised prior to CT, only 773 (10%) turned out to have
intraparenchymal cerebral haemorrhage on CT. Thus this group of patients is not likely
to be representative of intracranial haemorrhage in general and conclusions must be
drawn with great caution.
How does this evidence help with clinical decision-making?
Despite these problems, some inferences of clinical value can still be drawn from this
information. For antiplatelet drugs, the point estimates of effect on death and recurrent
intracranial haemorrhage for patients with any intracranial haemorrhage are neutral or
favourable, though less so if just patients with intraparenchymal cerebral haemorrhage
are examined (the group relevant to haemorrhagic stroke). The available evidence
cannot rule out modest harm, but equally they are also consistent with moderate benefit.
The low risk of further intracranial bleeding in patients with intracranial haemorrhage is
consistent with the low intracerebral bleeding risk with these agents observed in other
settings, although the fact that 65% of patients discontinued treatment after only a few
doses is important. Thus, in certain situations, the use of an antiplatelet agent soon after
acute intracranial haemorrhage would be justified perhaps if the patient were at
particularly high risk of cardiac ischaemic events, as a result of a recent myocardial
infarction or had a history of unstable angina3. The data do not allow us to answer the
question about use of antithrombotic drugs in patients with a new ischaemic cerebral
event who have had a known intracranial haemorrhage at some point in the more
remote past, or about the long term effects in patients with recent intracranial
haemorrhage if required for prevention or treatment of some other vascular
complication.
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The risks associated with heparin were only assessed for subcutaneous, not intravenous
heparin, and only in patients with intraparenchymal cerebral haemorrhage. Whilst the
lack of effect of heparin on deaths from all causes was reassuring, the non-significant
trend to a doubling of the risk of recurrent intracranial haemorrhage with heparin is a
concern. Yet, patients with intracranial haemorrhage do develop indications for the use
of heparin such as symptomatic deep vein thrombosis (DVT). It would be useful to
know precisely the balance of risk and benefit of giving heparin, and whether the
reductions in venous thromboembolism are offset by an increase in intracranial
haemorrhage. Unfortunately, the available data do not answer this question reliably.
Do these data aid scanning policy?
These data support the policy, in centres where CT resources are limited and access may
be delayed, of 'start aspirin pending CT if acute intracerebral haemorrhage is unlikely on
clinical grounds', and 'stop the aspirin if the patient turns out to have a haemorrhage
when scanned', provided the CT scan can be obtained within a day or so of starting
treatment. The value of aspirin where CT scanning is not performed until five to seven
days later (or more) or not at all, is not assessed by these data. A policy of widespread
use of aspirin without prior imaging - a suboptimal policy - in places where CT
scanning is available is not supported by these data. In places where CT scanning is not
available at all, widespread use of aspirin among patients with a high probability of
having an ischaemic stroke (e.g. selected with a clinical scoring system such as the Siriraj
score18) may well be reasonable, as the population benefits of aspirin may outweigh the
risks. However, such a policy would require further testing and these data certainly
provide no more than modest support for such an approach.
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4 The Sensitivity Of CT And MRI In The Identification Of
Intracerebral Haemorrhage
4.1 Introduction
Distinguishing intracerebral haemorrhage from ischaemic stroke is important
Chapter 2 demonstrated how inaccurate stroke incidence studies may have been in their
identification of the proportion of patients with intracerebral haemorrhage (ICH).
Chapter 3 showed that, although data are limited, there is the potential to cause harm if
antithrombotic drugs are given acutely following ICH. Aspirin may cause relatively less
recurrent ICH than heparin following stroke1 but is associated with a small but definite
risk2'3. Therefore, it is important to distinguish ICH from ischaemic stroke prior to
commencing antithrombotic therapy or giving thrombolysis.
CT orMRI, which is 'better?
Although access to MRI in the investigation of stroke has increased, CT is still by far
the most common type of brain imaging used4'5. It is also likely to remain so for the
foreseeable future as, compared to MRI, it is more readily available and easier to
perform. Haemorrhage can be easily demonstrated on CT as soon as clinical symptoms
appear6. However, these changes remain visible for only a finite amount of time7'8. The
issue of sensitivity of CT in the identification of ICH is less whether it can distinguish
acute ICH from ischaemic stroke, but rather the length of time for which these changes
remain visible and reliably differentiated from ischaemic stroke. Haemorrhage remains
visible on MRI for much longer9 and also has advantages over CT in the lack of
exposure of the patient to ionising radiation, as well as the level of detail of anatomical
structure it is possible to achieve. However, MRI is contraindicated for patients with
pacemakers and certain metal implants, and having the patient enclosed in a tunnel can
render them claustrophobic and make monitoring difficult. MRI takes longer than CT,
which may be relevant when scanning a population of acutely unwell people. If MRI
can only be safely and reliably used by a small proportion of a non-selected stroke
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population, it can hardly be hailed as the imaging modality of choice, however
impressive the results in highly selected individuals.
Why perform a systematic review of imaging studies?
As mentioned in the introduction, diagnostic tests have not often been subjected to the
systematic review process. There is no existing systematic review of the use of CT or
MRI scanning in stroke. From the 1970's to the early 1990's, when CT scanning for
stroke was less available than today, there was perhaps less of a need for precise
estimates of its accuracy. Compared with nothing (or existing investigations such as air
encephalography), CT provided abundant information. However, CT is now more
available, stroke is a common problem, and there are now treatments which depend
upon knowing the cause of the stroke. The misuse of imaging could create a very
costly burden to the Health Services. The development of MRI poses similar but
possibly greater problems as increasingly sophisticated and seemingly advantageous
techniques are developed. I therefore undertook a systematic review of the use of CT
and MRI, either alone or in combination, in the identification of haemorrhagic stroke,
not only to look for details on sensitivity, but also assess the quality of the methodology
of the studies performed.
4.2 Methods
Search strategy
I performed an electronic search of the medical databases, MEDLINE from the 1966
to the present day (MEDLINE databases are broken down into time periods, and the
earliest time period is 1966 to 1974, which overlaps with the inception of CT) and
EMBASE from 1980 (which was as far back as it was possible to search) to the present
day. To an extended search strategy for stroke (appendix III) were added specific
search terms for accuracy, sensitivity and specificity, and for CT and MRI. Because
patients with haemorrhagic and ischaemic stroke present with the same symptoms and
were often studied together, the main search strategy was designed to identify studies of
ischaemia as well as haemorrhage. Conference abstracts were also scanned, and further
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studies were identified by examination of the reference lists of studies already found.
Preliminary searches specifically for the accuracy of scanning in ICH revealed very
limited data. Therefore, the inclusion criteria were deliberately broad, to encompass all
studies of the use of CT and/or MRI in humans with ICH. Case reports were
excluded.
Data extraction
The following data were extracted on:
• The size of study;
• Its primary purpose;
• Details of the patient population and stroke severity;
• Whether the study was prospective;
• Timing of scanning in relation to onset of stroke symptoms;
• In studies comparing CT andMRI, the timing of each type of scan in relation to
each other;
• Whether the order ofCT andMRI was random or not;
• Whether scans were read blinded to clinical details or other imaging; and any
data on sensitivity available.
Data were also collected on whether patients in the study had been examined by a
stroke physician or neurologist, (which was assumed to be the case if the study was
from a department of neurology or neurosurgery, even if there was no reference in the
text), compared to a more general population referred for imaging by clinicians with
less experience of stroke presentation. Any information on clinical feasibility and
acceptability of scanning (e.g. the number of patients unable to tolerate scanning, or
number of inadequate images) was noted.
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Data analysis
Included studies were entered into an Access database and assessed with descriptive
statistics.
4.3 Results
4.3.1 CT and the identification ofhaemorrhage
Included studies
1047 references pertaining to the accuracy of CT alone in stroke (haemorrhagic and
ischaemic) were captured, and their abstracts reviewed. Fifty-three studies (including a
total of 4491 patients) that were specifically concerned with ICH identified by CT were
identified (table 1). Studies in which both CT and MRI were performed at some stage
were analysed separately (see 4.3.3). Studies concerning inter-observer reliability of
image interpretation (some of which included ICH) will be addressed in chapter 6.
Twenty-four studies (1310 patients) described various characteristics of ICH in an
anatomically specific site (clinicotopography), merely documenting the scan findings in
groups of patients with similar clinical symptoms (often retrospectively identified).
Nineteen studies (2138 patients) attempted to predict prognosis following ICH, using
clinical or imaging parameters. Both of these groups of studies used CT uncritically as
the tool to identify and characterise haemorrhage(e.g. site, size, extension), and as such
provided no information on accuracy.
Studies concerning haemorrhage on CT at differing time-points
Six studies (819 patients) documented CT characteristics of haemorrhage at different
time points7,8'10"13. Two of these (623 patients) reviewed a population with acute ICH
and multiple scans within the first few days after ictus, looking for the proportion of
patients with haematoma enlargement10,11. One study (204 patients) found that 17% of
haematomas continued to expand after six hours, but that further enlargement after 24
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hours was rare10. The other (419 patients) found 14.3% of haematomas had expanded
between the first CT (within 24 hours of onset of symptoms) and second CT (within 24
hours of admission)11. Both used retrospectively collected data and scans were not read
blinded to each other, but they highlight the important point that one scan of an acute
haematoma is merely a snapshot in a dynamic process.
Two studies (160 patients) investigated residual lesions late after ICH. Initial scans
were within a week of onset of stroke symptoms and follow-up scans were over two
months afterwards. Between 17%12 and 27%13 showed no residual lesions at all. Areas
of hypodensity that would be indistinguishable from ischaemic stroke were found in
37%13 to 52%12. Focal calcification was found in 5%12 to 10%13. Slit-like hypodense
lesions were identified in 14%12 to 25%13 at the site of previous haemorrhage, but it is
not clear whether these are only found following ICH.
Two studies (36 patients) commented on the time-course over which signs of
haemorrhage could disappear. One study looking at small haemorrhages (less than
20mm, comprising 6% of their ICH population) performed follow-up scanning
between six days and three months in 8/31 (26%) patients. They found that 2/8 (25%)
were isodense within nine days of stroke7. The other study reported on five patients
with ICH (maximum diameter 33mm), identified as part of a community stroke
incidence study, in whom the haematomas had become isodense on repeat CT within a
few weeks of the original scan. The earliest repeat CT had been performed 13 days
after stroke, and it is possible that the haematomas may have become isodense earlier8.
Studies of haemorrhagic transformation
One study (15 patients) reported a case series of patients with ischaemic stroke who
had undergone neuroimaging twice within the first 24 hours, the first scan negative and
the second scan positive for haemorrhage14. They raised the issue that early
haemorrhagic transformation may present as primary intracerebral haemorrhage if
patients are not scanned very early. Unfortunately, they did not document the
proportion of patients in their population that this group represented.
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Increasing use ofCT and the incidence of ICH
Two studies not based on case series were also identified that investigated the incidence
and outcome of cases of ICH in relation to the use of CT. One study found that the
rising incidence of ICH in their institution paralleled their use of CT15, and both found
that case fatality of ICH dropped with increasing use of CT15'16, i.e. smaller, less deadly
ICH was being identified with increased frequency as more patients were being scanned
with CT.
General methodological details
Methodological detail in the majority of these studies was poor; although in 36 studies
(71% of total identified) patients were assessed by a stroke physician or neurologist,
information on stroke type and severity were very limited, as was timing of scanning in
relation to onset of stroke symptoms. Only two studies blinded scan readers to clinical
history17 or other imaging14. Only six studies (12%, 656 patients) documented that
cases were collected prospectively or consecutively7'17"21; the majority of studies used
retrospectively collected data. There were no other standards used (e.g. post-mortem)
against which CT could be judged, although admittedly this would have introduced a
bias towards the more severe strokes. There were no papers identified on CT alone
and ICH after 1998.
Summary of studies of CT and ICH
Acute ICH on CT is very characteristic and immediately visible but the only data on the
length of time these features last are anecdotal. No studies were found where the
primaiy purpose was to establish the sensitivity of CT in the identification of
haemorrhage at specific time points after stroke. There may be features characteristic
of previous haemorrhage on CT but there are no data on how specific they are, or how
reliably they can be interpreted. Increased use of CT has led to the realisation that ICH
can cause mild stroke or even transient ischaemic attacks22.
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4.3.2 MRI and the identification ofhaemorrhage
Included studies
2098 references were captured concerning MRI and stroke, either alone or in
combination with CT, and their abstracts were reviewed. Twenty-two studies (1512
patients) concerning MRI and ICH were identified (table 2). Eight studies (235
patients) concentrated on MRI alone in ICH. Four were technical studies23"26
investigating specific MRI sequences and their use in ICH, two of which (82 patients)
demonstrated the superiority of gradient echo (GRE) technique over other MRI
sequences in the identification of ICH 23'26. Five (47 patients) were descriptive case
studies, documenting the clinical characteristics and signs seen on imaging
(clinicotopography) of haemorrhage on MRI27"31. Six studies (427 patients), although
including a small number of patients with haemorrhage, were primarily concerned with
comparing CT andMRI in ischaemic stroke, and thus little information could be drawn
from these32"37. None of these studies documented numerical data on the sensitivity of
MRI for identification of ICH. In 14 studies (1239 patients), CT was also performed at
some stage.
4.3.3 Studies that directly compared CTandMRI
In only two studies (165 patients) were MRI and CT scanning performed at similar
times enabling some comparison of sensitivity to be made (table 3). One (published in
2000) investigated the incidence of haemorrhagic transformation in cerebral
infarction38, and the other (published in 1990) the sensitivity of both modes of scanning
in intracranial haematoma39. Imaging was performed in both studies 'acutely' (less than
two days), 'subacutely' (between two and ten days) and in the 'chronic' phase (over 10
days). In only one of the studies were images read blinded (to clinical details but not to
other imaging38). These studies suggested that in the acute phase, CT was more
sensitive in identifying haemorrhage and MRI was better in the chronic phase. One
study used specific blood-sensitive sequences (gradient echo)39. Neither study
mentioned the order in which scans were performed, or whether they were performed
on the same day.
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One small study (nine patients) that retrospectively compared CT and MRI in patients
with hyperacute ICH40 described how MRI demonstrated haemorrhage in all cases.
The main conclusion of the study was that acute haemorrhage could be detected on
MRI as easily as CT, which is generally held not to be the case. The methodological
weakness of the study (patients were retrospectively identified from an already highly
selected cohort, and images were read unblinded by stroke physicians highly trained in
MRI interpretation) make their conclusion impossible to extrapolate to a more general
stroke population.
MRI and asymptomatic haemorrhage
Five studies (653 patients) used MRI to investigate the incidence of previous
(asymptomatic) haemorrhage, as demonstrated by the presence of paramagnetic
breakdown products of haemoglobin41"45 (table 4). The study populations varied in age
and clinical history, and included patients with a history of ICH, ischaemic stroke and
also some with no history of cerebrovascular disease. Signs indicating asymptomatic
haemorrhage were identified in up to 66% and 36% respectively. In patients with a
history of ICH,MRI scans were performed 3 days to two years after the event.
General methodological details
14/22 studies (1119 patients) included patients that had been assessed by a stroke
physician or neurologist24'27"29'32"34'36"38'41'42'44'46. Only eight (43%) studies (755 patients)
reported any details on the case-mix of patients28;29;32"34;41;42;44. Eight (38%) studies (865
patients) gathered data prospectively32"34'37'38,41'43'44. Only five (23%) studies (643
patients) read scans either blinded to other imaging33 or clinical history32'34, or both38'44.




The only studies that directly compared CT to MRI in the detection of ICH were small
(138 patients in total), and had substantial flaws in their study method, making their
conclusions difficult to generalise to an unselected stroke population. There were no
studies investigating the length of time for which signs of haemorrhage persist on MRI
after stroke. There were no studies concentrating on the feasibility of MRI in an
unselected stroke population, or the acceptability of MRI for patients. No study gave
details of the absolute proportion of patients presenting to their hospital with stroke
symptoms who weren't scanned because MRI was unavailable, or in whom MRI was
deemed unsafe, or contraindicated.
4.4 Discussion
CT identifies ICH but it is not possible to derive its sensitivity
Published studies demonstrate that ICH on CT appears acutely as an area of obvious
hyperdensity, but the duration of its appearance is time-dependent. Even moderately-
sized haematomas can become isodense within 14 days8 and smaller ones in an even
shorter time7. After a few months, there may be little to see on CT, and even less that
is pathognomonic for previous haemorrhage12'13. Certainly no such signs in the region
of previous ICH have been assessed for specificity, and it was not possible from the
published studies to derive a value for the sensitivity of CT in the identification of ICH.
Also, two studies by the same team investigating inter-observer variability in the
identification of ICH on CT have shown that not all clinicians and radiologists were
equally proficient47'48 (see 6.3.1). Therefore, although it is likely that, in good hands, CT
can identify most, if not all ICH within a few days of ictus, the temporal changes
documented can confuse diagnosis, as can tissue calcification and luxury perfusion,
meaning that the sensitivity of CT is unlikely to be 100%. However, the difficulty of
finding an appropriate gold standard against which to judge CT in the acute phase of
stroke (MRI is likely to be more difficult to interpret in this phase, and post mortem
introduces selection bias towards the more severe strokes) may mean that determining
its sensitivity is an impossible task.
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Can we derive a sensitivity forMRI in the identification of ICH?
When MRI first became available, it was clear that identifying ICH was more
complicated than with CT, and a number of studies merely described the
clinicotopographical changes seen with different sequences. Certainly all sequences are
not equally sensitive, for example gradient echo (GRE) sequences (which are not
routinely used) have been shown to be highly effective in demonstrating ICH, and for
longer periods of time than CT23,43,44'49. However, the data on GRE sensitivity in
relation to routine structural imaging such as Tl or T2-weighted sequences, and other
specialised sequences such as FLAIR, are limited. Also, the data for how long ICH
remains visible on MRI is limited. There are data for the late MRI appearances of ICH
due to trauma (haemosiderin was still identified in 90% of scans, up to five years after
trauma50, but it is not clear whether the proportion of scans on which ICH remains
visible is the same in stroke patients. As radiologists have become more familiar with
MRI, studies have been published which demonstrate that it is possible to distinguish
haemorrhage, however early. This is useful work but falls short of allowing us to
quantify the merit ofMRI in relation to CT. The two studies that attempt to do so38'39
are therefore important, but sample sizes were small, and conclusions drawn far from
definitive. The additional problems encountered withMRI of patient acceptability and
contraindicated patients are barely addressed. The complete lack of robust data on
these subjects considerably weakens our ability to gauge the usefulness of MRI in
relation to CT in a non-selected stroke population.
Why has there been such a lack of interest in the sensitivity of CT (and MRI) in
ICH?
It may be due in part to the fact that from its introduction in the 1970's, CT was
embraced rather uncritically as the new gold standard. Certainly encouraging editorials
on the use of CT at the time left little doubt as to how important it was going to be to
clinicians11. In 1973, in the British Journal of Radiology, Ambrose stated that 'in the
overall investigation of cerebrovascular disease, computed tomography will without
doubt, come to be an invaluable means of distinguishing between haemorrhage and
infarction'52. It was certainly the case that CT delivered more information, less
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invasively than existing investigations such as air encephalography, angiography or
lumbar puncture53'54. For MRI, it may be that because it is still being used relatively
rarely in acute stroke5 its sensitivity is not yet seen as an issue. Also, for both CT and
MRI, the rapid improvements in scanner technology means the standards against which
techniques have to be compared are constantly shifting.
Scientific approach in published studies could be improved
As well as a lack of acknowledgement of the importance of the issue, there is the
concern that the paucity of data available may also be due to a general lack of scientific
approach in all but a minority of these studies. The majority of studies of CT orMRI
in the identification of haemorrhagic stroke are barelymore than elaborate descriptions
of the images of groups of highly selected patients. Although it is not difficult to see
why few studies judged imaging results by another objective standard, prospective study
design and blinding of imaging analysis are both extremely important and can easily be
addressed. The results of retrospective series of highly selected patients tell us little
about how an imaging technique would perform in a non-selected stroke population.
Conclusion
ICH is clearly visible on CT acutely but appearances are time-dependent. Identifying
ICH on MRI acutely can be more difficult but is possible, and signs of ICH remain
apparent much longer than on CT. Data on sensitivity of CT for the detection of
haemorrhage were not available and was extremely limited forMRI.
When there were few options in terms of scanning modalities available to the clinician
for the investigation of stroke, it was perhaps excusable not to have a thorough grasp of
their accuracy. However, this issue becomes increasingly important as the range of
available modalities increase. The dwindling of publications on the identification of
ICH on CT in the last two years when unanswered questions remain is also a cause for
concern. The clinical neuroimaging literature in stroke is now dominated by studies
concerning more advanced neuroimaging strategies (chapter 7). This suggests a trend
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to the publication of what is 'fashionable' rather than important and promotes the
argument that allocation of radiological resources should not be left in the hands of
clinicians and radiologists.
We have attempted to address some of the methodological issues raised in this chapter
in our own studies comparing CT and MRI. We also aimed to address some of the
questions raised in this chapter such as: what are the best MRI sequences for detecting
haemorrhage, and how much better are they? How long does haemorrhage remain
visible onMRI after ICH? In what proportion of patients with ICH do signs disappear
completely? Are there signs on the scans of such patients that will indicate
disappearance? How often does CT show signs of previous haemorrhage? What are
the relative sensitivities of CT and MRI in the identification of ICH at different time-
points? When does MRI become more useful in detecting ICH than CT? The results
of our studies are documented in the following chapter.
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Mizukami59 81 17 Clinicotopography
(putaminal)
No No
Weisberg60 81 12 Clinicotopography (multiple
PICH)
Yes No
Hunger Buhler61 83 108 Clinicotopography No No
Mayr62 83 100 Prognosis No No
Garde63 83 100 Prognosis,
clinicotopography
No No
Helweg Larsen64 84 8 Prognosis Yes No
Stein65 84 12 Clinicotopography (caudate) Yes No
Steiner66 84 37 Prognosis Yes No
Weisberg67 84 8 Clinicotopography (caudate) Yes No
Hung7 85 31 Prognosis (and serial CT
characteristics)
Yes No
Mori68 85 174 Clinicotopography (lacunar) Yes No
Weisberg69 85 50 Clinicotopography
(subcortical lobar)
Yes No
Tanaka70 86 25 Prognosis Yes No
Gates71 86 5 Clinicotopography Yes No
Carbonin72 86 5 Clinicotopography No No

























Weisberg77 88 18 Clinicotopography
(occipital)
Yes No
Iwasaki78 88 10 Clinicotopography (lacunar) No No
Weisberg79 89 25 Clinicotopography (parietal) Yes No
Astarloa80 89 114 Prognosis Yes No




Schutz21 90 100 Clinicotopography Yes No
Cerillo82 90 83 Prognosis Yes No
Weisberg83 90 100 Clinicotopography Yes No
Daverat20 91 166 Prognosis Yes No




Kreel13 91 120 CT characteristics (residual
lesions)
No No
Franke12 91 42 CT characteristics (residual
lesions)
Yes No
Franke19 92 157 Prognosis Yes No
Lisk84 94 75 Prognosis Yes No
Berlit85 94 326 Prognosis Yes No




Halpin17 94 38 CT characteristics (whether
to perform angiography)
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Passero86 95 112 Recurrent ICH (incidence) Yes No
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Lampl18 95 279 Prognosis Yes No
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* to other imaging
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Melhem23 98 32 Technical (gradient echo
sequence in haemorrhage)
No No No
Edelman24 86 16 Technical (modification of
pulse)
No Yes No
Gomori25 85 20 Technical No No No
Zimmerman3
0
88 37 Clinicotopography No No No
Shimizu31 92 4 Clinicotopography No No No
Liang26 99 50 Technical (gradient echo
sequence in haemorrhage)
Yes No No
Tanaka42 99 89 Asymptomatic haemorrhage Yes Yes No
Patel28 96 6 Visualise haemorrhage,
clinicotopography
Yes Yes No
Greenberg43 96 25 Asymptomatic haemorrhage Yes No No




Steinbrich39 90 129 Compare CT andMR Yes No No
Tanaka46 88 30 Compare CT andMR Yes Yes No
Schellinger27 99 9 Visualise haemorrhage Yes Yes No
Kinoshita41 2000 198 Asymptomatic haemorrhage Yes Yes No
Kwa44 98 221 Asymptomatic haemorrhage Yes Yes Yest
Salgado32 86 60 Compare CT andMR Yes Yes Yes**
















Mohr34 95 80 Compare CT andMR Yes Yes Yes**
* blind to other imaging, **blind to clinical history, f blind to both
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5 Changes Over Time In CT And MRI In The Detection Of
Intracerebral Haemorrhage
5.1 Introduction
More information is required on the relative merits of CT and MRI in the
identification of intracerebral haemorrhage
Chapter 2 demonstrated the potential inaccuracy of the proportions of stroke subtypes
reported in stroke incidence studies because of inadequate scanning. Chapter 3 highlighted
the potential harm that could occur if patients with intracerebral haemorrhage (ICH) are
given antithrombotic drugs. Chapter 4 highlighted how limited the data are on the
sensitivity of CT and MRI in the detection of ICH. It is evident that not enough is known
about the relative merits of CT andMRI in the detection of ICH.
Many questions remain unanswered by the existing literature. Small studies1,2 have
demonstrated that haemorrhage on CT will become indistinguishable from ischaemic
stroke within days. Were the patients in these studies rare exceptions? How representative
of the stroke population are they? MRI can identify haemorrhage at some time after
ictus3,4, but for how long after? Does MRI reliably identify all old haemorrhage? Detection
of old haemorrhage on MRI relies on the paramagnetic effects of the haemoglobin
breakdown product, haemosiderin, which is thought to persist in macrophages at the edges
of old haematomas indefinitely. However, pathological studies have demonstrated that not
all haematomas form haemosiderin3. Some, especially in babies, form haematoidin which
lacks magnetic properties, so theoretically would not produce the characteristic MRI
features of old haemorrhage. The proportion of haematomas in which this may occur
however, is unknown, as no systematic follow-up study has been performed in
haemorrhagic stroke either with pathology or MRI. Is the situation the same as for the
persistence of ICH after trauma6? How much better at detecting late haemorrhage is MRI
when directly compared to CT? If MRI is better, what difference does it make? Does
knowing a patient previously had an ICH alter their subsequent management?
96
The potential scale of the problem
According to the Stroke Association Survey (SAS), about 85% of patients with stroke
symptoms are admitted to UK hospitals7, thereby leaving 15% of patients with stroke
symptoms being dealt with in the community. This represents around 22000 people
according to SAS estimates, some of which will present to hospital as outpatients, and the
rest will be managed by their General Practitioners. These patients are likely to be
considered for aspirin or anticoagulation for secondary prevention. What proportion of
this population of perhaps 22000 people may have had ICH?
Prospective observational studies undertaken at theWestern General Hospital
To investigate the duration of signs of haemorrhage on MRI, the relative sensitivities of
various MRI sequences in the detection of haemorrhage, the proportion of patients
presenting with minor stroke who have had ICH, the relative sensitivities of CT and MRI
in the detection of ICH in such a population, the acceptability of each type of scanning for
the patients, and the effect of scan findings upon clinical decision making , we performed
two prospective observational studies.
• The late haemorrhage study. The aim was to investigate the proportion of haemorrhages
and the length of time haemorrhage remains visible on MRI following primary
intracerebral haemorrhage (PICH), and the relative sensitivities of various MR imaging
sequences. The hypotheses were that haemorrhage would persist in a similar
proportion of patients to that following head injury (about 90%6), and that not all MRI
sequences would be equally sensitive.
• The CTversusMRI study. The aim was to investigate the relative sensitivities of CT and
MRI in the detection of haemorrhage in a population of patients with milder stroke
symptoms, who often do not present until weeks after their event. The hypotheses
were: that a proportion of these patients would have had ICH, thatMRI would identify
more ICH than CT; that a proportion of patients would not tolerate MRI: and that
knowledge of a previously unknown ICHwould alter clinical decision-making.
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5.2 The Late Haemorrhage Study
5.2.1 Methods
Patient recruitment
Between February 1991 and February 1999, patients presenting with acute stroke
symptoms and in whom PICH had been identified on CT scan, were retrospectively
identified from the local stroke register. The stroke register at the Western General
Hospital in Edinburgh recruited inpatients from 1991 to 1999 and outpatients from 1994
to 1999. Patients were recruited consecutively as far as possible. Each patient was
examined prospectively by a Stroke Physician or Clinical Fellow in Stroke Medicine, and
underwent regular follow-up by questionnaire and telephone. Each case was discussed
with at least one other Stroke Physician for consensus on diagnosis. Patients who had had
the PICH at least three months prior to the start of the study in June 1999 and were still
alive, were invited to attend for a follow-up MRI scan. Before contacting patients directly,
permission was sought from their Stroke Physician and their General Practitioner. Any
patients with contraindications to MRI (e.g. pacemaker, intracranial aneurysm clip) were
excluded from the study. Approval for the study was obtained from the local ethics
committee.
Image acquisition
Patients who attended for MRI underwent routine structural imaging using an Elscint 2T
Prestige scanner. The following images were performed: Tl-weighted sagittal images (Tl-
WI, TR 500 ms, TE 12 ms, 1 NEX), fast spin-echo (FSET2, TR 5000 ms, TE 96 ms, 1
NEX) and spin echo T2-weighted (SET2), FSE proton density (PD, TR 2300 ms, 16 ms, 1
NEX), fluid attenuated inversion recovery (FLAIR, TR 6000 ms, TE 2000 ms, TI 126 ms,
1 NEX) and gradient-echo (GRE, TR 510 ms, TE 18 ms, 2 NEX) axial sequences. Slice
thickness was 5 mm, slice gap was 5 mm, 22.0 x 22.0 field of view, 256 x 128 matrix. Total
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scanning time was about 30 minutes (from the time the patient was put in the scanner to
coming out). See Appendix IV for a glossary of imaging parameter terms.
Image analysis
MRI images were read by one neuroradiologist, with no knowledge of the patient's clinical
signs (other than they had had a PICH somewhere in the brain, sometime in the past) or
baseline CT, or the time elapsed from the original event. MRI scans were read
independently of the original CT scan. MR sequences were read independently of each
other in batches of the same sequence, with a suitable interval of time (minimum of two
weeks) in between batches to prevent recall of the findings of other sequences. The
baseline CT scans were also retrieved and read after the MR images were read to identify
the presenting PICH.
Data recorded
From the baseline CT scan, the following were noted:
• The sites of the haematoma(s) (primary lesions);
• The estimated volume of haematoma (maximum length and width, multiplied by the
slice thickness (mm) and the number of slices on which the haematoma was seen);
• Any other findings (secondary lesions).
Lesions identified on follow-upMRI sequences were coded as:
• Visible as haemorrhage (all lesions were documented, if there was more than one
haematoma, the largest haematoma was recorded as the primary lesion. If there was
evidence of haematoma and infarct together, the lesion was documented as haematoma
first);





Scans were also coded for atrophy, leukoariosis, enlarged perivascular spaces (on FSE T2),
small vessel disease (FLAIR), and microhaemorrhage in the basal ganglia or elsewhere
(GRE).
Any secondary lesions seen, (i.e. that had appeared in the time after the original CT scan)
were documented. This was done matching up information in the database, not at time of
reading scans. If an MRI scan demonstrated multiple haematomas, it was compared
directly with the original CT to identify which was the primary lesion and which the
(asymptomatic) secondary lesion.
Data analysis
Results were entered into a Microsoft Excel spreadsheet, an SPSS (Statistical package for
Social Sciences) database, and analysed with simple descriptive statistics.
5.2.2 Results
Patients, tolerability, inadequate scans
Seventy-three patients were identified from the stroke register. From the the initial
permission letters sent to General Practitioners, 20 patients were thought unfit for further
scanning or had died. 53 patients were invited to return for follow-upMRI scanning. One
patient died before attending, one had aneurysm clips, 13 patients declined or were unable
to attend, 11 did not attend for their appointments, one patient attended but was
claustrophobic. A total of 26 people were scanned with both CT and MRI. Three people
had two primary haematomas on their CT scan, therefore the MR results of a total of 29
haematomas were documented. Of a total of 156 MRI scans, three were uninterpretable
(two FSET2 sequences, one FLAIR sequence) due to patient movement or because the
imaging had to be discontinued due to patient intolerance.
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Baseline characteristics of patients
The clinical status of the original 73 patients identified, according to the the OCSP
classification, were: 11 total anterior circulation strokes (TACS), 30 partial anterior
circulation strokes (PACS), 6 lacunar strokes (LACS), 15 posterior circulation strokes
(POCS) and 11 in whom it was not possible to make a classification. In the group of 26
patients who were ultimately scanned, there were 3 TACS, 12 PACS, 2 LACS, 5 POCS,
and 4 that were unclassifiable. At the time of their original PICH, the median age of the
patients who attended for scanning was 66 years (range 39 - 83). At the time of follow-up
MR scanning, their median age was 69 years (range 42-87).
Distribution of haematomas ofCT
The mean haematoma volume was 23.9cm3, the median haematoma volume was 18cm3
(range 1-80) (table 1). Haematomas were distributed as follows: five in the frontal lobe; 10
in the basal ganglia; two in the thalamus; four in the parietal lobe; two in the temporal lobe;
three in the occipital lobe; one in the occipito-parietal lobe; two in the
brainstem/cerebellum (table 2).
Findings on follow-up MRI sequences
The proportion of haemorrhage identified varied between the five MRI sequences. GRE
identified all haemorrhages (100%). Tl identified haemorrhage on 28/29 (97%), FSET2
identified 27/29 (93%), PD identified 17/29 (59%), and FLAIR failed to identify any
lesions as old haemorrhage (0%) (table 3).
The longest period from CT to follow-up MRI was 100.3 months (8.4 years), and
concerned a right hemisphere 1cm3 basal ganglia lacunar haemorrhage that was still visible
on Tl, T2 and GRE sequences. No patient or brain imaging features, such as timing of
scan, age of patient, or size of haematoma distinguished the haematomas that did remain
visible from those that did not.
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Any secondary lesions seen on initial CT are documented in table 4, with the
corresponding findings on follow-up MRI. In 19/26 patients (73%), an ischaemic infarct
not documented on the initial CT was seen on at least one sequence of follow-up MRI. In
12/26 (46.2%), there was evidence of definite new, presumably asymptomatic haemorrhage
since the original CT.
Other findings on follow-up MRI are documented in table 5. GRE identified
haemorrhagic spots in the basal ganglia and cortex in the same eight (28%) of patients.
FLAIR identified small vessel disease on 18 (62%). FSET2 identified enlarged perivascular
spaces on 16 (55%). Atrophy was identified on 20 (69%) of scans.
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5.3 The CT Versus MRI Study
5.3.1 Methods
Patient recruitment
Between August 1998 and July 2000, patients presenting to the Western General Hospital
with minor stroke symptoms (defined as symptoms lasting greater than 24 hours but
causing little or no functional impairment), or presenting more than five days after onset of
stroke symptoms regardless of stroke severity, were scanned on the day of presentation
with CT andMRI. The majority of the population recruited were outpatients presenting to
a neurovascular clinic, and all were assessed prior to scanning by a consultant stroke
physician, or a clinical research fellow in stroke medicine. Patients were classified
according to the Bamford classification8 (appendix I), and the Canadian Neurological Score
(CNS, a neurological disability score ranging from 1.5 indicating very severe stroke, to 10
indicating little or no residual disability, appendix V)9. Medically unstable patients, and
patients with contraindications to MRI (e.g. pacemaker, intraocular metal, intracranial
aneurysm clips) were excluded.
Image acquisition
The order of scanning was determined by availability of each scanner, i.e. not randomly.
CT was performed using a GE spiral scanner (17 images, 5mm slice thickness, total scan
time from patient going into and coming out the scanner was about 7 minutes). MR
imaging was performed on two scanners; up to October 1999 using an Elscint Prestige 2T
scanner, and from Januaiy 2000, using a GE 1.5 Signa Horizon LX scanner. Patients
underwent routine structural MR imaging and the imaging parameters for the two scanners
were as follows: on the Elscint scanner Tl-weighted sagittal images (TR 500 ms, TE 12 ms,
1 NEX), T2-weighted fast spin echo (TR 5000 ms, TE 96 ms, 1 NEX), proton density (TR
2300 ms, 16 ms, 1 NEX), FLAIR (TR 6000 ms, TE 2000 ms, TI 126 ms, 1 NEX), and
gradient echo (TR 510 ms, TE 18 ms, 2 NEX) axial images. Slice thickness was 5 mm,
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slice gap was 5 mm, 22.0 x 22.0 field of view, 256 x 128 matrix. On the GE Signa Horizon
scanner TI sagittal images (TR 440 ms, TE 9 ms, 2 NEX), T2-weighted axial (TR 6300 ms,
TE 106 ms, 2 NEX), proton density (TR 2000 ms, TE 9.8 ms, 4 NEX), FLAIR (TR 10002
ms, TE 147 ms, TI 2500 ms, 1 NEX), gradient echo (TR 2599 ms, TE 80, 4 NEX). Slice
thickness was 5mm, slice gap was 5 mm, 24.0 x 24.0 field of view, 256 x 256 matrix.
Patient preference questionnaire
Following completion of scanning, patients were asked to complete a questionnaire on the
acceptability of both scanning procedures (appendix VI). They were asked what type of
scan they had undergone first, which scanner they preferred, and whether they would have
either CT or MRI again if they had to. They were also asked to make any additional
comments.
Image analysis
CT and MRI scans were read independently of each other by one neuroradiologist, using
forms generated using Microsoft Access on which was a brief clinical history (appendix
VII). Scans were classified as showing:
• Recent (ischaemic) infarct;
• Recent infarct with haemorrhagic transformation (HTI);
• Recent haemorrhage;
• Old lesion probable infarct;
• Old lesion probable haemorrhage;
• Multiple periventricular lucencies;
• Cortical atrophy;
• Another diagnosis (e.g. tumour);
• No abnormality.
'Recent' was taken to mean consistent with the duration of symptoms given in the brief
clinical history. 'Old' was taken to mean a lesion that appeared older than the clinical
history.
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The effect of scan results on clinical decision-making
Nine physicians with an interest in stroke were presented with a selection of anonymised
histories of scanned patients, initially without imaging results. They were asked for their
strategy for secondary prevention for the patient in terms of the use of antiplatelet drugs,
anticoagulants, or referral for carotid endarterectomy. On the decision forms were details
of ECG, echocardiography or carotid Duplex scanning if these had been performed
(appendix VIII). On each occasion, each physician was asked to rate their confidence in
their diagnosis in terms of percentage for: stroke versus non-stroke, haemorrhage versus
ischaemic stroke, and cause of haemorrhage or ischaemic stroke. They were not required
to state a definitive diagnosis. They were initially instructed to decide on a management
strategy assuming no neuroimaging would be performed. After a number of weeks (not
less than four), they were presented with the histories (each physician being given the same
histories as they had had originally) along with a brief report of the CT findings, and asked
again for their secondary prevention strategies. After a number of weeks, they were again
given their respective patient histories, this time with results ofMRI.
Data analysis
Data on scan findings, and doctor's decisions were entered along with baseline
characteristics, brief histories, and relevant associated investigations onto a password-
protected Access database. The proportions of haemorrhage and HTI on CT and MRI
were analysed with simple descriptive statistics and confidence intervals. The effect on
doctor's decisions was determined by the number of altered decisions; a prospective power
calculation identified that, assuming the CT result altered management in 10% of patients,
and MRI altered management in 10% of patients in whom the CT result is already known,
a study population of 225 patients would have an 80% power to detect this 10% difference
at the 95% significance level. Differences in the degree of certainty of diagnosis were
analysed using a single sample t-test, differences between doctors were analysed with
ANOVA, using SPSS. The neuroradiolologist reading the scans completed a small sample
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of scans twice, and two Stroke Physicians also completed a small sample of decisions twice
in order to check intra-observer variation.
5.3.2 Results
Patient baseline characteristics, and acceptability of scanning
232 patients were recruited, MRI was not performed in 4 (1.7%) patients (three patients
were claustrophobic, one was too large for the scanner). A total of 228 patients had both
CT andMRI. No images were uninterpretable.
The mean age of the population was 67.5 years, median age 68 years (range 35 to 89 years).
The mean CNS was 9.5, median CNS was 9.5 (range 5.5 to 10). The mean time from onset
of stroke symptoms to scanning was 21.7 days, median time 20 days (range 2 to 112) (table
6). According to the Bamford classification, there were 95 (41.7%) PACS, 73 (32%) LACS,
36 (15.8%) POCS, and in 24 (10.5%), it was not possible to define a subtype (table 7).
There were no patients with TACS. Prior to scanning (on presentation), 144 (63.2%) were
on aspirin, three (1.3%) were on warfarin, and ten (4.3%) were in atrial fibrillation.
Findings on CT andMRI
Table 8 documents the main findings on CT and MRI. Note that more than one type of
lesion could be found on the same scan (e.g. many scans with a recent infarct also had
cortical atrophy). The findings on the images of the 228 patients are documented in a
hierarchy i.e. PICH, HTI and recent infarct are documented in favour of any other
diagnosis. Other diagnoses are documented in the table only if they were the only
significant finding on the scan. The findings with regards haemorrhage and tumours are
given below. Details of CT and MRI findings with regards to recent infarction are
documented in section 6.3.4.
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Recent haemorrhage
MRI identified recent PICH in 8 (3.5%, 95% CI 1.5-6.8%) patients. CT agreed in only 2
(0.9%, 95% CI 0.1-3.1%) cases. Corresponding findings on CT when recent haemorrhage
was not identified were: recent infarct (5 patients), and old lesion probable infarct (1
patient). Thus in patients with recent haemorrhage identified on MRI, CT missed the
diagnoses in 6/8 (75%) (figures 1 to 6).
Recent infarct with haemorrhagic transformation (HTI)
MRI identified HTI in 15 (6.6%, 95% CI 3.7-10.6%) patients. The extent of haemorrhagic
changes seen varied from minor petechial spots to frank haematoma. CT agreed in only 2
(0.9%, 95% CI 0.1-3.1%) cases. Corresponding findings on CT when HTI was not
identified were: recent haemorrhage (1 patient), recent infarct (10 patients), old lesion,
probable infarct (1 patient), multiple periventricular lucencies and cortical atrophy only (1
patient). CT therefore missed the haemorrhagic changes seen on MRI in 12/15 (80%)
(figures 7 to 18).
CT identified HTI on one scan that was interpreted as recent infarct only on MRI. On
review of both scans, The CT result was judged to be incorrect, the changes seen on
imaging being due to the contrast of normal cortex next to infarct, as there was no
evidence of haem on GRE MRI.
Timing of scans identifying haemorrhage
The range of times from onset of symptoms to scan for both CT and MRI in patients
found to have either recent haemorrhage or HTI along with clinical presentation is
documented in table 9. The shortest time from onset of symptoms to scan when HTI was
missed on CT was five days, and the shortest time PICH was missed on CT was 11 days
(although this may have been sooner if scans were performed earlier). The two patients in
whom CT correctly identified recent haemorrhage were scanned on nine and 14 days after
stroke.
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Signs of previous haemorrhage
Signs suggestive of an old lesion that was probably haemorrhagic were seen on 15 (6.6%,
95% CI 3.7-10.6%) ofMRI scans but no CT scans. They were the only significant findings
in five patients (2.3%). In the remaining ten, these signs were seen alongside signs of
recent infarction (eight patients), and HTI (two patients).
Tumours
CT scans identified 5 tumours in 228 patients (1.7%): 2 intra-axial, 3 extra-axial (three
meningiomas; two of which were incidental, less than 1cm in diameter, and not responsible
for symptoms). MRI also identified the 2 intra-axial tumours and the symptomatic
meningioma, but not the two incidental meningiomas.
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Figures. Missed haemorrhages
Unless otherwise stated, the CT scan is on the left, T2-weightedMRI centre and zebere available, gradient
echoMRI on right
The relevant area ofhypodensity on CTpreswned to he ischaemk infarct is highliglTtedwith an arrow, and
the corresponding area onMRI ofhyperintensity surrounded by dark rim, or dark rim alone ismarked by
arrows onMRI.
Figure!. 72year oldmanwith left homonymous hemianopia, scanned 28 days after onset ofsymptoms.
Figure 2. 69 year oldman with mild right hemiparesis, residual mildfacial weakness. Scanned 13 days
after onsetofsymptoms.
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Figure 3. 60 year oldman with right hemiparesis and right facial numbness, residual reducedfinefinger
movements. Scanned 21 days after onset ofsymptoms.
Figiire 4. 69 year oldwoman with right arm and hand numbness lasting 12 days. Scanned14 days from
onset ofsymptoms.
Figure 5. 51 year old woman with ataxia, blurring ofvision, no residual signs. Scanned 17 days from
onset ofsymptoms.
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Figure 6. 68 year oldmanwith right hemiparesis and dysphasia, mildweakness persisting. Scannedat 11
days.
Figure 7. 77 year old woman with dysphasia, right homonymous hemianopia, resolved Scanned 6 days
after onset ofsymptoms. CTon left, gradient echo right.
Figure 8. 52 year oldwoman with expressive dysphasia almost resolved Scanned 28 days after onset of
symptoms.
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Figiire 9. 88 year oldwoman with dysphasia and right inattention. Scannedat 5 days.
Figure 10. 82 year oldwoman with right handweakness, mildweakness persists. Scanned 21 days after
onset ofsymptoms.
Figure 11. 72 year oldwomanwith 4 transient episodes ofrightfacial numbness, one associatedwith right
handparasthesia. Scannedat 28 days. CTon left, gradient echo right.
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Figure 12. 72 year oldmanwith ataxia and loss ofbalance to right, no residual abnormality. Sea rmedat
20 days. CTon left, gradient edx> right.
Figiire 13. 70 year oldmanwith expressive dysphasia, mild symptomspersist. Scannedat 19 days.
Figure 14.70 year oldwomanwithpersistentmild leftfacial weakness. Scannedat 14 days.
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Figure 15. 70 year old woman with right homonymous hemianopia, no residual signs. Scanned at 28
days. CTon left, gradient echo on rigfit.
Figure 16. 72 year oldwctnanwith left homonymousfield deficit Scannedat 49 days.
Figure 17. 62 year oldmanwith right arm weakness and expressive dysphasia, mosdy resolved Scanned
at 28 days. CTon left, gradient echoMRI on right.
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Figure 18. 72 year oldmanwith left homonynousfield deficit. Scannedat 56 days.
Effect of scan results on clinical decisions
A total of 223 clinical histories with accompanying relevant clinical details, were used. The
nine stroke physicians (five Consultants and four Clinical Research Fellows) were each
given a selection of histories ranging in number from 11 to 44 according to the physician's
time constraints.
The physicians' diagnoses
Physicians were not asked to say definitively whether symptoms were due to stroke versus
non-stroke, or infarct versus PICH. However, taking a physician certainty of greater than
90% as a definite diagnosis, the following diagnoses were made:
• With information on clinical features, examination and general investigations (i.e. no
scan findings), physicians made the diagnosis of stroke (as opposed to non-stroke) in
153 cases (69%), of which 100% were felt to be due to infarction (with greater than
90% certainty).
• When also given the corresponding findings on CT, the diagnosis of stroke was made
in 166 cases (74%), of which 153 (69%) were felt to be due to infarction, two (1%) to
be PICH and 11 (5%) were equivocal (diagnosis could not be made with greater than
90% certainty).
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• When also given the findings on MRI, the diagnosis of stroke was made in 169 cases
(76%), of which 160 (72%) were felt to be due to infarction, eight (4%) to PICH and
one (0.5%) was equivocal.
CT increased certainty of diagnosis of stroke versus non-stroke (p = 0.006), MRI less so (p
= 0.5). However, MRI greatly increased certainty in the making of a diagnosis of PICH (p
<0.001).
Decisions changed following scan residts
Management decisions were changed following knowledge of CT results in 39 cases overall
(17.5%, 95% CI 12.5-22.5%). With MRI results, a further 28 (13%, 95% CI 8-17%)
changes were made compared to decisions with CT findings (table 11).
Decisions changed regarding the use of an antithrombotic drug in 17 (7.6%) patients when
histories were reviewed with CT results. Aspirin or another antiplatelet drug was started in
seven patients (who were not previously on antithrombotic therapy), stopped in six, and
continued in four when they had been stopped on history alone). Decisions regarding
warfarin were changed in 12 (5.4%) patients (warfarin was started in nine patients, stopped
in two patients, and continued in one patient following CT results when it had been
stopped on histoiy alone). If a warfarin decision was associated with an antiplatelet
decision change, the latter was not counted separately. Decisions regarding endarterectomy
were changed in 10 (4.5%) patients when CT results were available (eight patients were not
referred, two patients were referred).
Decisions regarding using an antithrombotic agent were further altered in 14 (6.7%)
patients with MRI results. Aspirin or another antiplatelet drug was started in one patient,
and stopped in 13. Decisions regarding warfarin were changed in six (2.7%) patients
(warfarin was stopped in three patients, all of whom had PICH orHTI, and started in three
patients). Endarterectomy decisions were changed in eight (3.6%) patients (six patients
were referred, two patients were not).
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The pathway ofclinical decisions inpatients with scans showing haemorrhage
How decisions changed in patients with haemorrhage on their scans is documented in table
12.
• In the two patients in whom PICH was also seen on CT, antithrombotic drugs were
continued in one patient and another antiplatelet drug was added to aspirin in the other
on history alone. These were discontinued when haemorrhage was demonstrated on
CT (and remained discontinued followingMRI results).
• In the six patients in whom PICH was only identified on MRI, four had aspirin started,
one continued aspirin, and in one patient warfarin was stopped on history alone. With
knowledge of CT results, aspirin or another antiplatelet agent was commenced or
continued in four patients, and the one patient on warfarin continued anticoagulation.
Following MRI results all antithrombotic drugs or warfarin were stopped or not
commenced.
• In the three patients with HTI documented on CT, aspirin was started or continued in
two, and stopped in one on history alone. Following CT results, aspirin was not started
in one patient, stopped in one, and was continued in one. Decisions were unchanged
followingMRI results
• In the twelve patients with HTI seen only on MRI, it seemed that describing the extent
of HTI (as trivial or moderate, no patients had extensive HTI) had no bearing on
management. Aspirin or another antiplatelet drug were commenced or continued in all
12 patients on history alone. With CT results, aspirin or another antiplatelet agent were
commenced in ten patients, and warfarin commenced in two. With MRI results,
aspirin or another antiplatelet drug was started in all 12, warfarin was not started in any
patients.
Variability of scan reading and management decisions
The neuroradiologist interpreting scans read 20 scans twice with a suitable time period
between readings. Diagnoses were identical in 17 (85%), and in no scans with
haemorrhage was a different diagnosis reached. One stroke physician repeated ten
decision forms, another repeated five. Decisions were consistent in 90% and 40%
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respectively. Comparing means of how certain the different physicians were in their
diagnosis, there was significant variation (p = 0.009).
Patient preference questionnaire
Questionnaires were available for 192 patients. Of these patients, 82 (43%) underwent CT
first, and 110 (57%) underwent MRI first. 150 patients (78%) preferred CT, compared
with 13 (7%) preferringMRI and 29 (15%) expressing no preference. All patients felt they
would agree to a further CT scan if they had to, and 99% would agree to an MRI, although
four patients added that it would be under duress. 21 patients commented on the
friendliness and helpfulness of the staff. Other comments included: the MRI was noisy
(11), claustrophobic (6), too long (5), and frightening (2). One patient liked the noise of
the MRI scanner, one felt more secure in the MRI scanner and found it more relaxing than
CT (they felt they would fall off the CT table).
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5.4 Discussion
Blood-sensitive MRI sequences can identify ICH years after the event
In our late haemorrhage study, the blood-sensitive gradient-echo sequence (GRE)
identified evidence of ICH on all scans (100%). The next most sensitive sequences were
Tl and T2-weighted spin echo imaging, identifying ICH on 97% and 93% of scans
respectively. PD and FLAIR sequences were much less effective at identifying ICH.
These values compare favourably with the study investigating the persistence of evidence
of ICH following traumatic head injury (90%), although GRE was not performed in that
study6. Although the proportions of routine Tl and T2-weighted imaging on which
haemorrhage could still be seen are high, they are not 100%, and our series was small.
Gradient-echo imaging is not performed routinely, and thus there is the likelihood that a
small proportion of patients (in our case series, 3%) with previous ICH will be missed if
only routine structural imaging is performed.
Evidence of ICH was identified over eight years after the original event, remaining visible
on GRE, Tl and T2-weighted imaging. Whether haemosiderin persists indefinitely is
unclear. Also, the reason why haemorrhage disappears completely from a small proportion
of images is unclear.
The late haemorrhage study demonstrates that in the vast majority of this population of
patients with ICH, the evidence of ICH remained on certain sequences ofMRI for as long
after the original event as we were able to scan, which in this study was over eight years.
This makes it an ideal imaging tool to detect late haemorrhage, so long as the correct
sequences, i.e. gradient echo, are performed.
MRI is well tolerated
In the CT versus MRI study, we found that only a very small proportion of our study
population (1.7%) were unable to undergo MRI, and that although the vast majority
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preferred CT, they would undergo MRI again if necessary. One important feature that
improves the acceptability of the procedure seems to be friendly and reassuring staff.
MRI identified more haemorrhage than CT
In our CT versus MRI study, MRI identified more haemorrhage than CT. MRI proved
superior in the detection of both primary intracerebral haemorrhage (PICH) and
haemorrhagic transformation (HTI). CT did not identify any cases of haemorrhage that
were not also identified on MRI. We have no criteria against which to judge MRI, but
assuming MRI to be the gold standard, the sensitivity of CT in the detection of PICH and
HTI in this group of patients was 50% and 20% respectively.
How many minor strokes may have had haemorrhage in the general population?
The estimated number of patients being treated in the community in the UK is about
22000 per year. The use of aspirin has increased dramatically in the last decade7'10 and
stroke physicians are exhorted to consider warfarin in increasingly older populations of
patients with atrial fibrillation11,12. The frequency of PICH in our study population was
3.5% and of HTI was 6.6%. From Stroke Association Survey estimates of patients in the
community presenting with stroke symptoms, these would represent around 2200 patients
per year in whom antithrombotic or anticoagulant treatment would be considered.
Timing of scanning in relation to sensitivity of CT
This group of patients, which represented a typical population presenting in the main, to a
neurovascular clinic were scanned an average of three weeks after their stroke. A major
delay to scanning was the time to presentation to the GP, as there was only a short delay
once referred. This time delay definitely has a detrimental effect upon the sensitivity of CT
in the detection of ICH13'14. In our study, CT missed 17/23 (74%) of all haemorrhage
identified on MRI. The earliest time-point at which a PICH was missed on CT was 11
days (and because the scan was not performed any earlier, it is impossible to say precisely
the earliest time-point at which the PICH would have been missed). The latest time PICH
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was identified on CT was 14 days. These timings, both of presentation to scan and CT
findings highlight an important point. The much-reduced sensitivity of CT for identifying
haemorrhage more than 10 days after onset of stroke symptoms is such that its use to rule
out the possibility of haemorrhage (as opposed to identifying a non-stroke lesion) must be
must be questioned.
What is the true frequency of asymptomatic haemorrhage?
Follow-up scanning identified evidence of haemorrhage in 12/26 (46.2%) patients in the
late haemorrhage study, which was presumed asymptomatic as further scanning had not
been performed in the interim. Signs of old asymptomatic haemorrhage were also found
on MRI in the CT versus MRI study but in far fewer patients (15, 6.6%). Although in
patients with recent haemorrhage or haemorrhagic transformation in the CT versus MRI
study, the proportion was slightly higher (8.9%), it was still far from the values of up to
68% given in previous studies looking for asymptomatic haemorrhage specificalfy3'4'15'16 (see
chapter 4). Differences in case-mix between studies, both in terms of age and clinical
presentation maywell account for much of this variation.
Do imaging results really matter?
It may be that patients with PICH found only on MRI would have come to no harm had
their antithrombotic treatment not been stopped. Certainly, the outcome of patients with
minor haemorrhagic stroke given antiplatelet drugs or warfarin is not known. However,
the analysis of IST/CAST data on antithrombotic treatment following PICH (chapter 3)
does include the possibility of harm. In our study, knowledge of scan results made a
difference to clinical management in 17% of cases following CT results, and in a further
12% following MRI results. Whether the proportion of changes is large enough to alter
scanning policy however, is debatable. Although clinicians prefer to have scans (certainty
of diagnosis was increased), and patients prefer to have scans (personal observation), if
access to imaging is relatively limited, figures such as found in our study may not prove
convincing enough to justify a 'scan everyone' policy. The variability within and between
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doctor's decisions in our study makes it impossible to say these figures are definitive, but
do help to quantify the contribution of imaging to the overall management of the patient.
Should we be usingMRI more?
To be sure that a patient presenting with stroke symptoms more than ten days after the
event has not had a haemorrhagic stroke, an MRI is required. Access to MRI is very
limited in the UK11, and where accessible there may be waiting times of many weeks. If we
were to wait forMRI before treating all patients presenting after ten days (assuming it was
possible to get an MRI), this would create an unacceptable level of delay in commencement
of secondary prevention treatment for the majority of patients. However, there is no
doubt that in specific groups of patients, MRI provides more information than CT, and
this information, as demonstrated in the CT versus MRI study patients with PICH, may
alter clinical management. The next challenge will be to determine precisely who should be
placed on the MRI waiting list (and whether they should be given aspirin whilst they are
waiting). Certainly 'salvage' byMRI because it is too late to CT would rarely be a credible
option. More realistically, patients should be encouraged to seek medical attention early
after any stroke, and hospital clinics and imaging departments should offer responsive and
rapid access to medical and CT assessment in line with current guidelines.
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Table 1. Late haemorrhage study. Baseline characteristics
Mean Median Range Standard Deviation
Age (years) 66.5 69 42-87 10.9
Time from CT(months) 39.9 30.7 7.6-100.3 22.9
Infarct volume (cm3) 23.9 18 1-80 22.9
Table 2. Late haemorrhage study. Distribution of haematomas on original CT
Site Left Right Midline
Frontal lobe 1 4
Basal ganglia 6 4
Thalamus 2
Temporal lobe 2
Parietal lobe 2 2
Occipital lobe 1 2
Occipito-parietal lobe 1
Brainstem/cerebellum 1 1









Lesion visible as haemorrhage 28 (97) 17 (59) 27 (93) 0 29 (100)
Lesion thought to be infarct 0 5(17) 0 18 (62) 0
Uncertain 0 2(7) 0 1(3) 0
No residual lesion 1(3) 5(17) 0 9(31) 0
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Table 5. Late haemorrhage study. Other findings on follow-up
Number Percentage (%)
Atrophy 20 69
Enlarged perivascular spaces (T2) 16 55
Small vessel disease (FLAIR) 18 62
Haemorrhage spots (GRE) 8 28
Basal ganglia spots (GRE) 8 28
Table 6. CT versus MRI study. Baseline characteristics
Age (years) Time from onset of Canadian Neurological
symptoms to scanning score at examination
(days)
Mean 67.5 21.7 9.5
Median 68.0 20 9.5
Range 35-89 2-112 5.5 - 10
Standard Deviation 9.9 15.3 1.0
Table 7. CT versus MRI study. Distribution of stroke subtype according to the OCSP classification
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6 The Sensitivity Of CT And Conventional MRI Techniques In
Making A Positive Diagnosis Of Ischaemic Stroke
6.1 Introduction
Making a positive diagnosis of stroke is important when considering hyperacute
stroke treatment
Chapters 2, 3 and 4 addressed the importance of accurately distinguishing haemorrhagic
from ischaemic stroke. Having excluded haemorrhage and non-vascular causes of
stroke, making a positive diagnosis of infarction on neuroimaging is currently of less
importance; aspirin would be started on the basis of an appropriate history and
examination and a scan with no obvious abnormality. However, the introduction of
thrombolysis for hyperacute stroke may mean that current practice will change. The
benefits of thrombolysis may be much greater than for antiplatelet agents, but
unfortunately, so are the risks1. Although the precise time window within which
thrombolysis can be given to good effect is uncertain, it is relatively short, probably
only a matter of hours. Consequently clinicians do not have the luxury of time to help
them decide whether to give the drug. Experience from the USA, where rtPA
(recombinant tissue plasminogen activator, a thrombolytic agent) has been licensed for
some time shows that only a small fraction of patients arriving in hospital and are
eligible for the drug are receiving it2;3. Part of the reason for this may well be the
reluctance of physicians to expose their patients to the (potentially fatal) risk of
thrombolysis if they are not certain that the patient is definitely having a stroke (as
opposed to a severe TLA for instance). Making a positive identification of ischaemia
would increase clinical certainty.
A systematic review of CT and MRI in the positive identification of ischaemic
stroke
It is important therefore, to have a grasp of the relative merits of both CT and MRI in
making an accurate diagnosis. For example, involvement of greater than one third of
the territory of the middle cerebral artery has been suggested as a contraindication to
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thrombolysis4. Is this a realistic criterion? Although changes associated with ischaemic
stroke can be demonstrated on conventional CT very soon after onset of stroke
symptoms, they can be subtle5"7. It is important to know whether these changes can be
identified consistently by multiple observers. Also, objective methodological criteria are
again important. Sensitivities derived from a retrospective study of high quality scans
interpreted alongside other imaging are likely to give a different result from one in
which a more clinically realistic scenario was attempted. Bearing these issues in mind, a
systematic review of the sensitivity of CT and conventional MRI in the positive




An electronic search of all published records of sensitivity of CT, MRI or both in the
identification of ischaemic stroke was performed, using the electronic databases
MEDLINE, from 1966 and EMBASE, from 1980 to the present day. In view of the
overlap in studies and to ensure maximum capture of references, the same search
strategy was used as for the identification of studies of the sensitivity of scanning in
ICH (chapter 4 and appendix III). Reference lists were also consulted in articles found.
Data extraction
Data were extracted on:
• The number of patients in the study;
• Its primaiy purpose;
• The nature of the stroke population (e.g. unselected strokes, or a specific clinical
type);
• Whether patients were assessed by a stroke physician or neurologist;
• Whether imaging was read blinded to clinical history or other imaging;
• The criteria upon which the final diagnosis of stroke was made;
• Timing of scanning in relation to stroke symptoms; and
• Values for scanning sensitivity in the positive identification of ischaemic stroke.
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Only sensitivity data from studies in which the patient population had been seen by a
stroke physician (as opposed to a potentially retrospective collection of patients in
whom the differential diagnosis included stroke) were used. In studies concerning
MRI, any details on the feasibility of scanning in the acute setting (e.g. numbers of
patients it was not possible to scan or uninterpretable scans) were also noted. Case
reports and descriptive studies of only one specific sign of ischaemia (e.g. hyperdense
middle cerebral artery sign) were excluded.
Also, from the main search, studies were identified concerning either the accuracy of
observer interpretation of lesions or the inter-observer reliability of interpretation of
images.
Data analysis
Data were entered into an Access database and analysed with descriptive statistics.
6.3 Results
6.3.1 Studies ofCT alone in the identification of ischaemia
Included studies
Thirty-one studies (7393 patients) concerning CT and stroke were identified, 15 of
which (4604 patients) documented patient populations that had been seen by a
neurologist or a physician with an interest in stroke, and documented values from
which sensitivity for CT in the positive identification of ischaemic stroke could be
calculated (table 1). These studies are discussed further below (see table 2 for the
excluded studies).
Study populations
In the 15 included studies, the population group under investigation varied; five studies
(895 patients) specifically excluded haemorrhage8"12; three studies (853 patients)
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investigated unselected stroke populations13"15; three studies (145 patients) included
infarcts of the middle cerebral artery territory only16"18; two studies (156 patients)
included thrombolysis patients only19;20; one study included patients with various
neurological diseases (1191 patients, 386 of which had stroke symptoms)21, and one
study included patients with mild stroke symptoms only22. These marked differences in
case-mix make it difficult to draw any generalisable conclusions.
General methodological details
Nine studies (3571 patients, 60% of studies) recruited patients prospectively8;10;12;13;15"
I7;21;22. Only six studies (3001 patients, 40% of studies) were blinded to clinical history9;11
or clinical history and other imaging16;18;19;22. The objective criteria for the final
diagnosis of ischaemic stroke was: clinical progress and diagnosis at discharge in 11
studies (3334 patients, 73% of studies)915;17;18;20;21, follow-up scan in two studies (83
patients, 13% of studies)19;23, and undefined in three studies (1233 patients, 20% of
studies)8;16;22.
Values for sensitivity and specificity
No study examined a population from which an estimate of specificity could be made.
The sensitivity of CT in the demonstration of an appropriate ischaemic lesion varied
from 0.4 to 0.95. With the exception of one study in which a proportion of images
were read by two neurologists22, all images in included studies were read by radiologists
or neuroradiologists. In an attempt to identify factors other than case-mix that had an
effect upon sensitivity, studies were grouped according to timing of scanning, and
whether studies were retrospective or prospective. As ischaemic lesions become more
obvious with time24, it was assumed that if timing of scanning in relation to symptoms
was the only major feature in determining sensitivity, then the lowest values would be
for those studies performing scanning at the earliest time points. This was not found to
be the case; in fact, some of the highest values for sensitivity were recorded from
studies in which scans were performed within 6 hours (table 3). Grouping studies by
whether images were read prospectively rather than retrospectively made no difference,
the ranges for sensitivity of positive identification being 0.4-0.95 and 0.53-0.81
respectively.
138
Inter-observer agreement in CT scan interpretation
Twelve studies documented the proportions of observer agreement of interpretation of
CT scans, or the inter-observer reliability of interpretation of scans using kappa values.
The kappa statistic25 is a measure of agreement between two observers beyond that
expected from chance alone, where: k = 0 indicates agreement no better than chance, k
= 1 perfect agreement, k = 0 - 0.2 poor agreement, k = 0.21 - 0.4 fair agreement, k =
0.41 - 0.6 moderate agreement, k = 0.61 - 0.8 good agreement, k = 0.81 - 1 excellent
agreement.
None of the seven studies that documented kappa values (994 scans)4'26"31 were
designed to imitate the reading of scans in a true clinical situation. All included
selections of retrospectively collected scans of patients with acute stroke (including
scans from four thrombolysis trials) that were presented to different observers. They
were asked to identify the presence of varying indicators of ischaemia, and kappa values
were calculated for level of agreement (table 4). With the exception of the
identification of haemorrhagic transformation, there was no sign of ischaemia that
could be identified by all observers with better than moderate agreement.
The six studies (948 scans) that documented observer agreement as either proportions
in agreement or percentage accuracy, tended to be the closer to real clinical
situations23;32"36. Two studies documenting accuracy of interpretation of scans by
emergency physicians noted 87 to 98% accuracy for all pathological lesions32;33. Values
fell to 67% however, when emergency physicians were asked to identify lesions
pertinent to the interpretation of ischaemia and haemorrhage only35. In this study,
neurologists and radiologists interpreted ischaemia and haemorrhage on scans with
greater accuracy (83%). In a study where one neuroradiologist (blinded to clinical
history other than 'stroke' and all other imaging) assessed CT scans performed within
six hours of stroke for parenchymal hypodensity and brain swelling, the sensitivity of
interpretation was 82%23. However, in another study investigating agreement for
whether there was greater than a third involvement of the middle cerebral artery
territory (a scan criterion put forward as a contraindication to thrombolysis37), there was
still only 64% agreement between neuroradiologists (table 5).
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6.3.2 Studies of conventional MRI alone in the identification of
ischaemia
Included studies
Eighteen studies (1638 patients) were identified concerning MRI alone in stroke (table
6); 15 (1560 patients) included patients assessed at some stage by a neurologist or stroke
physician. Only four studies of three quite different groups of patients reported values
for sensitivity. Two studies (64 patients) that scanned patients within the initial two
days after stroke found sensitivities of 84%38 and 88%39 compared with follow-up MRI.
One study (53 patients) found a sensitivity 65% for FLAIR MRI in patients scanned
within 6 hours of their stroke compared with follow-up scan40. One study of 79
patients with clinical transient ischaemic attacks found a sensitivity of 35% for clinically
compatible lesions41. In only one of the four studies, was imaging read blinded to
clinical history38. As with CT, the differences in case-mix, timing of scanning and small
numbers make these results of interest but difficult to generalise.
Excluded studies
In the remaining (excluded) studies, the primary purposes were: descriptions of
clinicotopography or specific MRI characteristics (eight studies, 990 patients)42"49;
explorations around the use of contrast agent or imaging parameters (five studies, 167
patients)51"54; and one study (seven patients) highlighting the important issue of negative
MRI scans in clinically definite stroke35.
6.3.3 Studies ofboth CT andMRI in the identification of ischaemia
- existing data
Included studies
Twenty-eight studies (1650 patients) comparing CT and MRI directly in stroke were
identified, of which 18 studies (808 patients) included patients who had been assessed
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by a neurologist or stroke physician. 12 studies (609 patients) documented the number
of positive findings on scans performed and are detailed below (table 8). See table 9 for
details of the remaining studies.
Study populations
As previously, the patient groups under investigation differed (some studies including
more than one patient group), ranging from: transient ischaemic attack (two studies, 41
patients)56;57; lacunar stroke (five studies, 166 patients)56;58"61, cerebellar stroke (one study
14 patients)62; lateral medullary syndrome (one study, 6 patients)63; and unselected
stroke (four studies, 356 patients) 64"67. Again, studies were uniformly small.
General methodological details
Nine studies (75% of studies) collected data prospectively56"58^61164"67, six studies (50%)
blinded readers of scans either to clinical history56157160'65'67 or other imaging64. In only
one study (0.8%), was the order in which CT orMRI were performed varied (although
not randomised)67; two studies performed both scans on the same day but did not
document the order in which they were done57;59; in five studies, CT was always
performed before MRI56'60'64"66. The extent of the difference in times varied; in one
study where all patients were scanned within 24 hours, CT was performed a mean of
four hours earlier65. In another comparing strokes within the First three weeks, CT was
performed a median of four days earlier56. In three studies the order of scanning was
not defined58;61;63.
Sensitivities ofCT andMRI in the positive identification of stroke
In the two studies (82 patients) that included patients with transient ischaemic attack,
MRI was markedly better at demonstrating ischaemic lesions in one study (21% on CT
compared with 68% on MRI56), but less obviously better in the other (MRI
demonstrated lesions not seen on CT in 14%, but CT demonstrated lesions not seen on
MRI in 9%57).
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In all four studies (356 patients) of unselected stroke patients, the proportions of scans
that demonstrated ischaemic lesions ranged from 43 to 68% for CT, and 51 to 98% for
MRI64"67 (table 10). Only one study tested the difference between the two scan findings
statistically and found no significant difference67. In the study where difference in
positive identification was most marked, MRI had been performed up to a week after
CT66. One study documented the results of two observers interpreting CT and MRI in
stroke and found considerable differences between their interpretation of images
(positive findings on CT ranged from 48-68%, and forMRI from 77-87%).
In all four studies of lacunar strokes, MRI demonstrated more clinically compatible
lesions (table 11). The proportion of ischaemic lesions identified on scans ranged from
17 to 50% for CT and 78 to 94% for MRP8 61. In one studyMRI scans were performed
one to three days after CT60; in the rest, the order of scanning was not defined.
In the two remaining studies, MRI was consistently superior in the positive
identification of ischaemic stroke, both in the cerebellum (100%, 14/14 compared with
43%, 6/14 for CT62), and in lateral medullary syndrome (83%, 5/6 compared with 33%,
2/6 for CT63). Both studies were extremely small and retrospective.
6.3.4 The CT versus MRI study - new data on the positive
identification of ischaemia
Recent infarction
Char prospective case study comparing CT and MRI in stroke is a major new study. It
is the largest to date (228 patients) and the only to scan all patients with both CT and
MRI on the same day, varying the order of scanning. In this section new data on the
ability of CT and conventionalMRI to identify relevant recent infarction are presented.
'Relevant' is defined as a lesion in keeping with the timing and site of patient
symptoms. See section 5.3 for methods, baseline characteristics and overall findings.
CT scanning identified a relevant recent infarction in 119 (52.2%, 95% CI 46.2 to
59.5%). MRI agreed in 86/119 (72.2%) of cases. In the patients where MRI did not
agree with CT diagnosis, the findings on MRI were: HTI in 10 (8.4%), recent
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haemorrhage in 5 (4.2%), old lesion probable infarct in 2 (1.7%), old lesion probable
haemorrhage in 2 (1.7%), multiple periventricular lucencies with or without cortical
atrophy in 10 (8.4%), negative scan in 4 (3.4%) (table 12).
MRI identified a relevant recent infarction in 122 (53.5%, 95% CI 47.0 to 60.0%)
patients. CT agreed in 86/122 (70.5%) of cases. In the patients where CT did not agree
with MRI diagnosis, findings on CT were: HTI in 1 (0.8%), old lesion probable infarct
in 8 (6.6%), multiple periventricular lucencies with or without cortical atrophy in 14
(11.5%), meningioma incidental to symptoms in 1 (0.8%), negative scan in 12 (9.8%)
(table 13).
Since we were investigating the ability ofMRI to demonstrate ischaemic stroke as well
as CT, MRI was not taken to be the gold standard against which we could make an
estimate of sensitivity.
6.4 Discussion
Values for the sensitivity ofCT vary widely
Studies documenting the sensitivity of CT in the identification of ischaemic stroke
demonstrate that high levels of sensitivity can be achieved, but not consistently. The
range of sensitivities were wide and confounded by the variety of stroke populations
investigated, as well as timing of scanning in relation to onset of stroke symptoms, and
level of experience of person interpreting the images. For instance, grouping studies
according to timing of scanning (table 3) did not reveal that scan interpretation was
necessarily less accurate in the hyperacute stage. Neuroradiologists were generally more
sensitive in their interpretation of CT changes than emergency physicians3/ However,
the more impressive results associated with (highly trained) neuroradiologists were from
retrospective studies. Neuroradiologists may not always be available, especially within
six hours, and hence it may not be possible to reproduce these results in real-life. A
good example of how different those results could be is the practice audit by general
physicians in a Canadian hospital of the sensitivity of CT scanning in demonstrating a
diagnostic lesion at 24 hours, and where it was found to be only 23%68. Another factor
confounding a definitive estimate of the sensitivity of CT is the continuously evolving
technology, rendering studies potentially obsolete almost as soon as they are published.
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Inter-observer reliability is important
Since CT scanners became available for clinical use in the mid-1970s, with the
increasing sophistication of scanning technology, the complexity of information we can
derive and the quality standards we demand have also increased. When CT was first
introduced, as was the case with ICH, early studies were content to merely describe
clinicotopographical findings69;70. In this era of thrombolysis however, it may be
necessary accurately (and reliably) to demonstrate the earliest changes of an ischaemic
infarct. As changes become increasingly subtle, the inter-observer reliability with which
such changes can be seen becomes critically important. If a sign on CT cannot be
distinguished reliably by multiple observers with varying levels of ability, it is of no use
as a marker by which to alter clinical decisions (such as whether or not to give
thrombolysis). So far, it seems that signs of early ischaemia on CT are too subtle for
multiple observers to consistently identify reliably.
Is MRI really more sensitive than CT in the positive identification of ischaemic
stroke?
Studies comparing the sensitivities of CT and MRI would seem to demonstrate that
MRI is consistently more sensitive in the positive identification of ischaemic stroke.
This is probably the case, but inadequacies in the methodology of the studies make it
unsafe to draw very robust conclusions. Sample sizes were small, which make any
statistical conclusions drawn vulnerable to the play of chance (see chapter 7). In fact,
only one study tested the differences between CT and MRI statistically (finding no
significant difference67). Blinding the interpreter of images to clinical history or other
imaging is essential for maximum objectivity and the prevention of bias, and only 58%
of studies comparing CT and MRI were blinded. Perhaps most importantly in these
studies, was the timing of CT and MRI in relation to each other. Only one study (8%
of studies) varied the order in which scans were performed, and five studies (42%)
consistently scanned patients with MRI later (often days later) than CT. Strokes can
take days to evolve; ifMRI was always performed after CT, it is very likely that it would
demonstrate more lesions. To derive the most accurate measure of sensitivity, scans
should at the very least be performed on the same day, and ideally (especially in the
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hyperacute and acute stages) the order in which they are performed should be
randomised.
Sensitivity ofCT andMRI in the CT versus MRI study
In our study, scans were performed on the same day. In view of the length of time
from stroke to scanning (median 20 days), randomisation of the order of scanning was
of less importance than in hyperacute studies. The patients in this study had mild
strokes (median Canadian Neurological Score of 9.5), and many had few residual signs.
Therefore there were no objective criteria against which to judge scanning in general.
In our study, CT and MRI were of equal efficacy overall in demonstrating acute
infarction (about 50% of patients), and agreed with each other in a similar proportion
(about 70%).
Conclusion
Compared to the number of scans performed routinely on patients with acute stroke,
the number of patients involved in these studies is extremely small. This makes
significant results vulnerable to chance, and means that studies with serious flaws in
their methodology are given more credence than perhaps they deserve. It also means
that, as in the identification of intracerebral haemorrhage, we lack robust data on the
relative merits of CT and MRI. This renders decisions on the use (or provision) of
neuroimaging vulnerable to whim or anecdotal experience. Accumulating a large
enough prospective case series with appropriate blinded interpretation of images may
be difficult, but would not be impossible. It is also becoming increasingly important to
try, as it will not be possible to gauge the significance of new imaging techniques such
as diffusion-weighted imaging if we do not have reliable data on the sensitivity of
conventional imaging against which to compare it.
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Table 10. Sensitivity of CT andMRI in the positive identification of ischaemia in unselected strokes













Table 11. Sensitivity ofCT and MRI in the positive identification of ischaemic lacunar stroke







Table 12. CT versus MRI study. CT showed recent infarct, correspondingMRI findings
Scan findings Number of findings on
MRI (%)
Recent infarct 86 (72.2)
Recent infarct & haemorrhagic 10 (8.4)
transformation
Recent haemorrhage 5 (4.2)
Old lesion probable infarct 2 (1.7)
Old lesion probable haemorrhage 2 (1.7)
Multiple periventricular lucencies and/or 10 (8.4)
cortical atrophy
Tumour 0(0)
No abnormality 4 (3.4)
Total 119
Table 13. CT versus MRI study. MRI showed recent infarct, corresponding CT finding:
Scan findings Number of findings on CT
(%)
Recent infarct 86 (70.5)
Recent infarct & haemorrhagic 0(0)
transformation
Recent haemorrhage 0 (0)
Old lesion probable infarct 8 (6.6)
Old lesion probable haemorrhage 0 (0)
Multiple periventricular lucencies and/or 15 (12.3)
cortical atrophy
Tumour 1 (0.8)
No abnormality 12 (9.8)
Total 122
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7 The Sensitivity Of Diffusion-Weighted Imaging And Perfusion
Imaging In The Identification Of Ischaemic Stroke.
7.1 Introduction
Why do we need better imaging techniques in stroke care?
When thrombolysis began to be used in stroke, it was hoped that by reopening acutely
occluded arteries, thrombolytic agents would produce a clinical improvement that was
so obvious that the clinician at the bedside would see it. Although this can happen, in
the majority of patients the immediate effects are not that obvious1. Also, as more
patients are seen in the hyperacute phase, spontaneous early improvements are more
often seen. To gauge whether any potential new treatment is effective, we currently
rely on patient clinical outcome measures like death or functional outcome. These are
obviously the most relevant factor to patients, carers and care-providers, but clinical
outcome may require large numbers of patients i.e. it may not be sensitive enough to
demonstrate a potentially encouraging physiological effect of a treatment, which
following refinement may prove to be clinically beneficial.
Advanced imaging techniques such as magnetic resonance diffusion-weighted imaging
(DWI) and perfusion imaging (PI, which can be performed on both MR and CT
scanners) may prove useful in this area of stroke research, as well areas with more direct
clinical relevance. Consequently, considerable enthusiasm has been expressed for these
techniques213. The combination of DWI and PI (combined in one appealing imaging
sequence on MRI) may provide important detail on the status of the damaged brain.
Principles of diffusion weighted imaging
DWI makes use of the fact that molecules are in a constant state of (Brownian) motion.
By applying a series of two sequential gradient pulses to a conventional MRI sequence,
molecules moving after the pulse has been applied acquire phase shifts that lead to the
failure of such molecules to rephase completely, the molecule of interest for biological
scanning purposes generally being water. This effect can be measured, the resulting
signal being interpreted on a scan as an area of altered intensity4. The amount of signal
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remaining after application of the second gradient pulse is related to two factors: the
diffusion coefficient of the substance and duration and strength of the magnetic field
gradients. This relationship was originally described by two physical chemists, Stejskal
and Tanner, as follows:
SDocebD
SD = degree of signal drop
D = diffusion coefficient
b = duration and strength of the (encoding) gradient
Effectively, it means that for a given encoding gradient, substances with high diffusion
coefficients lose signal more rapidly than those with a low diffusion coefficient. In a
region of infarcted tissue, the diffusion of water molecules is restricted and will
therefore undergo signal loss more slowly than surrounding normal tissue (resulting in
increased signal on imaging).
By obtaining images with gradients of different strengths (multiple b values, two
readings giving the necessary accuracy), an apparent diffusion coefficient (ADC) can be
calculated, providing a quantitative measurement of water motion independent of
magnetic field strength and gradient. Because molecules can theoretically move in any
direction, the measurement of ADC is a three-dimensional quantity, known as a tensor
(as opposed to a scalar or vector quantity). It is the apparent diffusion coefficient that is
measured, rather than the true diffusion coefficient because of the uncertainty
surrounding the origin of water mobility. The ADC also takes into account the fact
that the movement of water molecules in a biological system is not truly random, rather
there is constraint along tissue planes, making movement in one direction easier than
another ('diffusion anisotropy'). If anisotropy is not taken into account, results can be
misleading; for instance, while ADC values (i.e. the average mobility) is similar for
water molecules in both grey and white matter, white matter shows a strong directional
preponderance. Measuring ADC values in only one plane would therefore lead to
misleading values which would depend upon the ease with which water molecules
could move in that plane, a factor not recognised in early diffusion studies5. This
problem is solved by sampling the ADC in at least three different directions. Also, as
well as the direction in which water molecules move not being truly random, the degree
to which they move is dependent on exogenous factors. One of the most clinically
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relevant factors is the level of energy in the system, with molecules moving more at
higher temperatures6.
Principles of Perfusion Imaging
Perfusion imaging can detect hypoperfused regions of brain either by monitoring the
transit of a rapidly injected contrast agent7 or magnetically tagged water molecules in
arterial blood8 through the brain. In regions distal to an arterial occlusion, the arrival of
the contrast agent or tagged water molecules may be delayed. The resulting signal-time
curve can be converted into a concentration-time curve, from which several functions
that describe regional perfusion can be determined.
The need for a systematic review on diffusion and perfusion imaging
The ease with which ischaemia can be identified on DWI compared to CT and
conventional MRI can be striking (figure 1). However, as has been discussed, before a
new imaging procedure is introduced for use in a general population, it should have
been demonstrated that images such as these are reproducible in the general population
rather than a highly selected case series.
Figure 1. CT (left), conventional MRI (Tl-weigfted, middle) and DWI (right) scans performed
within 24 hours ofeach other, ofa patient with sudden onset left leg weakness and left arm tingling.
Note no identifiable area ofhypodensity on CT, various areas ofincreased signal on T2 MR but none
distingiiishmg and obvious small area of increased signal in the rigft internal capsule on DWI
(arrows).
Not only should DWI and PI produce reliable and accurate results, but they should also
be clinically feasible and ideally have a positive therapeutic impact9. In recent years, the
enthusiasm for DWI and PI has grown with a consequent explosion of publications on
these techniques. Are they an improvement on CT or standard MRI techniques in the
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investigation of stroke? What information has been obtained so far on patient
characterisation that was previously not readily available? Have they had any effect on
acute stroke treatment guidance? To find out whether these questions had been
addressed, as well as determining the methodological quality of studies published so far,
and to identify where more information might be needed, a systematic review of
magnetic resonance DWI and PI was performed.
7.2 Methods
Search strategy
An electronic search was performed for all published articles on DWI, PI or a
combination of the two, in the English and non-English language literature in Medline
and Embase from 31st October 1999 back to the earliest studies available (1990). The
Cochrane library extended search strategy for stroke (appendix III) was combined with
the search terms: 'diffusion weighted', 'perfusion weighted', 'dynamic susceptibility',
'haemodynamically weighted', expanded to maximise the number of hits. Also, six
relevant journals (Stroke, Radiology, American Journal of Neuroradiology, American
Journal of Roentgenography, Magnetic Resonance in Medicine, Journal of Magnetic
Resonance Imaging) were hand-searched from November 1999 to January 2000, and
reference lists were examined from all the identified studies. The inclusion criteria were
published studies in which DWI, PI or both in combination had been conducted in
humans with stroke. Case reports and studies that had so far only appeared in abstract
form were excluded. A further search was performed in April 2001. Although the data
from the first search will be the main subject of this chapter, any important findings in
later studies will be highlighted.
Data extraction and analysis
Information was extracted on: the sample size of each study; its main purpose, the time
window from onset of stroke symptoms to imaging, how the diagnosis of stroke had
been made and by whom, the patient inclusion criteria, the DWI or PI scanning
method, the image analysis method, whether interpretation of diffusion or perfusion
images was blinded to clinical details and the results of other imaging modalities,
whether any patients had been imaged but then excluded from further analysis and
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why; whether any data on clinical outcome had been collected and at what time after
stroke, and the overall conclusion of the study. The extracted information was entered
into an Access database and assessed with descriptive statistics.
7.3 Results
7.3.1 Studies ofdiffusion-weighted imaging alone
Identified studies and general methodological details
Searching captured 50 studies concerned specifically with DWI in humans with
ischaemic stroke (2342 patients, median sample size 32). In these studies, although the
technical information on the imaging sequences was good, the information on general
methodological details (blinding, patient selection and exclusions, and the proportion of
uninterpretable scans) was limited, and generally these details were not mentioned. In
only 10/50 (20%) were scans interpreted blinded to clinical details or other imaging10"
18;7°, and only seven (14%) gave specific details on patient inclusions and
exclusions16;17;19~23. Only nine studies gave details on the number (and reasons for)
inadequate scans that were excluded from further analysis16;17;19;21;24"28, although it is likely
that patients with poor quality scans were excluded from the analysis in other studies.
There were no details in any of the studies on patient tolerability of the investigation or
evaluation of the risk to the patient. Table 1 lists the fifty studies concerning DWI
alone identified, with their primaiy purpose and main findings. The majority of studies
were performed in association with departments with an interest in stroke.
Primary purposes of identified studies
Studies ofa technical nature
Seventeen studies (567 patients) investigated DWI techniques or refinements of
techniques of image acquisition of processing, methods of calculations of the
j/^Q£i4;i6;i9;24-26;28-38^ usefuJ comparisons could be made between them as all covered
different aspects and mentioned little about the type of patients included.
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DWI lesions at differing time points
Six studies (564 patients) studied the visibility of DWI lesions or changes in ADC
values over time. In five, the proportions of patients where repeated scanning was
completed successfullywere limited39"41 or impossible to determine15;42. In these studies,
the time over which lesions remained visible on DWI was inferred by using scans of
different patients at different time points, rather than repeated imaging of the same
patients. In only one study were the majority of patients repeatedly scanned, and it
found reduced ADC values for up to 85 days after stroke21.
DWI lesions, neurological disability and clinical outcome
Two studies (92 patients) investigated the correlation of early DWI (within 24 and 60
hours) with measures of clinical stoke severity at the time of imaging and at a later date
(three and 42 weeks)l2;17. Both studies demonstrated that acute lesion volumes on DWI
correlated with both the National Institute of Health Scale (NIHSS) (both acutely and
at follow-up) and the modified Rankin Scale (RS) at follow-up. In both studies, images
were read blinded to clinical details, and in one also to initial T2-WI.
DWI compared to CTand conventionalMRI
Thirteen studies (457 patients) suggested that DWI demonstrated more lesions in the
symptomatic anatomical area at an earlier time-point than did conventional imaging.
Although one study directly compared CT and DWI (17 patients)10, the majority of
studies compared DWI to conventional MRI15'18;27;41;43"50. All indicated that more lesions
were visible on DWI than conventional imaging. Timing of scanning varied between
studies from: less than six hours10;15;41;44;46, within 48 hours45;47, within 4 days18;43, to 'the
time period under investigation (eight hours to 12 days)27. Scans were interpreted
blinded to clinical details in only two studies15118, to other imaging in only one44, and to
both imaging and clinical details in only one10. No study randomised the order, or even
stated the order in which scans were performed. Sample sizes ranged from 103 to only
nine patients. The proportion of patients in which DWI was felt to be superior to
conventional MR imaging ranged from five to 71%. In one study, it was impossible to
define in how many patients DWI had proven superior48.
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Differentiating new from old lesions on DWI
Eight studies (454 patients) found that in patients with multiple lesions of MRI, it was
possible to distinguish new from old lesions with DWI16;18;27;42;51"54. Acute lesions
appeared hyper-intense, and old lesions hypo-intense. Timing of scanning in these
studies ranged from less than seven hours to 11 days. In only two studies were the
scans read blinded to clinical details16;18. The proportion of patients where DWI was
felt to be superior in distinguishing new from old lesions compared with conventional
MRI ranged from four to fifteen of 220 patients with multiple lesions, i.e. less than 10%
the total number of patients included.
Clinicotopography ofDWI lesions
Six studies (261 patients) concentrated on the clinicotopography of a specific stroke
subtype such as lacunar stroke55"58 or transient ischaemic attack597,0. The studies
concentrating on lacunar symptoms demonstrated that DWI could identify appropriate
subcortical areas of ischaemia. One study (62 patients) noted that 16% of patients
presenting with lacunar syndrome had multiple lesions identified on DWI58. One study
concerned with transient ischaemic attacks demonstrated that 48% of patients whose
symptoms resolved within 24 hours had relevant lesions on DWI within 24 hours of
symptom onset. Patients whose symptoms resolved by 24 hours had smaller and less
obvious lesions on DWI than patients whose symptoms had lasted longer59.
Feasibility ofa DWI scantling protocol
Six studies (13%, 518 patients), two of which were retrospective analyses, addressed the
feasibility of undertaking an advanced imaging protocol in acutely ill stroke patients and
suggested that it was possible597,1"65. None of the imaging was read blinded, which is
clinically realistic, but data on patient inclusion and exclusions, as well as clinical
characteristics was often limited, i.e. information to identify patients who would be
poor subjects for DWI, or any problems that were encountered were not given. Two
studies (20 patients) demonstrated that it was possible to identify acute haemorrhage, a
subset of patients previously thought to present difficulty on DWI66;67. However,
neither study was blinded to other imaging results.
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False negatives and inter-observer reliability of image analysis
One retrospective study (27 patients) raised the important issue of patients with stroke¬
like deficits and negative DWI imaging68 and described their case series. They explained
that specificity had not been addressed because their entire (and substantial) case series
(782 patients) had not been reviewed. One study (19 patients) investigated the inter-
observer reliability of DWI in the detection of greater than a third involvement of the
middle cerebral artery in ischaemic stroke compared to CT69. Lesions were identified
correctly in all cases on DWI, compared to between 42 and 63% of those on CT. DWI
scans were performed on average 2.6 hours after CT. One study explored the yield of
potentially relevant information on DWI, noting clinically significant findings on DWI
alone in 48% of patients. In the discussion, they mentioned that 'the active clinical
relevance was not addressed'. Of note was the observation that 9/40 (23%) of patients
refused follow-up scanning at 30 days70.
7.3.2 Studies ofperfusion imaging alone
Included studies
Fourteen studies concerning MR PI alone were identified (198 patients, median 10), as
well as four studies combining MR PI with another advanced imaging modality such as
single photon emission computed tomography (SPECT) (38 patients, median 10).
MR PI alone
Of the 14 studies concerning PI alone, one study (15 patients) attempted to evaluate the
clinical usefulness of PWI71. The other 13 studies (183 patients) were concerned with
the technical aspects of demonstrating abnormalities of regional cerebral perfusion7""5,72
82. All bar one81, which attempted to quantify the arterial input function, a constant
required for the calculation of absolute blood flow, assessed relative rather than
absolute cerebral blood flow. All studies used the gadolinium bolus tracking method of
measuring blood transit time. A variety of perfusion abnormalities were demonstrated;
one study (11 patients) noted a heterogeneous distribution of rCBF in the expected
regions of interest in all examinations73; three studies (102 patients) documented
hyperperfusion as well as delayed or absent perfusion in the region of interest7;8;72; and
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one study (11 patients) documented no perfusion deficits in four out of the eleven
subjects despite marked clinical signs and repeat MRI within 48 hours confirming
infarction71.
MR PI combined with other imaging modalities
Of the four studies that combined MR PI with another advanced imaging modality,
perfusion MRI was correlated with SPECT findings in three83"85, and with xenon CT in
one86. All found that MR perfusion techniques correlated well with the perfusion
deficit demonstrated on these other modalities. Sample sizes were small and it was not
made clear whether perfusion images were read blinded to other forms of imaging.
7.3.3 Studies ofDWI andPI in combination
Identified studies and general methodological details
Nineteen studies were identified with a total sample size of 563 (median 21). The main
purpose of three (197) was to document the clinicotopography of the combined
imaging87"89. Sample sizes were small and it was not documented whether DWI and PI
were read blinded to clinical details. One study (nine patients) compared DWI/PI to
CT in the interpretation of haemorrhage, and again no details were given with regards
blinding90. One study (41 patients) explored the clinical feasibility of DWI/PI91.
Although the resulting data were encouraging on the speed of the process, they were
lacking on patient clinical characteristics and importantly, the proportion of patients the
imaged group represented in relation to the total number of patients with stroke
symptoms presenting to the study hospital.
DWI/PI, final infarct size and clinical outcome
Fourteen studies (316 patients) were mainly concerned with the use of DWI/PI in
predicting either the final size of infarct on conventional imaging92"97 or final infarct size
and clinical outcome98"105. The median sample size was 20 patients and four of these
studies reported inclusion of patients from previously published papers. Follow-up
imaging was performed between three and 277 (median eight) days after initial
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scanning. Studies that used later time points did not make clear whether ex vacuo
effects (potentially leading to an underestimation in infarct size106, see discussion) were
taken into account.
In the nine studies that related DWI/PI patterns to clinical outcome, follow-up ranged
from one to 90 days after stroke. The scales used varied, the commonest being the
NIHSS92;98;99;102;103;105, which is a measure of neurological deficit not functional outcome.
The size of lesion on acute DWI or PI correlated with final clinical outcome using both
the NIHSS, the Canadian Neurological Scale (CNS)100;101, and the European Stroke
Scale (ESS)104.
The DWI/PI 'mismatch'
Varying patterns of 'mismatch' between lesion extent on DWI and PI were seen and
opinions given as to what these patterns represented. Where PI lesions were larger
than DWI, investigators inferred a larger area of brain under threat of ischaemia that
outlined by the DWI lesion, i.e. an ischaemic penumbra. Where DWI lesions were
larger than PI lesions, or no associated PI lesion was visible, the investigators inferred
that a degree of reperfusion had occurred but that an area of permanent damage,
represented by the DWI lesion had already occurred. Where no DWI lesion was visible
in the presence of a PI deficit, it was inferred that there was an arterial occlusion but no
ischaemic damage at the time of imaging101. 11 studies (225 patients) used MR
angiography (MRA) in their imaging protocols as well as PI and DWI, some of which
helped to support the findings of PI by demonstrating an appropriately occluded
artery88;90;94;95;97;99"102;104:105, but otherwise there was no other objective way for
substantiating the 'mismatch' theory. The proportion of patients in whom the lesion
behaved as predicted on the follow-up imaging (i.e. where PI > DWI, the area of
ischaemia on the follow-up scan increased in size) varied from 100% to only 56%.
7.3.4 Data from more recently published studies
Between October 1999 and April 2001, a search of MEDLINE and EMBASE revealed
a further 102 studies published on DWI and PI. Of 52 studies that were reviewed, the
median sample size was 27, scans were examined blinded to clinical history or imaging
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in 17/52 (33%). Documenting the patterns seen in small samples remained the primary
purpose in a large proportion of studies (44%). 14 studies explored technical issues
such as the differences in ADC values between grey and white matter107"109, or in lesions
with haemorrhagic transformation110. Two studies commenting on the feasibility of
DWI protocols documented significant numbers of exclusions1111112; one of which
performed a DWI protocol in only about 10% of strokes presenting to their facility112.
Further work was published on the significance of DWI/PI mismatches11*114, but
exactly what the mismatch represents remains unresolved. Three studies (197 patients)
documented the superiority of DWI over conventional imaging in the demonstration of
lesions115"117.
7.4 Discussion
The importance of demonstrating clinical benefit with DWI/PI
Acutely ill patients are poor MRI subjects; they are restless, may be confused and
unable to lie still for prolonged scan times, and observing their clinical state is difficult.
Lying supine when the ability to protect the airway is impaired increases the risk of
aspiration (roughly 50% of all strokes have impaired swallowing reflex acutely118). To
justify their incorporation into patient care, DWI and PI have to genuinely provide
information over and above that which is readily available on a plain CT, and this
information should alter clinical management. The quality of any information gained
should also outweigh any loss of treatment efficacy resulting from added time delay to
start of treatment, an important criteria in this era of thrombolysis. Are the data
available with which to start making such judgements?
Published studies are methodologically weak
The results of this systematic review show that publications in this field so far are
repeating the mistakes of CT and conventional MRI, in that they tend not to include
important methodological details. In many studies, the advanced imaging was not read
blinded to the more routine imaging, there was little information on patients unable to
complete DWI or PI, and most studies lacked clinical details of patient selection and
case mix. No details were given on the order in which imaging was performed, and if
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DWI was always performed after conventional imaging, as with studies so far that have
compared conventional MRI to CT, it is likely therefore, that DWI would always show
more lesions.
The data needed to determine the sensitivity and specificity of DWI for identifying
acute ischaemic lesions and of DWI/PI for identifying salvageable tissue were not
available. One important case series of patients with stroke but negative scans (taken
from a series of over 700 patients) mentioned that specificitywas not addressed68. Such
a task would indeed have been a major undertaking, but it would give us information
on sensitivity and specificity of DWI with an accuracy that smaller studies that have
attempted to address this issue37 have not achieved. Other studies have attempted to
define specificity and sensitivity of DWI61;44, but selection bias make it difficult to
extrapolate these values to the general population with stroke-like symptoms.
Although it is likely that DWI is more sensitive to acute ischaemic stroke than
conventional MRI or CT, the sample sizes were so small, and there were insufficient
details of clinical features, inclusion and exclusion criteria, and unsuccessful
examinations to make an accurate estimation of its merit compared to CT or
conventionalMRI to be made.
The importance of case-mix
Descriptions of case-mix in studies so far are scanty at best, and this is one of the main
weaknesses of the existing data; case-mix is crucial for a number of reasons. Firstly,
some conditions that mimic stroke clinically can also manifest abnormalities on
DWI27;119;12°. Few studies mentioned whether or not any of their prospectively
identified patients later turned out not to have had a stroke, though it would be
unusual, in a prospective sample even as small as 40, not to find the occasional patient
thought initially to have had a stroke, to turn out to have a non-vascular cause of their
symptoms121. Conversely, the study by Ay68 and other case reports122;123 have
highlighted the potential for DWI to be negative in patients with ischaemic stroke.
Although PI may be of some use in these patients, clarification around this issue is
sorely needed.
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Secondly, as stroke is a heterogeneous condition and the case mix of patients is likely to
differ between hospitals (even within one small geographical area), this will have led to
differences between studies in the type of stroke patients included. However, unless
sufficient details of the patients' clinical characteristics at baseline (age, gender, some
measure of neurological deficit, prestroke morbidity etc) and clinical status at a
recognised, valid outcome point (e.g. three months), by a validated outcome score are
given, it is impossible to gauge the generalisability of the individual study results, hence
the relevance to the stroke population in general. One month after stroke is far too
early to determine clinical outcome, and still too early for radiological outcome. There
may still be either swelling (overestimating final infarct size124) or fogging (grossly
underestimating final infarct size125). In fact, use of any radiological outcome is difficult
if a volume measure or image co-registration are used because (in addition to swelling
and fogging), loss of volume in the affected area and ex-vacuo effects in surrounding
tissues from four to six weeks onwards124 will lead to underestimation of final infarct
volume.
Thirdly, the clinical severity of the stroke is a profound determinant of clinical
outcome, correlating strongly with the site and extent of the lesion on CT and
conventional MRI. Stroke severity must be taken into consideration before any
additional information contributed by an imaging technique to the identification of
particular patients, or the determination of outcome can be identified126. Most studies
failed to do this adequately. Stroke severity also influences the time to admission to
hospital (severe strokes are admitted sooner after stroke than milder ones127), and hence
will influence the time to imaging. This in turn will probably influence the ADC values
found in individual patients. Failure to take account of case-mix may have also
contributed to perceived differences between studies that compared ADC changes over
time where 'snapshots' of different patients at different times were used instead of the
same patients scanned serially at different times. A similar effect most probably affects
the findings in studies of DWI with PI where the proportion of patients with
diffusion/perfusion mismatch and its size will depend on the severity of stroke
included and the time delay to imaging.
177
The problem with small sample sizes
In all cases, the sample size was small. Also, our totals may overestimate the true
number imaged, as some patients were included in several different publications. Small
sample size makes the studies vulnerable to the play of chance in the mix of patients
included and the study results. Examples of how profound an effect the play of chance
can have, can be found in the systematic review of early trials of thrombolysis for acute
myocardial infarction128 (in which studies with sample sizes up to several hundreds had
diametrically opposite results), and in an exercise to demonstrate the effect of chance
on small sample sizes (DICE therapy - Don't Ignore Chance Effects)129. Investigators
should be encouraged to combine their existing individual patient data from different
individual studies, and participate in new multi-centre studies wherever possible,
thereby achieving much larger sample sizes and over-coming some of the case mix
problems outlined above. The numbers of patients required to obtain more robust data
on the efficacy of DWI and/or PI in individual studies are not large however. Only 84
patients would be required to show (with 90% power) that DWI demonstrated lesions
in 90%, as opposed to CT showing lesions in 60% of patients.
Unresolved technical issues
Although many studies gave ample details of the imaging sequences used, there are
problems with the precise DWI or PI parameters to be measured, more so with PI.
Most MR PI techniques measure relative not absolute perfusion changes and Positron
Emission Tomography (PET) studies have demonstrated drawbacks with this
approach130. Relative perfusion values may not precisely demonstrate which tissue is at
greatest risk of infarction, added to which, is the unresolved debate about which is the
best parameter of the PI curve to use in the analysis. Attempting to ascribe a
physiological mechanism to PI findings on the basis of our current knowledge is to risk
mistaking association for causation. Very detailed analysis of small datasets (e.g. 30
patients) may be used to generate hypotheses to test in new studies. However
conclusions from such analysis are data-dependent in themselves, and placing too much
reliance on the results might be misleading131, particularly in the absence of any
spontaneous or pharmacologically induced tissue recovery to identify what tissue really
is salvageable. An example of this type of error about 10 years ago was the
overemphasis of the association between haemorrhagic transformation and
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cardioembolic stroke. Then, it was incorrectly assumed that cardioembolic stroke caused
haemorrhagic transformation, because of an observed association, when in fact, it was the
size of the infarct rather than the mechanism per se that was responsible132;133. The
relevance of this is that investigators then used the presence of haemorrhagic
transformation to diagnose cardioembolic stroke, when of course any arterial infarct
may become haemorrhagic, as may venous infarction.
Mismatch equals penumbra - appealing theory based on what evidence?
Three of the studies that compared DWI/PI with final infarct size commented on the
nature of the lesion visualized by DWI. Opinions varied; one study92 implied that the
DWI lesion was infarcted tissue, another stated that 'DWI lesions do not reflect closely
the extent of functionally compromised tissue'101, and another93 stated that diffusion
abnormalities indicated reversible and irreversible ischaemia. No studies used any other
imaging methods to corroborate these theories therefore, it was not clear on what
evidence these statements were based.
Do more recent studies resolve any of these issues?
In spite of the continuing interest in DWI and PI, as demonstrated by the high volume
of publications since the original search, little has been resolved. Samples are still too
small and highly selected. Studies are still commonly not blinded. There have been
encouraging studies of the superiority of DWI in the demonstration of lesions
compared to conventional imaging, but the majority concentrate on the first one or two
days after stroke, which would inevitably limit its use. Encouraging work with SPECT
is beginning to attempt to quantify viable ischaemic tissue134, but we are barely any
further forward in determining the physiological significance of the diffusion/perfusion
mismatch.
Conclusion
DWI and PI may represent an exciting step
the studies using these techniques published
determine their precise therapeutic impact.
forward in the management of stroke, but
so far do not contain the data necessary to
Before we can be sure they represent an
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improvement over and above plain CT, we need to determine what it is these images
depict with greater certainty, and get some measure of how much more clinically useful
they are than conventional imaging, if that is indeed the case. Some of the issues raised
above concerning the effect of stroke severity on ADC values (and visibility of lesions),
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8 Diffusion-Weighted Magnetic Resonance Imaging In Stroke -
Exploratory Analyses From Our Observational Case Series
8.1 Introduction
What do we need to know about diffusion-weighted imaging?
Although the quality of studies published so far on diffusion-weighted imaging (DWI) is
not ideal, it is likely that DWI can demonstrate acute ischaemic stroke more frequently
than computed tomography (CT)1'2 or conventional magnetic resonance imaging
(MRI)3'4 and is likely to represent an exciting step forward in stroke imaging. However,
questions remain over precisely how superior DWI is to conventional imaging, and in
which patients it is most clinically useful. For instance, DWI can demonstrate lesions
very early after stroke onset, but so too can CT and T2 MRI, especially in patients with
clinically more severe strokes with larger lesions5'6, who tend to present to hospital
early7. It is not clear that DWI is more sensitive than conventional imaging in these
hyperacute patients8. In fact, undue attention on using DWI in hyperacute stroke may
have overlooked other important clinical uses of DWI in stroke. DWI may actually be
more useful in milder strokes because of its ability to detect very small lesions better
than conventional imaging9,10. Small lesions can be difficult to visualise using CT or
conventional structuralMRI u'12.
There are a number of settings when making a positive diagnosis of, or confidently
excluding, an ischaemic stroke would be clinically useful. For example, in a patient with
prior stroke and further weakness (deterioration could be due to a further stroke or an
intercurrent illness); if there was a suspicion of an unwitnessed seizure; or if it was
unclear whether symptoms were due to a single occluded vessel or multiple emboli.
The need to quantify ischaemic damage in stroke - a role for DWI?
The changes due to ischaemic damage demonstrated on DWI can be quantified by
calculating the apparent diffusion coefficient (ADC)13 and measuring the volume of the
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visible lesion. These variables may provide an objective assessment of tissue damage
and this could be the ideal outcome predictors if they added predictive information
beyond that obtained from baseline clinical examination alone, and the relationship with
functional outcome were well characterised.
There have been several studies suggesting that the ADC and/or DWI lesion volume
can predict outcome, i.e. the more abnormal the ADC, or the larger the visible lesion on
DWI, the more severe the stroke and the worse the outcome.14"18. One study went so
far as to suggest a cut off value for ADC of 0.56, below which outcome was poor19'20.
However, the studies were small and did not specifically test for an independent
association of imaging parameters with outcome, i.e. they did not test the extra
predictive value of imaging over and above other prognostic factors.
The aims of our observational case series
We therefore set out to accumulate a prospective case series, with different stroke
severities and outcomes, large enough to test the questions: 'in which clinical group of
patients with stroke is visualising the responsible lesion with DWI of most use?' (the
'utility of DWI' study), and 'do DWI parameters such as ADC and DWI volume add
independent prognostic information over and above clinical outcome predictors alone?'
('DWI and stroke severity' study).
8.2 Methods
Patient recruitment
As many patients as possible with acute ischaemic stroke admitted to our institution
were recruited consecutively between February 1996 and August 1999. Inclusion
criteria for this study were as follows: (i) well-defined onset of stroke symptoms; (ii)
absence of cerebral haemorrhage or other non-vascular abnormality on CT or
conventional MRI; (iii) no contraindications to MRI; (iv) subjects deemed able to
tolerate the imaging protocol; (v) and the availability of the research MR scanner. Mild
and severe strokes were included, and anterior as well as posterior circulation strokes.
195
No subjects received any investigational drugs. The study was approved by the local
Ethics Committee.
Patients were examined by myself and categorised according to the Oxfordshire
Community Stroke Project (OCSP) classification, and Canadian Neurological Scale
(CNS) (appendices I and V) as soon as possible after admission, and prior to scanning.
At six months after stroke, patients were followed up by telephone or postal
questionnaire by an operator who was blinded to the baseline clinical and imaging
results. The patient's functional status was classified according to the modified Rankin
scale (a global outcome measure with a 0 to 6 point scale: 0 indicating no symptoms, 5
indicating severe disability and 6 indicating dead, appendix IX)21.
Imaging acquisition
Patients were scanned as soon as possible after admission. During the course of the
study, the access to MRI changed so that the first 40 subjects were imaged on a 1.5 T
Siemens Magnetom SP scanner, the next 68 subjects on an Elscint 2T Prestige scanner,
and the remaining 45 subjects using a GE 1.5T Signa Horizon LX scanner. Both
patient groups had routine structural imaging (Tl-weighted T2-weighted and proton
density, see chapter 5 for parameters and appendix IV for glossary of terms) followed by
DWI. Patients were scanned as soon as possible after admission or on the day of their
outpatient clinic visit. Total scanning times were longer in the Siemens (non-
echoplanar, about 45 minutes), and shorter on the Elscint and GE systems (echoplanar,
15 minutes).
Diffusion-weighted images were obtained on the Siemens scanner using a modified
double spin echo sequence, which acquired an image echo (TE =121 ms) and then a
non-phase encoded navigator echo (TE = 152 ms). Before the image echo, two
symmetric diffusion sensitising gradient pulses of magnitude zero (baseline) and 9.64
mT m'1 were applied sequentially along the read, phase encode and slice-select
directions. The diffusion gradients were of duration 51 ms, and separation 57.4 ms,
giving scalar b-values of approximately 0 and 700 s mm'2. Motion artefacts arising from
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bulk patient motion were corrected using the navigator echo data22. Other image
acquisition parameters were as follows: 8 non-oblique axial slices, 1 NEX for both
baseline and diffusion-weighted images, 5 mm slice thickness, 128 x 128 image matrix
and a 230 x 230 mm field of view.
On the Elscint scanner, diffusion-weighted images were obtained using a single shot,
half-Fourier, echo-planar imaging sequence, in which two symmetric diffusion
sensitising gradient pulses of magnitude 0 (baseline) and 14 mT m"1, duration of 40 ms
and separation of 43.9 ms were applied sequentially in the read, phase-encode, and slice-
select directions. Scalar b-values for this sequence (approximately 0 and 700 s mm"2)
were calculated numerically2'. Other image acquisition parameters were as follows: 10
non-oblique axial slices, 1 NEX for both baseline and diffusion-weighted images, 6 mm
slice thickness, 128 x 72 half-Fourier image matrix (zero filled to 256 x 128), 44 x 22 cm
field of view, TR of 1 s per image and TE of 103 ms.
On the GE scanner, two diffusion sensitising gradient pulses of duration 32.2 ms with a
separation of 30.09 ms were applied in six directions. Scalar b values were 0 and 1000 s
mm"2. 10 axial or axial-oblique slices of 5mm slice thickness were acquired, the image
matrix was 128 x 128 and the field of view was 230 x 230 mm.
Image Analysis
The utility ofDWI
A neuroradiologist examined the printed films of T2-weighted (T2-WI) and diffusion-
weighted images on separate occasions, blinded to patient details and other imaging
results. Scans were classified according to whether they demonstrated a recent
infarction, a definite old infarct, or some other non-vascular lesion, or showed no lesion.
'Recent infarcts' were defined as an area of hyperintensitiy on DWI or on T2-WI in a
distribution consistent with known vascular patterns. On T2-WI new was distinguished
from old by the greater mass effect and less marked hyperintensity of the former than
the latter.
197
Thereafter, the T2-WI and DWI results were combined, and DWI scans rated for
'clinical influence'. DWI scans were rated as 'helpful' if they distinguished a new from
an old infarct, or identified a new infarct not visible on T2-WI. They were rated
'unhelpful' if recent infarction was visible on both DWI and T2-WI, or DWI did not
demonstrate a recent lesion, or scans were technically of poor quality.
Having a DWI scan which demonstrated no lesion could also be of value to the clinician
in making an appropriate diagnosis. Therefore, DWI scans were then reclassified as
'helpful' if they showed a definite new lesion not visible on T2-WI, or distinguished new
from old infarct, or if they definitely showed no new lesion. They were reclassified as
'unhelpful' if the recent infarct was clearly visible on T2-WI or the DWI scan was
technically poor, and so uninterpretable.
DWI and severity
A neuroradiologist examined the printed films of T2-WI and diffusion-weighted images
on separate occasions, blind to patient details and all other imaging results. Scans were
classified according to whether on T2-WI an infarct was not visible, faintly visible (slight
hyper-intensity) or obvious (definite distinct hyperintensity) and whether the lesion was
visible or not on the diffusion-weighted images. The T2-WI and DWI results were then
compared and a rank order of visibility of lesions produced, according to whether the
lesions were: (1) not visible on either T2-WI or DWI, (2) visible only on DWI, (3)
faintly visible on T2-WI and clearly visible on DWI, and (4) clearly visible on T2-WI and
DWI.
Images were processed off-line on a Sun Ultra Sparc Station 1 (Sun Microsystems,
Mountain View, CA, USA). Baseline and diffusion-weighted images were aligned using
SPM95 (http://www.fil.ion.ucl.ac.uk/spm) to correct for bulk patient movement
between scans. Within each voxel the three orthogonal ADC components (ADCX,
ADCy and ADQ), were estimated by linear regression from the measured baseline and
diffusion-weighted signal intensities. To avoid diffusion anisotropy effects24, these three
orthogonal ADC components were averaged to produce the apparent diffusion tensor
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trace (ADC). The three component diffusion-weighted images were also averaged
together to give average DWI maps. Maps of ADC were generated on a voxel-by-voxel
basis and converted into Analyze (Mayo Foundation, Rochester, MN, USA) format. In
patients with a hyper-intense lesion visible consistent with ischaemia, these regions were
outlined on the ADC maps by a neuroradiologist blinded to all clinical and other
imaging data. A mirror image area in the contralateral (normal) hemisphere was also
outlined. For each slice, values of ADC for the lesion and mirror (contralateral) normal
tissue regions were measured. Overall mean ADC values for the entire hyperintense
lesion (and control) volumes were then calculated from these data. A ratio of the mean
ADC for the lesion volume to the mean ADC of the normal (mirror image) brain
volume was calculated (ADCr = ADC[ischaemic lesion]/ADC[normal]), so that each
patient acted as their own control, and any effect of using different MRI scanners for
the project was minimised.
Statistical analysis
The baseline clinical data, the imaging data and the functional outcome data were
entered into a database, and analysed using the Statistical Package for Social Sciences
(SPSS). For the utility of DWI study, the proportions of scans demonstrating recent
infarction were compared using McNemar's test for matched data. The 'influence' of
DWI was compared across OCSP stroke subtypes using a chi-squared analysis, and with
the CNS using the non-parametric Mann-Whitney test. Odds ratios with 95%
confidence intervals were also calculated.
In the DWI and stroke severity study, we examined the relationships between ADCr
and imaging parameters (lesion volume on the ADC maps and infarct visibility on T2-
WI/DWI), clinical features (initial stroke severity - OCSP classification and CNS), and
six-month functional outcome. The non-parametric Kruskal Walks test was used to
compare: groups defined by their OCSP classification with timing of scanning, ADCr
and lesion volume; and groups defined by how visible lesions were on T2-WI with
Canadian Neurological Scale values and ADCr. The Mann Whitney U-test was used to
compare functional outcome (dichotomised as dead or dependent or independent on
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the modified Rankin scale, i.e. three to six versus zero to two respectively) with ADCr
and lesion volume. Spearman's coefficient of correlation was used to compare: CNS
values with timing of scanning, ADCr, lesion volume; and ADCr and lesion volume. As
this was an exploratory analysis, we felt it was justifiable to examine multiple potential
associations between clinical and imaging variables and outcome. We then performed a
multiple logistic regression analysis to determine whether the ADCr was an independent
predictor of outcome, over and above the initial clinical severity of the stroke (as
determined by CNS) and the age of the patient. Only three variables were used in this
exploratory analysis as there were too few patients and outcome events to build a more
complex model25.
8.3 Results
The analysis of the influence of stroke severity on DWI imaging parameters was
performed using a database of 108 patients scanned using the Siemens and Elscint
scanners. This group also formed the core of the analysis of the utility of DWI, to
which a further 45 patients scanned on the GE Signa machine were added. Each
study's baseline characteristics and results are described separately.
8.3.1 The utility ofDWI
Patient baseline characteristics
153 subjects were scanned, 148 of which presented with stroke, five with transient
ischaemic attack (TIA). The mean age was 67.6 years (range 19 to 93 years). The
median time to scanning was two days and mean time to scanning was six days (range
less than one to 77 days, in an outpatient), 102 (67%) were scanned within three days.
The remaining 33% of patients were scanned at later times because they had presented
late to hospital as outpatients. The median CNS was 8.5 (range 1.5 to 10) (table 1). In
two patients, DWI scans were technically poor and completely uninterpretable. In
patients presenting with a stroke, 13 (8.5% of total scanned) had total anterior
circulation syndromes (TACS); 71 (46.4%) had partial anterior circulation syndromes
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(PACS), 42 (27.5%) had lacunar syndromes (LACS); and 22 (14.4%) had posterior
circulation syndromes (POCS).
Imaging findings
A greater proportion of DWI scans (107, 70%) demonstrated a relevant recent
ischaemic lesion than did T2-WI (49, 32.0%), p < 0.001, (figure 1). In patients with
larger, more severe cortical syndromes (TACS), an infarct was visible on both DWI and
T2-WI in 8/13 (61%) patients, DWI being uniquely helpful in identifying recent
infarction in only 31% (95%CI, 10-61%) of patients with a TACS. In patients with
smaller anterior infarcts however (PACS or LACS), a recent infarct was demonstrated
by DWI alone in greater proportions of patients (42% of PACS (95% CI 31-5%), and
43% of LACS (95% CI 28-59%). The proportion of patients in which DWI was rated
as 'helpful' (identifying a relevant lesion not seen on T2-WI or distinguishing a new
from an old lesion) also varied according to clinical subtype: DWI was 'helpful' in 31%
of TACS, 62% of PACS, 62% of LACS, and 56% of POCS. DWI was of most use in
patients with smaller cortical lesions (PACS and LACS, odds ratio 3.66, 95% CI 1.06 -
12.6) (figure 2). When DWI scans was reclassified as 'helpful' if they showed no new
ischaemic lesion as well as distinguishing a new from an old infarct or demonstrating a
recent ischaemic lesion, this observation was even more pronounced (88% of LACS
compared to 39% TACS, odds ratio 11.8, p = 0.003, (figure 3). When clinical stroke
severity was rated according to the CNS, the group of patients in which DWI was
deemed to be 'helpful' (showing a recent lesion, distinguishing a new from an old
infarct, or showing no new ischaemic lesion) had higher CNS scores (i.e. milder strokes),
than the group in which DWI was 'unhelpful' (p = 0.001) (figure 4).
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8.3.2 DWI and stroke severity
Patient baseline characteristics
108 subjects were scanned, 102 of whom presented with stroke, and five with TIA. In
one patient, the diagnosis was undetermined. The median time from stroke to scanning
was two days, mean time three days (standard deviation 4.2). Sixty-eight (63%) patients
were scanned within two days, and 84 (78%) were scanned within three days (72 hours)
of stroke onset, i.e. 15% were scanned on day three, and only 7% later than that.
In patients presenting with a stroke, 12 (11% of total scanned) had total anterior
circulation syndromes (TACS); 52 (48%) had partial anterior circulation syndromes
(PACS), 24 (22%) had lacunar syndromes (LACS); 14 (13%) had posterior circulation
syndromes (POCS) (table 1). The CNS scores ranged from 1.5 (severe) to 10 (mild),
median 8.0. There was no significant difference in the time lapse from stroke to MR
imaging between either the OCSP subtypes (p = 0.23) or patients ranked according to
their score on the Canadian Neurological Scale (p = 0.42).
Univariate analyses
Clinical features at baseline
There was a significant association between the clinical status of the patient as measured
by the OCSP classification and the ADCr (p = 0.002). The mean ADCr values for
patients with a TACS differed significantly from those with a LACS or POCS (p =
0.006, figure 5). The mean ADCr was also significantly lower in those with lower initial
scores on CNS (correlation coefficient 0.30, p = 0.01, figure 6). There was a significant
correlation between the initial severity as measured by the CNS and the visibility of
lesion on T2-WI (p = 0.007, figure 7). The mean CNS score of patients with no lesion
visible on T2 or DWI was significantly milder than those with both barely and easily
visible lesions on T2-WI (p = 0.023 and 0.011 respectively). There was also an
association between the clinical stroke severity measured by the CNS and the volume of
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the visible lesion on DWI (correlation coefficient -0.23, p = 0.05) and between the
OCSP classification and the lesion volume on DWI (p < 0.001).
Imaging features
ADCr was associated with the size of lesion seen on DWI, i.e. the larger the DWI
lesion, the lower the ADCr (correlation coefficient -0.46, p = 0.05, figure 8). Note that
some patients had very small lesions on DWI making measurement of the ADC value
difficult. Patients with no visible lesion on DWI or where the lesion was simply too
small to be able to measure ADCr without risk of including normal brain (n = 27) were
not included in this particular analysis26. The ADCr was also associated with the
visibility of lesion on T2-WI (p < 0.001, figure 9), i.e. the more visible the lesion on T2-
WI, the lower the ADCr value.
Functional outcome
There was a significant association between the ADCr and outcome of the patients at
six months (p = 0.009, figure 10). Patients who were dead or dependent at six months
(Rankin value three to six) had lower baseline ADCr values than those who were alive
and independent (Rankin zero to two) at six months. Patients who were dead or
dependent at six months were also more likely to have visible lesions on T2-WI (chi
squared, p = 0.18, odds ratio 1.8 (95% CI, 0.8-3.9)), and a large lesion on DWI ( p =
0.17), although these associations were not significant.
Multivariate analyses
A simple forward, stepwise multiple logistic regression analysis was performed, using
only three variables (age, stroke severity (CNS) and ADCr) because the size of the study
population and the number of outcome events did not justify the inclusion of more than
these key variables. Both increasing age and lower CNS score were more likely to be
associated with a poor outcome (odds ratios 1.04 per year, 95% CI 0.76 to 1.43, p=0.01
and 1.82 per point on score, 95% CI 1.39 to 2.38, p <0.001 respectively). However,
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using a forward stepwise analysis, the addition ofADCr to the model did not confer any
additional benefit over and above age and stroke severity (p = 0.26). Thus, although
reduced ADCr correlates with severe strokes, a more visible lesion on T2-WI and a
larger lesion on DWI, it is not an independent predictor of functional outcome.
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Figure 6. Severity study. Relationship between ADCr and stroke severity as defined by CNS (10
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Figitre 10. Severity study. Relationship between the ADCr and dinical outcome at six months




















The utility of DWI in stroke
Before a new imaging technique is accepted as the new investigative standard, it should
have been shown to demonstrate new information relevant to the clinical management
of the patient that cannot be demonstrated with existing technology. This information
should be gained at no extra risk to the patient, or the information gained should be
worth the extra risk27. DWI is undeniably an exciting development in the investigation
of patients with stroke, but its true role needs to be defined. Stroke is an immense
world-wide problem, and as yet, there are very few centres where access to MRI
scanning is freely available on a 24-hour basis to all patients presenting with a stroke. If
the main use of DWI is to confirm a hyperacute stroke, its usefulness will be limited to
the very small fraction of patients presenting within a time frame that may make them
eligible for consideration of hyperacute treatment28. However, this study suggests that
DWI is actually of greater use in confirming the presence of an ischaemic lesion in
patients with milder strokes and for days after the stroke even in outpatients, and not
just in the hyperacute phase.
In this study we found that the patient groups in which DWI gave most information not
available on conventional imaging were those with medium or small cortical lesions or
lacunar lesions. As they are less severely affected, these patients often present outside
the time window for hyperacute treatment, even as outpatients, where the clinical issue
is ensuring appropriate secondary prevention. In patients with large strokes, the infarct
was often visible on more conventional imaging, therefore DWI was felt to be less
helpful in this group.
How does our study of clinical usefulness compare to previous studies?
Our study, which is the largest of its kind, agrees with earlier studies that found DWI
more sensitive than conventional MRI, particularly in patients with mild stroke. Albers
et al (40 patients) found that DWI identified clinically significant findings not seen on
conventionalMRI in 48% of patients and distinguished new from old lesions in 20% of
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patients29 (compared with 56% and 13% respectively in our study). Lansberg et al (52
patients) found that adding DWI to conventional MRI improved the accuracy of
identifying acute stroke lesions (acute lesions were identified on conventional T2 MRI in
71% compared to 94% of DWI scans)30. Oliviera-Filho et al (67 patients) found that
conventional MR imaging failed to demonstrate relevant lesions in around one quarter
of consecutive patients with small-penetrator infarct, all of which had had relevant
lesions demonstrated by DWI31. Rovira et al (100 patients) found that DWI added
relevant clinical information in 42% of their case series of subcortical infarcts32 over and
above conventional MRI. Both our study and these previous studies provide data that
help to delineate in whom, and for how long after stroke, DWI is superior to
conventional imaging. This information is essential if there is a choice of imaging
available. For example, in a patient having a large total anterior circulation stroke, there
may be little information gained from DWI over and above that seen on CT33.
Consequently, the potential risk to such a patient of using imaging that takes longer to
acquire than CT (during which the patient has to lie on their back, at risk of aspiration,
less accessible to medical staff) may not be justified. However, in the investigation of a
patient with a stroke that could have more than one cause, such as infarcts in multiple
territories due to cardioembolism, or a single territory due to carotid stenosis, the use of
DWI to help distinguish between them34"36, could accurately identify the most
appropriate secondary prevention strategy.
If imaging is limited, to what groups of patients could DWI be targeted?
In the hyperacute setting when time is extremely limited, lesions on DWI may be easier
for the less well trained observer to see, and may help guide clinical management. Also,
in patients where there remains clinical uncertainty; up to 20 percent of patients
presenting to hospital with stroke-like symptoms may not be having a stroke37, and
within the first day the conventional MRI or CT scans of a high proportion of patients
with (milder) strokes may be normal38. In such cases, if repeat neuroimaging is not
available, the only feature helping to distinguish stroke from non-strokes may be time,
as other clinical signs become evident or other investigations reveal other diagnoses. In
a small proportion of patients, this could present a delay in diagnosis that may be
deemed unacceptable. In such cases, consideration should therefore be given to using
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DWI, outside the hyperacute time-frame when it is important to determine a) whether
the patient has truly had a new infarct, and b) exactly what part of the brain has been
affected.
DWI and stroke severity
Ours is the largest study to date seeking to define the relationship between MR imaging
parameters such as lesions on DWI, clinical stroke severity and functional outcome. We
have identified that ADCr is indeed closely associated with the initial severity of the
stroke, other imaging parameters and six month functional outcome in a univariate
analysis, but not in a multivariate analysis taking account of age and stroke severity.
Thus ADCr on its own is unlikely to be a useful surrogate outcome predictor because it
is no better than the CNS (or equivalent clinical scale), which is quicker to obtain, much
less expensive and less risky to the patient. A much larger dataset would be required to
determine whether the ADCr is a weak independent prognostic variable. The close
inter-relationships between different imaging features of the ischaemic lesion (size on
DWI or visibility on T2-WI and ADCr) means that some imaging parameters may
independently predict poor outcome but much more data would be needed to test this
reliably. The close relationship between ADC and stroke severity means that careful
clinical characterisation of patients and inclusion of clinical characteristics in the analysis
is essential in studies where the purpose is to improve understanding of the interaction
between imaging features like ADCr, and functional outcome. The present study clearly
demonstrates that to be able to interpret changes in ADCr with any accuracy, stroke
severity must be taken into account.
What are the limitations of the severity study?
Some patients were scanned relatively late after onset of their symptoms yet still
included in this study. Contrary to initial reports39, studies have demonstrated that
ADCr values do not recover rapidly after stroke20'40'41, and furthermore lesions may still
be visible on DWI (regardless of ADC changes) up to three weeks after onset of
symptoms42. Certainly some of the patients scanned in the present study at a relatively
later time still had an abnormal ADCr. These patients reflect the fact that some patients
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present late, usually after a minor stroke, and we need to know what to expect if they
undergo DWI. However theywere few in number.
We used two differentMR imaging machines and two different techniques for obtaining
diffusion images. However, we countered any effect that this might have had by using
the ratio of the ADC in the infarct to that in normal brain.
What are the implications for other studies of the relationship between imaging
parameters and stroke severity or outcome?
Patients with more severe strokes tend to be admitted to hospital sooner than milder
strokes43. Therefore, it is possible that patients with more severe strokes, and so lower
ADCr values, may also reach the scanner sooner after stroke than those with milder
strokes and so higher ADCr values. There was no significant difference in the present
study in the time of scanning severe strokes versus the milder strokes. However,
previous studies that examined ADCr changes over time using 'snapshot' imaging of
individual patients (rather than serial imaging of the same patients at different times),
and observed low ADC values within the first few hours, and normal or high ADC
values by 24 hours39, may simply have been imaging severe strokes soon after stroke and
milder strokes later (the artefact of case-mix). Studies in which the same subjects were
scanned sequentially avoid the case-mix problem and show that the infarct ADC may
actually remain low for two weeks or more after stroke 19,23 18'20'41'41.
Previous smaller studies have shown a relationship between lesion volume on DWI and
functional outcome (total number of patients 145)14'16'18>44) as well as other imaging
parameters and outcome (35 patients)17,45 in univariate analyses. Warach et al (81
patients) also found associations between DWI lesion volume and hypoperfused lesion
volume in 81 patients randomised in the citacholine trial46. We have not found a
statistically significant association between DWI lesion volume and outcome, possibly
because our patient group reflected a broader case mix than was included in previous
studies. However we did find other imaging parameters that were associated with
clinical outcome, albeit not independently after clinical stroke severity and age had been
taken into consideration. This does not mean that there is no association between
213
imaging features and clinical outcome, but merely that they are so closely associated
with clinical stroke severity that huge sample sizes are needed to identify small
independent associations.
What next for DWI?
The next challenge for DWI is to improve understanding of exactly what the lesions
seen (and their associated ADC values) mean. In animal studies, DWI lesions can
recover completely47, and studies in humans have found patients with a definite recent
stroke but no visible lesion on DWI48. Therefore, a lesion on DWI cannot as yet be
taken to distinguish unsalvageable from salvageable tissue reliably. At the moment, the
ADC value that represents a 'cut-off', i.e. that distinguishes definitely unrecoverable
from recoverable tissue, is not precisely known. The use of an arbitrary cut off (e.g. a
40% reduction in ADCr19'20, may risk missing a substantial amount of permanently
damaged tissue in patients with milder strokes (note figure 5). The 40% reduction was
identified from a study of mostly severe strokes20. In the present study, the ADCr values
of most patients with a PACS or LACS were reduced by less than 40% (ie only about
20% reduced), so the lesion would have been missed on an automated analysis set to
identify 40% or more reduction. A 40% reduction would however in the present study
have distinguished virtually all TACS from PACS, LACS and POCS (figure 5) so might
be useful for that purpose, i.e. early identification of a subset of bad strokes. Although
we did not do late follow-up imaging, the functional outcome scores of the patients with
PACS and LACS (about 50% were dependent or dead) would suggest that most of the
DWI-visible lesion in these patients was actually permanently damaged tissue, despite
the fact that the mean ADCr in the patients with a PACS or a LACS was reduced by less
than 40% (figure 1). In other words, these patients would not have met the 40% ADCr
reduction for 'permanent damage' that has been suggested. Automated ADCr
measurement methods will require careful calibration so as not to overlook significantly
damaged tissue if too low an ADCr level is used49. Our results suggest that the ADCr
'cut-off' value indicating permanent damage maywell be different for different severities
of stroke. Thus the "threshold" value would need to be adjusted accordingly.
Furthermore, simultaneous integration of information from DWI, T2 and perhaps
perfusion imaging49 may be needed to achieve adequate tissue damage level
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discrimination, rather than just relying on one imaging parameter. However, much more
information will be required to achieve this degree of sophistication.
Conclusion
DWI does demonstrate more ischaemic lesions than conventional imaging and as such
may prove valuable in the management of patients in terms of both acute treatment and
secondary prevention. The ADCr may be a powerful way of quantifying the degree of
ischaemic damage, and as such is an exciting step forward in the management of stroke.
However, much more careful quantification of the relationship of the ADC to time,
stroke severity and the possibility of recovery are needed before we can interpret a
specific ADC value precisely, and therefore use ADC as a surrogate outcome measure
or determine the contribution of diffusion-weighted imaging to future stroke care.
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Summary
Neuroimaging has a number of important roles in the management of patients with stroke.
It is used:
• To exclude non-stroke pathology,
• To distinguish ischaemia from haemorrhage;
• To determine the extent of damage (for example, identifying intraventricular extension
in intracerebral haemorrhage, the volume of involved territory in ischaemia);
• To detect complications such as hydrocephalus, oedema, haemorrhagic transformation;
• To investigate the state of intracerebral vessels, identifying occlusion or rupture;
• To determine the site of a lesion, thereby helping to deduce its cause, or assess
suitability for surgery; and
• As an aid in clinical outcome prediction; and in the future, as the ischaemic penumbra is
better characterised, as a surrogate clinical marker.
The use of CT in stroke has increased markedly within the last ten years, as has MRI,
although MRI is still used far less frequently than CT. The beneficial effect of aspirin
following ischaemic stroke has made it important to distinguish ischaemic stroke from
intracerebral haemorrhage (ICH). The advent of thrombolysis, as well as ongoing research
into other acute therapies, is making it increasingly important to define more accurately the
site and extent of ischaemic damage.
Thus, as the availability and choice of neuroimaging has increased, so has the complexity of
information the stroke physician requires from it. Information on the relative strengths and
weaknesses of CT, conventional MRI and DWI are needed to make best use of a resource
that has many competing demands made upon it from other specialities. Even if geography
or financial constraints restrict the choice of scanner (or timing of access to it), it is
important to be aware of what it can and can not do.
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Not scanning patients with stroke, or not scanning with CT rapidly enough, may miss ICH.
Not identifying ICH has important consequences both for the accuracy of epidemiological
data (and consequently any dependent research, such as genetics studies), and for patient
care. The risk of anticoagulants in acute ICH may be self-evident but the limited data
available for antithrombotic drugs in this setting also include the possibility of harm.
The ideal imaging modality to identify haemorrhage varies depending upon the timing of
scanning. The limited information available from the literature as well as new data from our
CT versus MRI study show that signs of haemorrhage can be easily identified on CT very
soon after onset of stroke symptoms but these can disappear without trace within a matter
of days. Both the CT versus MRI study, and the late haemorrhage study confirm that MRI
is superior to CT in the demonstration of haemorrhage at a later time point, and that with
the correct MRI sequence, signs can be identified for many years after the event. The CT
versus MRI study demonstrated that neuroimaging has important effects on patient care.
Scanning with CT increased clinical certainty of diagnosis and use of MRI increased
certainty that an ICH is not being missed. Results of MRI led to changes to secondary
prevention strategies for patients with previously unidentified ICH.
In the CT versus MRI study, CT and conventional MRI were equally good at demonstrating
ischaemic lesions, but both failed to demonstrate a lesion in around 50% of patients. Our
study of the clinical usefulness of DWI showed that DWI was far better than conventional
MRI at detecting ischaemic lesions, and delivered clinically relevant information not gained
from conventional imaging in a high proportion of patients. Our study of the relationship
between clinical stroke severity, apparent diffusion coefficient (ADC) value and visibility of
lesions on DWI demonstrated the relationship between the clinical status of the patient and
the ADC and hence lesion visibility.
Performing systematic reviews of imaging literature revealed disturbing weaknesses of
methodology in the majority of published studies. This weakness is not just historical;
methods used in recent DWI and PI studies are barely any better than those of studies
published on CT one or even two decades ago. Small samples of highly selected patients,
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undergoing imaging that is often interpreted without blinding has resulted in weak,
subjective data that is impossible to generalise. On the evidence of these reviews,
performing a systematic review of imaging literature with the aim of extracting data with
which to compare imaging modalities has little point. However, they do perform an
important role in highlighting the consistent study weaknesses that, if addressed, will
improve the data that is collected.
Neuroimaging is vital for stroke management, but if performed inappropriately, will deliver
less information, or less accurate information than it has the potential to. Appropriate
attention must be paid to the sensitivity and specificity of imaging techniques in order to
make best use of them. Without sufficient attention, any dependent research, for instance
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Appendix I. Classification systems for ischaemic stroke
a) Bamford Classification
Groups patients into four categories that define the site and size of the stroke, and gives an
indication of their likely outcome. Patients will present with the following combination of
symptoms:
i) Total Anterior Circulation Infarct (TACI) - disorder of higher cerebral dysfunction (e.g.
dysphasia), homonymous visual field defect, and ipsilateral motor/sensory deficit.
ii) Partial Anterior Circulation Infarct (PACI) - two of the three components of the TACI,
or with a motor or sensory deficit more restricted than would be classified as LACI
iii) Lacunar Infarct (LACI) - pure motor stroke, pure sensory stroke, sensori-motor stroke,
or ataxic hemiparesis
iv) Posterior circulation Infarct (POCI) - ipsilateral cranial nerve palsy with contralateral
motor and/or sensory deficit, bilateral motor and/or sensory deficit, disorder of conjugate
eye movement, cerebellar dysfunction without ipsilateral long-tract deficit, isolated
homonymous visual field deficit.
b) TOAST classification
Separates patients into five categories based on the presumed aetiology of the ischaemic
stroke, and makes use of brain imaging, cardiac imaging, and Doppler ultrasound of
extracranial arteries.
i) Large-artery atherosclerosis (embolus/thrombosis)*
ii) Cardioembolism (high-risk/medium risk)*
iii) Small-vessel occlusion (lacune)*
iv) Stroke of other determined aetiology*
v) Stroke of undetermined aetiology
a. Two or more causes identified
b. Negative evaluation
c. Incomplete evaluation
"'Possible or probable depending on results of ancillary studies
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Appendix II. Clinical scoring systems for distinguishing intracerebral haemorrhage
and ischaemic stroke
1. Sirarai Stroke Score (SSS)
SSS = (2.5 x consciousness) + (2 x vomiting)
+ (2 x headache)
+ (0.1 x diastolic blood pressure)







Vomiting headache within 2 hours










> 1 Cerebral haemorrhage
< -1 Cerebral infarction
-1 to 1 Uncertain diagnosis
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2. Allen Score
Multiply blood pressure by 0.17 and add to total of clinical rating scores below
Clinical ratings
Clinical feature Standardised coefficient Clinical status Score
Apoplectic onset
Loss of consciousness
Headache within 2 h
Vomiting
Neck stiffness



















(24 h after admission)















Any number of events
0
-6.7


















<+4 probability of infarction is >90%
>+24 probability of haemorrhage is >90%
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Appendix III. Electronic search strategies
Glossary of search terms
/ MEDLINE subject heading (MESH)
mp. Title, abstract, heading word, trade name, manufacturer name
.tw Identifies the word specified in the title or abstract
ti. Identifies word specified in title
$ Identifies anyword beginning with the text preceding it
or In the search parameter specified, the article only has to be found in one of the
search terms
and In the search specified, the article must be found in all search terms
Expanded search strategy for stroke.
Table 1. EMBASE
Search History
1 exp cerebrovasc disease/
2 strokeS .tw
3 cerebrovascularS.tw
4 (cerebral or cerebellar or brainstem or vertebrobasilar) .tw
5 (infarctS or isch?emi$ or thromboS or emboli$).tw
6 4 and 5
7 carotidS.tw
8 (cerebral or intraventricular or brainstem or cerebellar) .tw
9 (infratentorial or supratentorial or subarachnoid) .tw
10 (brain or intraventricular or brainstem or cerebellar) .tw
11 8 or 9 or 10
12 (haemorrhage or hemorrhage or haematoma or hematoma) .tw
13 (bleeding or aneurysm).tw
14 12 or 13
15 11 and 14
16 thromboS.tw
17 (intracranial or (venous ad)5 sinusS) or (sagittal adj5 venous) or sagittal vein).tw
18 16 and 17
19 transient ischPemic attackS.tw
20 reversible ischPemic neurologicS deficitS.tw
21 venous malformationS.tw
22 arteriovenous malformationS.tw
23 21 or 22






30 (aphasiS or dysphasiS or hemianop$).tw
31 (hemiplegS or hemipar$).tw
32 exp carotid artery surgery/




1 exp cerebrovascular disorders/
2 strokeS.tw
3 cerebrovasculars.tw
4 (cerebral or cerebellar or brainstem or vertebrobasilar) .tw
5 (infarct$ or isch?emi$ or thromboS or emboli$).tw
6 4 and 5
7 carotidS.tw
8 (cerebral or intracerebral or intracranial or parenchymal) .tw
9 (brain or intraventricular or brainstem or cerebellar) .tw
10 (infratentorial or supratentorial or subarachnoid) .tw
11 8 or 9 or 10
12 (haemorrhage or hemorrhage or haematoma or hematoma) .tw
13 (bleeding or aneurysm) .tw
14 12 or 13
15 11 and 14
16 thromboS.tw
17 (intracranial or (venous adj5 sinusS) or sagittal adj5 venous) or (sagittal adj5 vein)).tw
18 16 and 17
19 transient isch?emic attackS.tw
20 reversible ischPemic neurologicS deficit.tw
21 venous malformationS.tw
22 arteriovenous malformationS.tw
23 21 or 22




28 (aphasiS or dysphasiS or hemianop$).tw
29 (hemiplegiS or hemipar$).tw




34 exp dementia, vascular/
35 exp vascular headache/
36 migrainS.tw
37 32 or 33 or 34 or 35 or 36
38 31 not 37
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Appendix IV. Glossary ofMR imaging parameters
TR Relaxation time (ms)
TE Excitation time (ms)
NEX Number of excitations
PD Proton density
FLAIR Fluid attenuated inversion recovery
GRE Gradient echo
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Appendix VI. CT versus MRI study: patient acceptability questionnaire
Patient preference sheet
Thank you for helping us in our research by having both the CT scan and the MR scan.
Please answer these few questions before leaving the department.
Please give this form to the radiographer before you leave.
(Please circle your answer to each question below).
Which test did you have first? CT MR
Which test did you prefer? CT MR
Would you have a CT scan again if you had to? Y/N
If no, please saywhy:
Would you have an MR scan again if you had to? Y/N
If no, please saywhy:
Any other comments?
Thank you for your help.
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Appendix VII. CT versus MRI study. Form for recording CT andMRI results.








Recent infarct with haemorrhagic transformation
Recent haemorrhage
Old lesion probable infarct



















Doctor's dilemmas - interpretation with CT scan
Doppler:
Echo:
a) Type of event, and how sure are vou? (0-100%)
Stroke □ Not stroke □
pich r ]













Continue aspirin j j












Continue anticoagulant | j
Not relevant □
iv) Other - specify
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Appendix IX. The Rankin outcome scale
Clinical status Score
No symptoms 0
Minor symptoms which do not interfere with lifestyle 1
Some restriction to lifestyle, but look after themselves 2
Significant restriction to lifestyle, preventing total independence 3
Severe handicap preventing independent existence but not 4
requiring constant attention
Severe handicap, totally dependent, requiring attention day and night 5
Dead 6
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Systematic Review of Diffusion and Perfusion Imaging in
Acute Ischemic Stroke
S.L. Keir, MRCP; J.M. Wardlaw, FRCR
Background and Purpose—Recent advances in neuroimaging have raised hopes of early and accurate identification of
ischemic brain and the discrimination of dead from salvageable tissue. We sought to determine whether the data
published so far are enough to establish the roles of these techniques in everyday clinical practice.
Methods—A systematic review of studies of MR diffusion-weighted imaging (DWI), perfusion imaging (PI), or a
combination of the two, in human stroke, excluding abstracts and case reports. One reviewer extracted information on
the size of each study, its main purpose, methodological details, and results.
Results—We identified 47 studies of DWI, 18 studies of MR PI alone or in combination with another advanced imaging
modality, and 19 studies of DWI and PI together. Although high proportions of the studies were prospective and gave
good details of the imaging sequences used, the majority gave very limited details on patient selection and clinical
characteristics or blinded imaging assessment. Pathophysiological changes were inferred from DWI/PI patterns that
were not supported by other data.
Conclusions—Despite considerable enthusiasm for and promise of these techniques, there is not sufficient information
available in these studies to enable us to draw firm conclusions about the sensitivity and specificity of these techniques
for identification of either ischemic lesions not visible by other means or salvageable tissue. Future studies should
include larger numbers of carefully described patients, assess the contribution of DWI over and above other imaging,
obtain follow-up at an appropriate time interval to determine accurate clinical and neuroradiological outcomes, and
assess DWI/PI abnormality with reperfusion in randomized treatment trials. Investigators should also be encouraged to
combine their individual patient data in meta-analyses to obtain a more robust assessment of the value of DWI and PI
from larger sample sizes. (Stroke. 2000;31:2723-2731.)
Key Words: magnetic resonance imaging, diffusion-weighted ■ magnetic resonance imaging, perfusion-weighted
■ stroke, acute ■ stroke, ischemic
Recent advances in brain imaging may likely underpin thefuture of stroke ca e. In particular, the introduction of
MR and development of advanced imaging-like spectroscopy
(MRS) and diffusion-weighted and perfusion imaging (DWI
and PI, respectively) have raised hopes of greater ability to
discriminate dead from salvageable tissue and thus to target
new treatments. Several reviews1-2 have summarized the
technical aspects and possible applications of these advances,
and considerable enthusiasm has been expressed for the use
of these techniques in stroke; relatively few, however, have
highlighted the problems that need to be overcome to maxi¬
mize the potential of these exciting techniques.3-4
DWI works on the principle that sensitizing a standard MR
image to diffusion weighting identifies regions of abnormal
water movement, occurring very early after onset of ischemia,
resulting in increased (bright) signal intensity.5 It is thought that
visualization of lesions at such an early stage might identify
patients before acute stroke treatment. The degree of water
movement abnormality (or tissue injury) may be quantified by
calculating the apparent diffusion coefficient (ADC).2
PI can detect hypopcrfused regions of brain either by moni¬
toring the transit of a rapidly injected contrast agent6 or magnet¬
ically tagged water molecules in arterial blood7 through the
brain. In regions distal to an arterial occlusion, the arrival of the
contrast agent or tagged water molecules may be delayed. The
resulting signal-time curve can be converted into a
concentration-time curve, from which several functions that
describe regional perfusion can be determined.
Combining DWI and PI may enable visualization of the
abnormal area soon after the onset of symptoms (previously,
one would expect CT or T2-weighted MR to show an infarct)
and provide information that may discriminate dead from
still-recoverable brain. In hyperacute stroke treatment, this
could help identify which patients are most likely to benefit
from potentially risky treatments.
A study to investigate a new imaging procedure should
give clear details of its aim, the definition and characteriza-
Received April 4, 2000; final revision received June 26, 2000; accepted June 30, 2000.
From the Department of Clinical Neurosciences, Western General Hospital NHS Trust, Edinburgh, UK.
Correspondence to Dr S. Keir, Department of Clinical Neurosciences, Western General Hospital NHS Trust, Bramwell Dott Building, Crewe Road,
Edinburgh EH4 2XU, UK. E-mail slk@skull.dcn.ed.ac.uk
© 2000 American Heart Association, Inc.
Stroke is available at http://www.strokeaha.org
2723
2724 Stroke November 2000
tion of its study population (eg, severity and type of ischemic
stroke), the technical details of the imaging tests, whether the
analysis was prospective or retrospective, how the images
were analyzed and read, and whether the reading was blinded
to clinical details and other imaging. If comparisons within
the study population are made, an objective statistical analy¬
sis should be used to compare the populations with a null
hypothesis being clearly stated. Thus, before we can establish
the role of these advanced imaging techniques, we need to be
confident that studies have demonstrated the efficacy, feasi¬
bility, and the reliability of the information so derived and
that they do indeed identify patients for specific reasons not
possible by othermeans. We therefore undertook a systematic
review of all published studies ofDWI, PI, or both in patients
with stroke to see how well the above criteria had been met,
what information had been obtained so far on patient char¬
acterization and acute stroke treatment guidance, and where
more information on DWI and PI might be needed, and so
where future research with DWI and PI should be directed.
Methods
We used the Cochrane Database of Systematic Reviews methodol¬
ogy8 to perform this systematic review. This methodology has been
developed for undertaking systematic reviews of randomized con¬
trolled treatment trials, but the same principles apply to the conduct
of systematic reviews of diagnostic tests and observational studies.
We have used these methods successfully previously to study risks
for and diagnosis of unruptured intracranial aneurysms.9
Search Strategy
We searched for all published articles on DWI, PI, or a combination
of the two in the English and non-English language literature in
MEDLINE and EMBASE from October 31, 1999, back to the
earliest studies available (using the search terms "diffusion weight¬
ed," "perfusion weighted," "dynamic susceptibility," "hemodynam-
ically weighted," expanded to maximize the number of hits, and
combined these with the Cochrane library search strategy for stroke,8
hand-searched 6 relevant journals (Stroke, Radiology, American
Journal of Neuroradiology, American Journal of Roentgenology,
Magnetic Resonance in Medicine, Journal ofMagnetic Resonance
Imaging) from November 1999 to January 2000, and examined
reference lists in the identified articles.
Inclusion criteria: published studies in which DWI, PI, or both in
combination had been conducted in humans with stroke. We ex¬
cluded case reports and studies that had so far only appeared in
abstract form. Where there was any doubt about the inclusion or
exclusion of a study, the paper was discussed and a consensus
opinion was reached.
Data Extraction and Analysis
One reviewer (S.K.) extracted information on the sample size of each
study, its main purpose (ie, use of imaging to predict outcome,
technical development of the imaging technique, comparison with
another imaging technique), the time window from onset of stroke
symptoms to imaging, how the diagnosis of stroke had been made
and by whom (ie, stroke physician, neurologist, general physician, or
not stated), the patient inclusion criteria, whether the patients had
received any stroke treatment and whether this was randomized, the
DWI or PI scanning method, the image analysis method, whether
interpretation ofdiffusion or perfusion images was blinded to clinical
details and the results of other imaging modalities, whether any
patients had been imaged but then excluded from further analysis and
why, whether any data on clinical outcome had been collected and at
what time after stroke, and the overall conclusion of the study.
Analysis
The extracted information was entered into an ACCESS database
and assessed with descriptive statistics.
Results
Forty-seven studies concerned specifically with DWI in
humans with ischemic stroke were identified (total number of
patients=2436, median 34). Also identified were 14 studies
concerning MR PI alone (n=198, median 10); 4 combining
MR PI with another advanced imaging modality, such as
single-photon emission computed tomography (SPECT;
n=38, median 10); and 19 studies concerning the combina¬
tion of DWI and MR PI (n=563, median 21).
General Methodological Details of All Studies
Sample populations ranged from 3 to 224 patients. In these
studies, although the technical information on the imaging
sequences was good, the information on general methodolog¬
ical details (blinding, patient selection and exclusions, and the
proportion of uninterpretable scans) was limited, and gener¬
ally these details were not mentioned. For instance, in the
DWI-only studies, only 9 of47 (<20%) mentioned that scans
were interpreted by researchers blinded to clinical details or
other imaging,10^18 and only 6 (13%) gave specific details on
patient inclusions and exclusions.10'16-17-19-21 Only 9 studies
gave details on the number (and reasons for) inadequate scans
that were excluded from further analysis,16-17-19-21-26 although
it is likely that patients with poor-quality scans were excluded
from the analysis in other studies. There were no details in
any of the studies on patient tolerability of the investigation
(Figures 1, 2, and 3).
Studies of DWI Alone
The 47 studies of DWI had the following primary purposes
(some studies had >1 primary purpose): technical develop¬
ment of the imaging sequence or analysis method (17
studies); change in visibility of lesions on DWI or ADC over
time (6 studies); correlation of DWI with measures of
neurological severity (2 studies); comparison with CT or T2
MR to see whether DWI showed more lesions (11 studies);
distinguishing old from new lesions (6 studies); use of DWI
to demonstrate ischemic lesions in patients with TIA or
lacunar stroke (4 studies); and feasibility of DWI in acutely ill
patients (6 studies). Two studies addressed identification of
hemorrhage on DWI and 1 addressed the important issue of
negative DWI in patients with strokelike deficits.27 These will
be described in turn.
Seventeen (36%) studies (total n=567) investigated DWI
techniques or refinements of techniques of image acquisition
or processing, or methods of calculation of the apparent
diffusion coefficient (ADC).1416.19-22"24.26.28-37 No useful
comparisons could be made between them, as they all
covered different technical aspects of the imaging and men¬
tioned little about the type of patients included.
Six (13%) studies (including a total of 564 patients) studied
the visibility of DWI lesions or changes in ADC values over
time. One study repeatedly scanned the majority of the
patients in the study21 and found reduced ADC values up to
85 days after stroke. In the rest of the studies, the proportion








Blinded clinical Blinded imaging Stroke physician Unsuccessful scans Prospective study Statistics Clinical follow-up
Figure 1. Proportion of studies documenting information, DWI (%).
of patients who had repeated scanning was much more
limited38-40 or impossible to determine.15-41 In these studies,
the time over which the DWI lesion remained visible was
inferred by using scans of different patients at different time
points, rather than repeated imaging of the same patient.
Using only "snapshots" of different individual patients means
that it is difficult to be precise about when a particular lesion
may disappear, or an ADC value change.
Two (4%) studies (including 92 patients) investigated the
correlation of early DWI (within 2412 and 6017 hours) with
measures of clinical stroke severity at the time of imaging and
at either 317 or 42 weeks.12 Both studies demonstrated that
acute lesion volumes on DWI correlated with the National
Institutes ofHealth Stroke Scale (NIHSS) scores both acutely
and at follow-up. In both studies, images were read blinded to
clinical details, and in one17 to initial T2 MR. However, as
infarction visualized on all imaging modalities tested so far
correlates with stroke severity, knowledge that DWI also
correlates does not add significantly to the body of
knowledge.
Eleven (23%) studies (total n=399) suggested that DWI
demonstrated more lesions in the symptomatic anatomical
area at an earlier time point than did conventional imaging.
Although one study directly compared CT and DWI10
50
67
Blinded clinical Blinded imaging Patient Stroke physician Unsuccessful scans Prospective study
characteristics
Figure 2. Proportion of studies documenting information, PI (%).
Clinical follow-up
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(n=17), the majority of studies compared DWI to conven¬
tional MR.15-18-25'40'42-47 All of these studies indicated that
more lesions were visible on DWI than on conventional
imaging: in 5 studies, within 6 hours or less,10-15-40-43'45 in 2
studies within 48 hours,44-46 in 2 studies within 4 days,18-42
and in 1 study "the time period under investigation" (8 hours
to 12 days).25 In only 2 of the studies the scans were read by
observers blind to clinical details,15-18 in only 1 study blind to
other imaging,43 and in only 1 the observers were blind to
both clinical details and other imaging,10 ie, in fewer than one
third of studies purporting to show that DWI was better than
conventional imaging was an attempt made to reduce bias by
blinding the DWI interpretation. None mentioned whether an
attempt was made to randomize the order in which the DWI
and conventional imaging were performed or stated the order
in which imaging was actually performed (ie, whether DWI
was always performed after conventional imaging, in which
case DWI would always be likely to show more lesions, or
vice versa). The sample sizes in these studies ranged from 9
to 103 patients, which is too small to determine accurately the
benefit ofDWI. The proportion ofpatients in which DWI was
felt to be superior to conventional MR ranged widely, from
5% to 71%. In 1 study it was impossible to define in how
many patients DWI had proved to be superior.47
Six of 399 studies (13%) found that in patients with
multiple lesions demonstrated on MR, it was possible to
distinguish new from old lesions with DWI, with the acute
lesion appearing hyperintense and the old hypointense on the
DWI.16-18-25-41-48-49 Timing of scanning from onset of symp¬
toms ranged from less than seven hours to 11 days. In only 2
studies were the scans read blinded to clinical details.16*18 The
proportion of patients in which DWI was said to distinguish
new from old lesions better than did conventional MR ranged
from four to 15 out of about 220 patients with multiple
lesions, ie, less than 10% of the total number of patients
included.
Four (8%) studies (n=159) concentrated on the clinicoto-
pography of a specific stroke subtype such as lacunar
stroke13-45-18 or transient ischemic attack.50 The studies con¬
centrating on lacunar symptoms demonstrated that DWI
could identify appropriate subcortical areas of ischemia. The
one study concerned with transient ischemic attacks demon¬
strated that 48% of patients whose symptoms resolved within
24 hours had relevant lesions on DWI within 24 hours of
symptom onset. Patients whose symptoms resolved by 24
hours had smaller and less obvious lesions on DWI than
patients whose symptoms had lasted longer.50 Nonetheless, as
with CT scanning,51 this means that DWI cannot be used to
discriminate between symptoms that will turn out to be TIAs
and those that will turn out to be strokes.
Six (13%) studies (n=518), two of which were retrospec¬
tive analyses, addressed the feasibility of undertaking an
advanced imaging protocol in acutely ill stroke patients and
suggested that it was possible.20-26-32-42-46-30 None of the
imaging was read blinded, which is clinically realistic, but
data on patient inclusion and exclusions, as well as clinical
characteristics was often limited, ie, information to identify
patients who would be poor subjects for DWI was not given.
Two studies (which included 20 patients with cerebral hem¬
orrhage) demonstrated that it was possible to identify acute
hemorrhage, a subset ofpatients previously thought to present
difficulty on DWI,52-53 although as neither study was blinded
to other imaging results, the validity of this conclusion must
be questioned.
One retrospective study (n =27) raised the important issue
of patients with strokelike deficits and negative DWI imag¬
ing27 and explained that specificity had not been addressed
because their entire (and substantial) case series (782 pa-
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tients) had not been reviewed. Such a task would indeed have
been a major undertaking, but it would have given us
information on sensitivity and specificity of DWI with an
accuracy that smaller studies which have attempted to address
this issue18 have not achieved. Other studies have attempted
to define specificity and sensitivity ofDWI,20 43 but selection
bias make it difficult to extrapolate these values to the general
population with strokelike symptoms.
Studies ofPI Alone
One of the 14 studies of PI alone attempted to evaluate the
clinical usefulness of PI54 (n=15); the other 13 studies
(n= 183) concentrated on the technical aspects of demonstrat¬
ing abnormalities of regional cerebral perfusion.6-7-55"65 All
but l,64 which attempted to quantify the arterial input function
(a constant required for the calculation of absolute blood
flow), assessed relative rather than absolute cerebral blood
flow. All studies used the gadolinium bolus tracking method
of measuring blood transit time. A variety of perfusion
abnormalities were demonstrated; 1 study56 (n= 11) noted a
heterogeneous distribution of rCBF in the expected regions of
interest in all examinations; 36-7-55 (n=16 to n=34) docu¬
mented hyperperfusion as well as delayed or absent perfusion
in the region of interest; and l54 (n=ll) documented no
perfusion deficits in 4 of the 11 subjects despite marked
clinical signs and repeat MR within 48 hours confirming
infarction.
Of the 4 studies that combined MR PI with another
advanced imaging modality, perfusion MRI was correlated
with SPECT findings in 3<*-<* and with xenon CT in l.69 All
found that MR perfusion techniques correlated well with the
perfusion deficit demonstrated on these other modalities.
Sample sizes were small, and it was not made clear whether
perfusion images were read by researchers blinded to other
forms of imaging.
DWI and PI in Combination
Nineteen studies were identified, with a total sample size of 563
(median 21). The main purpose of 3 of the studies was to
document the clinicotopography of the combined imaging70-72;
one of these71 documented important data on the variety of
patterns ofDWI and PI seen. However, sample size was small,
and it was not clear whetherDWI and PI were read with blinding
to clinical details. One study compared the combination to CT in
relation to acute determination of intracerebral hemorrhage,73
but no details were given about whether the DWI was read with
blinding to the CT. One study set out to determine the clinical
feasibility of a combined protocol74; the resulting data were very
encouraging with respect to the speed of the process but were
lacking in patient clinical characteristics and, importantly, the
proportion of patients the imaged group represented in relation
to the total number of patients with stroke symptoms presenting
to the study hospital.
Fourteen studies (74%; total sample size 316) were mainly
concerned with the use of DWI/PI in predicting either the
final size of infarct on conventional imaging75-80 or final
infarct size and clinical outcome.81-88 The median sample
size was 20 patients, and 4 of these studies reported inclusion
of patients from previously published papers. Follow-up
imaging was performed between 3 and 277 (median 8) days
after initial scanning. Note that if "final infarct size" is
measured at approximately 7 days or less, the infarct will be
edematous and the mass effect will lead to overestimation of
infarct size89; at approximately 10 to 21 days, "fogging"90
obscures the infarct and so will lead to an underestimation of
infarct size; and at 2 to 6 months, atrophy and ex vacuo effect
will lead to underestimation of infarct size. Thus, timing is
crucial for assessment of final infarct size, and many studies
used too early a time point. Those that used later time points
did not make clear whether ex vacuo effects were taken into
account.
Varying patterns of "mismatch" between lesion extent on
DWI and PI were seen and opinions given as to what these
patterns represented. When PI lesions were larger than DWI,
investigators inferred that a larger area of brain was under threat
of ischemia than that outlined by the DWI lesion, ie, an ischemic
penumbra. When DWl lesions were larger than PI lesions, or no
associated PI lesion was visible, the investigators inferred that a
degree of reperfusion had occurred but that an area ofpermanent
damage, represented by the DWI lesion, had already occurred.
When no DWI lesion was visible in the presence of a PI deficit,
the investigators inferred that there was an acute arterial occlu¬
sion but no ischemic damage at the time of imaging.84 Eleven
studies (n=225) used MR angiography in their imaging proto¬
cols as well as PI and DWI, some ofwhich helped to support the
findings of the PI by demonstrating an appropriately occluded
artery7'-73-77-78-80-82-85-87; otherwise, there was no objective way
in any of the studies for substantiating the "mismatch" theory. It
is difficult to judge how robust the mismatch theory is, because
the proportion of patients in whom the lesion had behaved as
predicted on the follow-up imaging (ie, where PI>DWI, the area
of ischemia on the follow-up scan increased in size) varied from
100%78 to only 56%.87
Three of the studies that compared DWI/PI with final
infarct size commented on the nature of the lesion visualized
by DWI. Opinions varied; 1 study75 implied that the DWI
lesion was infarcted tissue, another stated that "DWI lesions
do not reflect closely the extent of functionally compromised
tissue,"84 and another76 stated that diffusion abnormalities
indicated reversible and irreversible ischemia. However, it
was not clear on what evidence these statements were based.
In the 9 studies that related DWI/PI patterns to clinical
outcome (n=219), clinical follow-up ranged from 1 to 90
days after stroke. The scales used varied, the most common
being the NIHSS, which is a measure of neurological deficit
and not functional outcome.75-81-82-85-86-88 Lesion size on acute
DWI or PI correlated with final clinical outcome using the
NIHSS, the Canadian Neurological Scale (CNS),83-84 and the
European Stroke Scale (ESS).87 Because previous studies
have shown that lesion size on imaging (eg, CT) correlated
well with stroke severity, neurological deficit, and clinical
outcome, it is hardly surprising that DWI/PI also correlates.
The key question is what does DWI/PI add over and above
any information already known from previously available
imaging?
Discussion
Stroke medicine is now in an era of acute intervention, and
practical imaging techniques that help confirm an ischemic
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insult within minutes of the event and determine the amount
of salvageable brain tissue remaining would obviously be
invaluable tools. Hence the great flurry of enthusiasm around
the exciting results ofDWI and PI studies. The studies imply
that DWI identifies definitely (permanently) damaged tissue
and that DWI/PI mismatch identifies tissue at risk but still
salvageable. Is this correct? Acute stroke imaging has come a
long way in the last decade, but what has it really told us and
where do we go from here?
We had hoped to determine the sensitivity and specificity
ofDWI for identifying acute ischemic lesions and of DWI/PI
for identifying salvageable tissue, but that was not possible
from the given data. Although it is likely that DWI is more
sensitive to acute ischemic stroke than conventional MR or
CT, sample sizes were so small, or insufficient details of
clinical features, inclusion and exclusion criteria, and unsuc¬
cessful examinations were given to enable an accurate esti¬
mation of efficacy to be made. As the results of this
systematic review show, publications in this field so far tend
not to include important methodological details and so may
be leading stroke researchers into jumping to conclusions not
supported by the data. In many studies, the advanced imaging
was not read blinded to the more routine imaging, and there
were no details on the order in which imaging was performed.
In the studies comparing DWI with conventional MR, ifDWI
was always performed after conventional imaging (as with
studies to date that have compared conventional MR with
CT91), it is likely DWI would always show more lesions.
There was little information on patients unable to complete
DWI or PI, and most studies lacked clinical details of patient
selection and case mix, with the latter information being very
important for several reasons.
First, some conditions that mimic stroke clinically can also
manifest abnormalities on DWI.25-92-93 Few studies mentioned
whether any of their prospectively identified patients later
turned out not to have had a stroke—though it would be
unusual, in a prospective sample even as small as 40, not to
find the occasional patient thought initially to have had a
stroke who turned out to have a nonvascular cause of the
symptoms.94 Conversely, the study by Ay et al27 and other
case reports95-96 have highlighted the potential for DWI to be
negative in patients with ischemic stroke. Although PI may be
of some use in these patients, clarification about this issue is
sorely needed.
Second, because stroke is a heterogeneous condition and
the case mix of patients is likely to differ between hospitals
(even within a small geographical area), this will have led to
differences between studies in the type of stroke patients
included. However, unless sufficient details of the patients'
clinical characteristics at baseline (eg, age, gender, some
measure of neurological deficit, prestroke morbidity) and
clinical status at a recognized, valid outcome point (eg, 3
months) by a validated outcome score are given, it is
impossible to gauge the generalizability of the individual
study results and hence the relevance to the stroke population
in general. One month after stroke is far too early to
determine clinical outcome and still too early for radiological
outcome. There may still be either swelling (overestimating
final infarct size) or fogging (grossly underestimating final
infarct size). In fact, use of any radiological outcome is
difficult if a volume measure or image coregistration are
used, because (in addition to swelling and fogging) loss of
volume in the affected area and ex vacuo effects in surround¬
ing tissues from 4 to 6 weeks onward89 will lead to underes¬
timation of final infarct volume.
Third, the clinical severity of the stroke is a profound
determinant of clinical outcome. It correlates strongly with
the site and extent of the lesion on CT and structural MR and
therefore must be taken into consideration when any new
imaging techniques are described. Most studies failed to do
this adequately: the NIHSS (the most frequently used neuro¬
logical score) captures part, but by no means all, of the
severity of the patient's stroke; ie, it predicts a proportion but
by no means all of the patient's outcome. Stroke severity
must be fully adjusted before any additional information
contributed by an imaging technique to the identification of
particular patients, or the determination of outcome, can be
identified.97 Stroke severity also influences the time to
admission to hospital (patients with severe strokes are admit¬
ted sooner after stroke than those with milder strokes98) and
hence will influence the time to imaging. This, in turn, will
probably influence the ADC values found in individual
patients. The influence of stroke severity cannot be overem¬
phasized: failure to take account of it may have contributed to
perceived differences between studies that compared ADC
changes over time in which "snapshots" of different patients
at different times were used instead of the same patients
scanned serially at different times. A similar effect most
probably affects the findings in studies of DWI with PI, in
which the proportion of patients with diffusion/perfusion
mismatch and its size will depend on the severity of stroke
and the time delay to imaging.
Although many studies gave ample details of the imaging
sequences used, there are problems with the precise DWI or
PI parameters to be measured, moreso with PI. Most MR PI
techniques measure relative and not absolute perfusion
changes, and positron emission tomography studies have
demonstrated drawbacks with this approach.99 Relative per¬
fusion values may not precisely demonstrate which tissue is
at greatest risk of infarction, added to which is the unresolved
debate about the best parameter of the PI curve to use in the
analysis. Attempting to ascribe a physiological mechanism to
PI findings on the basis of our current knowledge is to risk
mistaking association for causation. Very detailed analysis of
small data sets (eg, 30 patients) may be used to generate
hypotheses to test in new studies. However, conclusions from
such analyses are data dependent in themselves, and placing
too much reliance on the results might be misleading,100
particularly in the absence of any spontaneous or pharmaco¬
logically induced tissue recovery to identify which tissue
actually is salvageable. An example of this type of error
approximately 10 years ago was the overemphasis of the
association between hemorrhagic transformation and cardio-
embolic stroke. Then, it was incorrectly assumed that cardio-
embolic stroke caused hemorrhagic transformation, because
of an observed association, when in fact the size of the infarct
rather than the mechanism per se was responsible.101-102
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In all cases, particularly in studies of DWI with PI so far,
the sample size has been small. Our totals may overestimate
the true number imaged, because some patients were included
in several different publications. Small sample size makes the
studies vulnerable to the play of chance in the mix of patients
included and the study results. Examples of how profound an
effect the play of chance can have can be found in the
systematic review of early trials of thrombolysis for acute
myocardial infarction103 (in which studies with sample sizes
up to several hundred had diametrically opposite results) and
in an exercise to demonstrate the effect of chance on small
sample sizes (DICE [Don't Ignore Chance Effects] thera¬
py).104 Investigators should be encouraged to combine their
existing individual patient data from different individual
studies and participate in new multicenter studies whenever
possible, thereby achieving much larger sample sizes and
overcoming some of the case-mix problems outlined above.
The numbers of patients required to obtain more robust data
on the efficacy ofDWI and/or PI in individual studies are not
large, however. Only 84 patients would be required to show
(with 90% power) that DWI demonstrated lesions in 90%, as
opposed to CT showing lesions in 60% of patients.
Finally, acutely ill patients are poor MR subjects: they are
restless, they may be confused and unable to lie still for
prolonged scan times, and observing their clinical state is
difficult. Lying supine when the ability to protect the airway
is impaired increases the risk of aspiration (roughly 50% of
all stroke patients have acutely impaired swallowing reflex).
DWI and PI have to genuinely provide information over and
above that which is readily available on a plain CT, and
which alters clinical management, and this information has to
outweigh any loss of treatment efficacy resulting from added
time delay to start of treatment, if their incorporation into
patient management is to be justified. Such a balance has not
yet been studied.
So, where do we go from here? Larger studies ofDWI with
PI are needed, with clear patient clinical details (inclusions,
exclusions, and failures), blinding of analyses, valid clinical
outcome measures, and comparison with a routine imaging
such as CT so that an assessment of added clinical value can
be made. Patient status during imaging should be assessed to
identify adverse events, such as hypoxia, which could then be
treated or avoided. DWI/PI should be evaluated in random¬
ized trials of new or existing acute stroke treatments because
that will continue to increase the knowledge pool on the
practical application of complex imaging, and only then will
we actually find out which tissue is still viable and recover¬
able and which is not. Then and only then will we know,
when faced with an individual acute stroke patient, at a
certain time after the stroke, with particular clinical features
and appearances on DWI/PI, what the best clinical manage¬
ment will be.
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